<i>CORYNEBACTERIUM GLUTAMICUM</i> GENES ENCODING PROTEINS INVOLVED IN HOMEOSTASIS AND ADAPTATION

Abstract: Isolated nucleic acid molecules, designated HA nucleic acid molecules, which encode novel HA proteins from <i>Corynebacterium glutamicum</i> are described. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing HA nucleic acid molecules, and host cells into which the expression vectors have been introduced. The invention still further provides isolated HA proteins, mutated HA proteins, fusion proteins, antigenic peptides and methods for the improvement of production of a desired compound from <i>C. glutamicum</i> based on genetic engineering of HA genes in this organism.

Description: CORYNEBACTERIUM GLUTAMICUM GENES ENCODING PROTEINS INVOLVED IN HOMEOSTASIS AND ADAPTATION Related Applications This application claims priority to prior filed U.S. Provisional Patent Application Serial No. 60/141031, filed June 25, 1999. This application also claims priority to prior filed German Patent Application No. 19931636.8, filed July 8, 1999, German Patent Application No. 19932125.6, filed July 9, 1999, German Patent Application No. 19932126.4, filed July 9, 1999, German Patent Application No. 19932127.2, filed July 9, 1999, German Patent Application No. 19932128.0, filed July 9, 1999, German Patent Application No. 19932129.9, filed July 9, 1999, German Patent Application No. 19932226.0, filed July 9, 1999, German Patent Application No. 19932920.6, filed July 14, 1999, German Patent Application No. 19932922.2, filed July 14, 1999, German Patent Application No. 19932924.9, filed July 14, 1999, German Patent Application No. 19932928.1, filed July 14, 1999, German Patent Application No. 19932930.3, filed July 14, 1999, German Patent Application No. 19932933.8, filed July 14, 1999, German Patent Application No. 19932935.4, filed July 14, 1999, German Patent Application No. 19932973.7, filed July 14, 1999, German Patent Application No. 19933002.6, filed July 14, 1999, German Patent Application No. 19933003.4, filed July 14, 1999, German Patent Application No. 19933005.0, filed July 14, 1999, German Patent Application No. 19933006.9, filed July 14, 1999, German Patent Application No. 19941378.9, filed August 31, 1999, German Patent Application No. 19941379.7, filed August 31, 1999, German Patent Application No. 19941390.8, filed August 31, 1999, German Patent Application No. 19941391.6, filed August 31, 1999, and German Patent Application No. 19942088.2, filed September 3, 1999. The entire contents of all of the aforementioned applications are hereby expressly incorporated herein by this reference. Background of the Invention Certain products and by-products of naturally-occurring metabolic processes in cells have utility in a wide array of industries, including the food, feed, cosmetics, and pharmaceutical industries. These molecules, collectively termed 'fine chemicals', include organic acids, both proteinogenic and non-proteinogenic amino acids, nucleotides and nucleosides, lipids and fatty acids, diols, carbohydrates, aromatic compounds, vitamins and cofactors, and enzymes. Their production is most conveniently performed through the large-scale culture of bacteria developed to produce and secrete large quantities of one or more desired molecules. One particularly useful organism for this purpose is Corynebacterium glutamicum, a gram positive, nonpathogenic bacterium. Through strain selection, a number of mutant strains have been developed which produce an array of desirable compounds. However, selection of strains improved for the production of a particular molecule is a time-consuming and difficult process. Summary of the Invention The invention provides novel bacterial nucleic acid molecules which have a variety of uses. These uses include the identification of microorganisms which can be used to produce fine chemicals, the modulation of fine chemical production in C. glutamicum or related bacteria, the typing or identification of C. glutamicum or related bacteria, as reference points for mapping the C. glutamicum genome, and as markers for transformation. These novel nucleic acid molecules encode proteins, referred to herein as homeostasis and adaptation (HA) proteins. C. glutamicum is a gram positive, aerobic bacterium which is commonly used in industry for the large-scale production of a variety of fine chemicals, and also for the degradation of hydrocarbons (such as in petroleum spills) and for the oxidation of terpenoids. The HA nucleic acid molecules of the invention, therefore, can be used to identify microorganisms which can be used to produce fine chemicals, e.g., by fermentation processes. Modulation of the expression of the HA nucleic acids of the invention, or modification of the sequence of the HA nucleic acid molecules of the invention, can be used to modulate the production of one or more fine chemicals from a microorganism {e.g., to improve the yield or production of one or more fine chemicals from a Corynebacterium or Brevibacterium species). The HA nucleic acids of the invention may also be used to identify an organism as being Corynebacterium glutamicum or a close relative thereof, or to identify the presence of C. glutamicum or a relative thereof in a mixed population of microorganisms. The invention provides the nucleic acid sequences of a number of C. glutamicum genes; by probing the extracted genomic DNA of a culture of a unique or mixed population of microorganisms under stringent conditions with a probe spanning a region of a C. glutamicum gene which is unique to this organism, one can ascertain whether this organism is present. Although Corynebacterium glutamicum itself is nonpathogenic, it is related to species pathogenic in humans, such as Corynebacterium diphtheriae (the causative agent of diphtheria); the detection of such organisms is of significant clinical relevance. The HA nucleic acid molecules of the invention may also serve as reference points for mapping of the C. glutamicum genome, or of genomes of related organisms. Similarly, these molecules, or variants or portions thereof, may serve as markers for genetically engineered Corynebacterium or Brevibacterium species. The HA proteins encoded by the novel nucleic acid molecules of the invention are capable of, for example, performing a function involved in the maintenance of homeostasis in C. glutamicum, or in the ability of this microorganism to adapt to different environmental conditions. Given the availability of cloning vectors for use in Corynebacterium glutamicum, such as those disclosed in Sinskey et al, U.S. Patent No. 4,649,119, and techniques for genetic manipulation of C. glutamicum and the related Brevibacterium species (e.g., lactofermentum) (Yoshihama et al, J. Bacteriol. 162: 591- 597 (1985); Katsumata et al., J. Bacteriol. 159: 306-311 (1984); and Santamaria et al., J. Gen. Microbiol. 130: 2237-2246 (1984)), the nucleic acid molecules of the invention may be utilized in the genetic engineering of this organism to make it a better or more efficient producer of one or more fine chemicals. This improved production or efficiency of production of a fine chemical may be due to a direct effect of manipulation of a gene of the invention, or it may be due to an indirect effect of such manipulation. There are a number of mechanisms by which the alteration of an HA protein of the invention may directly affect the yield, production, and/or efficiency of production of a fine chemical from a C. glutamicum strain incorporating such an altered protein. For example, by engineering enzymes which modify or degrade aromatic or aliphatic compounds such that these enzymes are increased or decreased in activity or number, it may be possible to modulate the production of one or more fine chemicals which are the modification or degradation products of these compounds. Similarly, enzymes involved in the metabolism of inorganic compounds provide key molecules (e.g. phosphorous, sulfur, and nitrogen molecules) for the biosynthesis of such fine chemicals as amino acids, vitamins, and nucleic acids. By altering the activity or number of these enzymes in C. glutamicum, it may be possible to increase the conversion of these inorganic compounds (or to use alternate inorganic compounds) to thus permit improved rates of incorporation of inorganic atoms into these fine chemicals. Genetic engineering of C. glutamicum enzymes involved in general cellular processes may also directly improve fine chemical production, since many of these enzymes directly modify fine chemicals (e.g., amino acids) or the enzymes which are involved in fine chemical synthesis or secretion. Modulation of the activity or number of cellular proteases may also have a direct effect on fine chemical production, since many proteases may degrade fine chemicals or enzymes involved in fine chemical production or breakdown. Further, the aforementioned enzymes which participate in aromatic/aliphatic compound modification or degradation, general biocatalysis, inorganic compound metabolism or proteolysis are each themselves fine chemicals, desirable for their activity in various in vitro industrial applications. By altering the number of copies of the gene for one or more of these enzymes in C. glutamicum it may be possible to increase the number of these proteins produced by the cell, thereby increasing the potential yield or efficiency of production of these proteins from large-scale C. glutamicum or related bacterial cultures. The alteration of an HA protein of the invention may also indirectly affect the yield, production, and/or efficiency of production of a fine chemical from a C. glutamicum strain incorporating such an altered protein. For example, by modulating the activity and/or number of those proteins involved in the construction or rearrangement of the cell wall, it may be possible to modify the structure of the cell wall itself such that the cell is able to better withstand the mechanical and other stresses present during large-scale fermentative culture. Also, large-scale growth of C. glutamicum requires significant cell wall production. Modulation of the activity or number of cell wall biosynthetic or degradative enzymes may allow more rapid rates of cell wall biosynthesis, which in turn may permit increased growth rates of this microorganism in culture and thereby increase the number of cells producing the desired fine chemical. By modifying the HA enzymes of the invention, one may also indirectly impact the yield, production, or efficiency of production of one or more fine chemicals from C. glutamicum. For example, many of the general enzymes in C. glutamicum may have a significant impact on global cellular processes (e.g., regulatory processes) which in turn have a significant effect on fine chemical metabolism. Similarly, proteases, enzymes which modify or degrade possibly toxic aromatic or aliphatic compounds, and enzymes which promote the metabolism of inorganic compounds all serve to increase the viability of C. glutamicum. The proteases aid in the selective removal of misfolded or misregulated proteins, such as those that might occur under the relatively stressful environmental conditions encountered during large-scale fermentor culture. By altering these proteins, it may be possible to further enhance this activity and to improve the viability of C. glutamicum in culture. The aromatic/aliphatic modification or degradation proteins not only serve to detoxify these waste compounds (which may be encountered as impurities in culture medium or as waste products from cells themselves), but also to permit the cells to utilize alternate carbon sources if the optimal carbon source is limiting in the culture. By increasing their number and/or activity, the survival of C. glutamicum cells in culture may be enhanced. The inorganic metabolism proteins of the invention supply the cell with inorganic molecules required for all protein and nucleotide (among others) synthesis, and thus are critical for the overall viability of the cell. An increase in the number of viable cells producing one or more desired fine chemicals in large-scale culture should result in a concomitant increase in the yield, production, and/or efficiency of production of the fine chemical in the culture. The invention provides novel nucleic acid molecules which encode proteins, referred to herein as HA proteins, which are capable of, for example, performing a function involved in the maintenance of homeostasis in C. glutamicum, or of participating in the ability of this microorganism to adapt to different environmental conditions. Nucleic acid molecules encoding an HA protein are referred to herein as HA nucleic acid molecules. In a preferred embodiment, an HA protein participates in C. glutamicum cell wall biosynthesis or rearrangements, metabolism of inorganic compounds, modification or degradation of aromatic or aliphatic compounds, or possesses a C. glutamicum enzymatic or proteolytic activity. Examples of such proteins include those encoded by the genes set forth in Table 1. Accordingly, one aspect of the invention pertains to isolated nucleic acid molecules (e.g., cDNAs, DNAs, or RNAs) comprising a nucleotide sequence encoding an HA protein or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection or amplification of H A- encoding nucleic acids (e.g. , DNA or mRNA). In particularly preferred embodiments, the isolated nucleic acid molecule comprises one of the nucleotide sequences set forth as the odd-numbered SEQ ID NOs in the Sequence Listing (e.g., SEQ ID NOT, SEQ ID NO:3, SEQ ID NO: 5, SEQ ID NO: 7....), or the coding region or a complement thereof of one of these nucleotide sequences. In other particularly preferred embodiments, the isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes to or is at least about 50%, preferably at least about 60%, more preferably at least about 70%, 80% or 90%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to a nucleotide sequence set forth as an odd-numbered SEQ ID NO in the Sequence Listing (e.g., SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7....), or a portion thereof. In other preferred embodiments, the isolated nucleic acid molecule encodes one of the amino acid sequences set forth in as an even- numbered SEQ ID NO in the Sequence Listing (e.g., SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8....). The preferred HA proteins of the present invention also preferably possess at least one of the HA activities described herein. In another embodiment, the isolated nucleic acid molecule encodes a protein or portion thereof wherein the protein or portion thereof includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of the invention (e.g., a sequence having an even-numbered SEQ ID NO: in the Sequence Listing), e.g., sufficiently homologous to an amino acid sequence of the invention such that the protein or portion thereof maintains an HA activity. Preferably, the protein or portion thereof encoded by the nucleic acid molecule maintains the ability to participate in the maintenance of homeostasis in C. glutamicum, or to perform a function involved in the adaptation of this microorganism to different environmental conditions. In one embodiment, the protein encoded by the nucleic acid molecule is at least about 50%, preferably at least about 60%, and more preferably at least about 70%, 80%, or 90% and most preferably at least about 95%, 96%, 97%, 98%, or 99% or more homologous to an amino acid sequence of the invention (e.g., an entire amino acid sequence selected from those having an even-numbered SEQ ID NO in the Sequence Listing). In another preferred embodiment, the protein is a full length C. glutamicum protein which is substantially homologous to an entire amino acid sequence of the invention (encoded by an open reading frame shown in the corresponding odd-numbered SEQ ID NOs in the Sequence Listing (e.g., SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7....). In another preferred embodiment, the isolated nucleic acid molecule is derived from C. glutamicum and encodes a protein (e.g., an HA fusion protein) which includes a biologically active domain which is at least about 50% or more homologous to one of the amino acid sequences of the invention (e.g., a sequence of one of the even-numbered SEQ ID NOs in the Sequence Listing) and is able to participate in the repair or recombination of DNA, in the transposition of genetic material, in gene expression (i.e., the processes of transcription or translation), in protein folding, or in protein secretion in Corynebacterium glutamicum, or has one or more of the activities set forth in Table 1, and which also includes heterologous nucleic acid sequences encoding a heterologous polypeptide or regulatory regions. In another embodiment, the isolated nucleic acid molecule is at least 15 nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising a nucleotide sequence of the invention (e.g., a sequence of an odd- numbered SEQ ID NO in the Sequence Listing). Preferably, the isolated nucleic acid molecule corresponds to a naturally-occurring nucleic acid molecule. More preferably, the isolated nucleic acid encodes a naturally-occurring C. glutamicum HA protein, or a biologically active portion thereof. Another aspect of the invention pertains to vectors, e.g., recombinant expression vectors, containing the nucleic acid molecules of the invention, and host cells into which such vectors have been introduced. In one embodiment, such a host cell is used to produce an HA protein by culturing the host cell in a suitable medium. The HA protein can be then isolated from the medium or the host cell. Yet another aspect of the invention pertains to a genetically altered microorganism in which an HA gene has been introduced or altered. In one embodiment, the genome of the microorganism has been altered by introduction of a nucleic acid molecule of the invention encoding wild-type or mutated HA sequence as a transgene. In another embodiment, an endogenous HA gene within the genome of the microorganism has been altered, e.g., functionally disrupted, by homologous recombination with an altered HA gene. In another embodiment, an endogenous or introduced HA gene in a microorganism has been altered by one or more point mutations, deletions, or inversions, but still encodes a functional HA protein. In still another embodiment, one or more of the regulatory regions (e.g., a promoter, repressor, or inducer) of an HA gene in a microorganism has been altered (e.g., by deletion, truncation, inversion, or point mutation) such that the expression of the HA gene is modulated. In a preferred embodiment, the microorganism belongs to the genus Corynebacterium or Brevibacterium, with Corynebacterium glutamicum being particularly preferred. In a preferred embodiment, the microorganism is also utilized for the production of a desired compound, such as an amino acid, with lysine being particularly preferred. In another aspect, the invention provides a method of identifying the presence or activity of Cornyebacterium diphtheriae in a subject. This method includes detection of one or more of the nucleic acid or amino acid sequences of the invention (e.g., the sequences set forth in the Sequence Listing as SEQ ID NOs 1 through 440) in a subject, thereby detecting the presence or activity of Corynebacterium diphtheriae in the subject. Still another aspect of the invention pertains to an isolated HA protein or a portion, e.g., a biologically active portion, thereof. In a preferred embodiment, the isolated HA protein or portion thereof can participate in the maintenance of homeostasis in C glutamicum, or can perform a function involved in the adaptation of this microorganism to different environmental conditions. In another preferred embodiment, the isolated HA protein or portion thereof is sufficiently homologous to an amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: in the Sequence Listing) such that the protein or portion thereof maintains the ability to participate in the maintenance of homeostasis in C. glutamicum, or to perform a function involved in the adaptation of this microorganism to different environmental conditions. The invention also provides an isolated preparation of an HA protein. In preferred embodiments, the HA protein comprises an amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing). In another preferred embodiment, the invention pertains to an isolated full length protein which is substantially homologous to an entire amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) (encoded by an open reading frame set forth in a corresponding odd-numbered SEQ ID NO: of the Sequence Listing). In yet another embodiment, the protein is at least about 50%, preferably at least about 60%, and more preferably at least about 70%, 80%, or 90%, and most preferably at least about 95%, 96%, 97%, 98%, or 99% or more homologous to an entire amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing). In other embodiments, the isolated HA protein comprises an amino acid sequence which is at least about 50% or more homologous to one of the amino acid sequences of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) and is able to participate in the maintenance of homeostasis in C. glutamicum, or to perform a function involved in the adaptation of this microorganism to different environmental conditions, or has one or more of the activities set forth in Table 1. Alternatively, the isolated HA protein can comprise an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, or is at least about 50%, preferably at least about 60%, more preferably at least about 70%, 80%, or 90%, and even more preferably at least about 95%, 96%, 97%, 98,%, or 99% or more homologous, to a nucleotide sequence of one of the even-numbered SEQ ID NOs set forth in the Sequence Listing. It is also preferred that the preferred forms of HA proteins also have one or more of the HA bioactivities described herein. The HA polypeptide, or a biologically active portion thereof, can be operatively linked to a non-HA polypeptide to form a fusion protein. In preferred embodiments, this fusion protein has an activity which differs from that of the HA protein alone. In other preferred embodiments, this fusion protein participates in the maintenance of homeostasis in C. glutamicum, or performs a function involved in the adaptation of this microorganism to different environmental conditions. In particularly preferred embodiments, integration of this fusion protein into a host cell modulates production of a desired compound from the cell. In another aspect, the invention provides methods for screening molecules which modulate the activity of an HA protein, either by interacting with the protein itself or a substrate or binding partner of the HA protein, or by modulating the transcription or translation of an HA nucleic acid molecule of the invention. Another aspect of the invention pertains to a method for producing a fine chemical. This method involves the culturing of a cell containing a vector directing the expression of an HA nucleic acid molecule of the invention, such that a fine chemical is produced. In a preferred embodiment, this method further includes the step of obtaining a cell containing such a vector, in which a cell is transfected with a vector directing the expression of an HA nucleic acid. In another preferred embodiment, this method further includes the step of recovering the fine chemical from the culture. In a particularly preferred embodiment, the cell is from the genus Corynebacterium or Brevibacterium, or is selected from those strains set forth in Table 3. Another aspect of the invention pertains to methods for modulating production of a molecule from a microorganism. Such methods include contacting the cell with an agent which modulates HA protein activity or HA nucleic acid expression such that a cell associated activity is altered relative to this same activity in the absence of the agent. In a preferred embodiment, the cell is modulated for one or more C. glutamicum processes involved in cell wall biosynthesis or rearrangements, metabolism of inorganic compounds, modification or degradation of aromatic or aliphatic compounds, or enzymatic or proteolytic activities. The agent which modulates HA protein activity can be an agent which stimulates HA protein activity or HA nucleic acid expression. Examples of agents which stimulate HA protein activity or HA nucleic acid expression include small molecules, active HA proteins, and nucleic acids encoding HA proteins that have been introduced into the cell. Examples of agents which inhibit HA activity or expression include small molecules and antisense HA nucleic acid molecules. Another aspect of the invention pertains to methods for modulating yields of a desired compound from a cell, involving the introduction of a wild-type or mutant HA gene into a cell, either maintained on a separate plasmid or integrated into the genome of the host cell. If integrated into the genome, such integration can be random, or it can take place by homologous recombination such that the native gene is replaced by the introduced copy, causing the production of the desired compound from the cell to be modulated. In a preferred embodiment, said yields are increased. In another preferred embodiment, said chemical is a fine chemical. In a particularly preferred embodiment, said fine chemical is an amino acid. In especially preferred embodiments, said amino acid is L-lysine. Detailed Description of the Invention The present invention provides HA nucleic acid and protein molecules which are involved in C. glutamicum cell wall biosynthesis or rearrangements, metabolism of inorganic compounds, modification or degradation of aromatic or aliphatic compounds, or that have a C. glutamicum enzymatic or proteolytic activity. The molecules of the invention may be utilized in the modulation of production of fine chemicals from microorganisms, such as C. glutamicum, either directly (e.g., where overexpression or optimization of activity of a protein involved in the production of a fine chemical (e.g., an enzyme) has a direct impact on the yield, production, and/or efficiency of production of a fine chemical from the modified C. glutamicum), or an indirect impact which nonetheless results in an increase of yield, production, and/or efficiency of production of the desired compound (e.g. , where modulation of the activity or number of copies of a C. glutamicum aromatic or aliphatic modification or degradation protein results in an increase in the viability of C. glutamicum cells, which in turn permits increased production in a large-scale culture setting). Aspects of the invention are further explicated below. Fine Chemicals The term 'fine chemical' is art-recognized and includes molecules produced by an organism which have applications in various industries, such as, but not limited to, the pharmaceutical, agriculture, and cosmetics industries. Such compounds include organic acids, such as tartaric acid, itaconic acid, and diaminopimelic acid, both proteinogenic and non-proteinogenic amino acids, purine and pyrimidine bases, nucleosides, and nucleotides (as described e.g. in Kuninaka, A. (1996) Nucleotides and related compounds, p. 561-612, in Biotechnology vol. 6, Rehm et al, eds. VCH: Weinheim, and references contained therein), lipids, both saturated and unsaturated fatty acids (e.g., arachidonic acid), diols (e.g., propane diol, and butane diol), carbohydrates (e.g., hyaluronic acid and trehalose), aromatic compounds (e.g., aromatic amines, vanillin, and indigo), vitamins and cofactors (as described in Ullmann's Encyclopedia of Industrial Chemistry, vol. A27, "Vitamins", p. 443-613 (1996) VCH: Weinheim and references therein; and Ong, A.S., Niki, E. & Packer, L. (1995) "Nutrition, Lipids, Health, and Disease" Proceedings of the UNESCO/Confederation of Scientific and Technological Associations in Malaysia, and the Society for Free Radical Research - Asia, held Sept. 1-3, 1994 at Penang, Malaysia, AOCS Press, (1995)), enzymes, polyketides (Cane et al. (1998) Science 282: 63-68), and all other chemicals described in Gutcho (1983) Chemicals by Fermentation, Noyes Data Corporation, ISBN: 0818805086 and references therein. The metabolism and uses of certain of these fine chemicals are further explicated below. A. Amino Acid Metabolism and Uses Amino acids comprise the basic structural units of all proteins, and as such are essential for normal cellular functioning in all organisms. The term "amino acid" is art- recognized. The proteinogenic amino acids, of which there are 20 species, serve as structural units for proteins, in which they are linked by peptide bonds, while the nonproteinogenic amino acids (hundreds of which are known) are not normally found in proteins (see Ulmann's Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97 VCH: Weinheim (1985)). Amino acids may be in the D- or L- optical configuration, though L- amino acids are generally the only type found in naturally-occurring proteins. Biosynthetic and degradative pathways of each of the 20 proteinogenic amino acids have been well characterized in both prokaryotic and eukaryotic cells (see, for example, Stryer, L. Biochemistry, 3 rd edition, pages 578-590 (1988)). The 'essential' amino acids (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine), so named because they are generally a nutritional requirement due to the complexity of their biosyntheses, are readily converted by simple biosynthetic pathways to the remaining 11 'nonessential' amino acids (alanine, arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, and tyrosine). Higher animals do retain the ability to synthesize some of these amino acids, but the essential amino acids must be supplied from the diet in order for normal protein synthesis to occur. Aside from their function in protein biosynthesis, these amino acids are interesting chemicals in their own right, and many have been found to have various applications in the food, feed, chemical, cosmetics, agriculture, and pharmaceutical industries. Lysine is an important amino acid in the nutrition not only of humans, but also of monogastric animals such as poultry and swine. Glutamate is most commonly used as a flavor additive (mono-sodium glutamate, MSG) and is widely used throughout the food industry, as are aspartate, phenylalanine, glycine, and cysteine. Glycine, L- methionine and tryptophan are all utilized in the pharmaceutical industry. Glutamine, valine, leucine, isoleucine, histidine, arginine, proline, serine and alanine are of use in both the pharmaceutical and cosmetics industries. Threonine, tryptophan, and D/ L- methionine are common feed additives. (Leuchtenberger, W. (1996) Amino aids - technical production and use, p. 466-502 in Rehm et al. (eds.) Biotechnology vol. 6, chapter 14a, VCH: Weinheim). Additionally, these amino acids have been found to be useful as precursors for the synthesis of synthetic amino acids and proteins, such as N- acetylcysteine, S-carboxymethyl-L-cysteine, (S)-5-hydroxytryptophan, and others described in Ulmann's Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97, VCH: Weinheim, 1985. The biosynthesis of these natural amino acids in organisms capable of producing them, such as bacteria, has been well characterized (for review of bacterial amino acid biosynthesis and regulation thereof, see Umbarger, H.E.Q978) Ann. Rev. Biochem. 47: 533-606). Glutamate is synthesized by the reductive amination of α- ketoglutarate, an intermediate in the citric acid cycle. Glutamine, proline, and arginine are each subsequently produced from glutamate. The biosynthesis of serine is a three- step process beginning with 3-phosphoglycerate (an intermediate in glycolysis), and resulting in this amino acid after oxidation, transamination, and hydrolysis steps. Both cysteine and glycine are produced from serine; the former by the condensation of homocysteine with serine, and the latter by the transferal of the side-chain β-carbon atom to tetrahydrofolate, in a reaction catalyzed by serine transhydroxymethylase. Phenylalanine, and tyrosine are synthesized from the glycolytic and pentose phosphate pathway precursors erythrose 4-phosphate and phosphoenolpyruvate in a 9-step biosynthetic pathway that differ only at the final two steps after synthesis of prephenate. Tryptophan is also produced from these two initial molecules, but its synthesis is an 11- step pathway. Tyrosine may also be synthesized from phenylalanine, in a reaction catalyzed by phenylalanine hydroxylase. Alanine, valine, and leucine are all biosynthetic products of pyruvate, the final product of glycolysis. Aspartate is formed from oxaloacetate, an intermediate of the citric acid cycle. Asparagine, methionine, threonine, and lysine are each produced by the conversion of aspartate. Isoleucine is formed from threonine. A complex 9-step pathway results in the production of histidine from 5 -phosphoribosyl-1 -pyrophosphate, an activated sugar. Amino acids in excess of the protein synthesis needs of the cell cannot be stored, and are instead degraded to provide intermediates for the major metabolic pathways of the cell (for review see Stryer, L. Biochemistry 3 rd ed. Ch. 21 "Amino Acid Degradation and the Urea Cycle" p. 495-516 (1988)). Although the cell is able to convert unwanted amino acids into useful metabolic intermediates, amino acid production is costly in terms of energy, precursor molecules, and the enzymes necessary to synthesize them. Thus it is not surprising that amino acid biosynthesis is regulated by feedback inhibition, in which the presence of a particular amino acid serves to slow or entirely stop its own production (for overview of feedback mechanisms in amino acid biosynthetic pathways, see Stryer, L. Biochemistry, 3 rd ed. Ch. 24: "Biosynthesis of Amino Acids and Heme" p. 575-600 (1988)). Thus, the output of any particular amino acid is limited by the amount of that amino acid present in the cell. B. Vitamin, Cofactor, and Nutraceutical Metabolism and Uses Vitamins, cofactors, and nutraceuticals comprise another group of molecules which the higher animals have lost the ability to synthesize and so must ingest, although they are readily synthesized by other organisms such as bacteria. These molecules are either bioactive substances themselves, or are precursors of biologically active substances which may serve as electron carriers or intermediates in a variety of metabolic pathways. Aside from their nutritive value, these compounds also have significant industrial value as coloring agents, antioxidants, and catalysts or other processing aids. (For an overview of the structure, activity, and industrial applications of these compounds, see, for example, Ullman's Encyclopedia of Industrial Chemistry, "Vitamins" vol. A27, p. 443-613, VCH: Weinheim, 1996.) The term "vitamin" is art- recognized, and includes nutrients which are required by an organism for normal functioning, but which that organism cannot synthesize by itself. The group of vitamins may encompass cofactors and nutraceutical compounds. The language "cofactor" includes nonproteinaceous compounds required for a normal enzymatic activity to occur. Such compounds may be organic or inorganic; the cofactor molecules of the invention are preferably organic. The term "nutraceutical" includes dietary supplements having health benefits in plants and animals, particularly humans. Examples of such molecules are vitamins, antioxidants, and also certain lipids (e.g., polyunsaturated fatty acids). The biosynthesis of these molecules in organisms capable of producing them, such as bacteria, has been largely characterized (Ullman's Encyclopedia of Industrial Chemistry, "Vitamins" vol. A27, p. 443-613, VCH: Weinheim, 1996; Michal, G. (1999) Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology, John Wiley & Sons; Ong, A.S., Niki, E. & Packer, L. (1995) "Nutrition, Lipids, Health, and Disease" Proceedings of the UNESCO/Confederation of Scientific and Technological Associations in Malaysia, and the Society for Free Radical Research - Asia, held Sept. 1-3, 1994 at Penang, Malaysia, AOCS Press: Champaign, IL X, 374 S). Thiamin (vitamin B \ ) is produced by the chemical coupling of pyrimidine and thiazole moieties. Riboflavin (vitamin B 2 ) is synthesized from guanosine-5 '-triphosphate (GTP) and ribose-5 '-phosphate. Riboflavin, in turn, is utilized for the synthesis of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). The family of compounds collectively termed 'vitamin B ' (e.g., pyridoxine, pyridoxamine, pyridoxa- 5 '-phosphate, and the commercially used pyridoxin hydrochloride) are all derivatives of the common structural unit, 5-hydroxy-6-methylpyridine. Pantothenate (pantothenic acid, (R)-(+)-N-(2,4-dihydroxy-3,3-dimethyl-l-oxobutyl)-β-alanine) can be produced either by chemical synthesis or by fermentation. The final steps in pantothenate biosynthesis consist of the ATP-driven condensation of β-alanine and pantoic acid. The enzymes responsible for the biosynthesis steps for the conversion to pantoic acid, to β- alanine and for the condensation to panthotenic acid are known. The metabolically active form of pantothenate is Coenzyme A, for which the biosynthesis proceeds in 5 enzymatic steps. Pantothenate, pyridoxal-5' -phosphate, cysteine and ATP are the precursors of Coenzyme A. These enzymes not only catalyze the formation of panthothante, but also the production of (R)-pantoic acid, (R)-pantolacton, (R)- panthenol (provitamin B 5 ), pantetheine (and its derivatives) and coenzyme A. Biotin biosynthesis from the precursor molecule pimeloyl-CoA in microorganisms has been studied in detail and several of the genes involved have been identified. Many of the corresponding proteins have been found to also be involved in Fe-cluster synthesis and are members of the nifS class of proteins. Lipoic acid is derived from octanoic acid, and serves as a coenzyme in energy metabolism, where it becomes part of the pyruvate dehydrogenase complex and the α-ketoglutarate dehydrogenase complex. The folates are a group of substances which are all derivatives of folic acid, which is turn is derived from L-glutamic acid, p-amino-benzoic acid and 6- methylpterin. The biosynthesis of folic acid and its derivatives, starting from the metabolism intermediates guanosine-5 '-triphosphate (GTP), L-glutamic acid and p- amino-benzoic acid has been studied in detail in certain microorganisms. Corrinoids (such as the cobalamines and particularly vitamin Bι 2 ) and porphyrines belong to a group of chemicals characterized by a tetrapyrole ring system. The biosynthesis of vitamin Bι is sufficiently complex that it has not yet been completely characterized, but many of the enzymes and substrates involved are now known. Nicotinic acid (nicotinate), and nicotinamide are pyridine derivatives which are also termed 'niacin'. Niacin is the precursor of the important coenzymes NAD (nicotinamide adenine dinucleotide) and NADP (nicotinamide adenine dinucleotide phosphate) and their reduced forms. The large-scale production of these compounds has largely relied on cell-free chemical syntheses, though some of these chemicals have also been produced by large- scale culture of microorganisms, such as riboflavin, Vitamin B , pantothenate, and biotin. Only Vitamin Bι 2 is produced solely by fermentation, due to the complexity of its synthesis. In vitro methodologies require significant inputs of materials and time, often at great cost. C. Purine, Pyrimidine, Nucleoside and Nucleotide Metabolism and Uses Purine and pyrimidine metabolism genes and their corresponding proteins are important targets for the therapy of tumor diseases and viral infections. The language "purine" or "pyrimidine" includes the nitrogenous bases which are constituents of nucleic acids, co-enzymes, and nucleotides. The term "nucleotide" includes the basic structural units of nucleic acid molecules, which are comprised of a nitrogenous base, a pentose sugar (in the case of RNA, the sugar is ribose; in the case of DNA, the sugar is D-deoxyribose), and phosphoric acid. The language "nucleoside" includes molecules which serve as precursors to nucleotides, but which are lacking the phosphoric acid moiety that nucleotides possess. By inhibiting the biosynthesis of these molecules, or their mobilization to form nucleic acid molecules, it is possible to inhibit RNA and DNA synthesis; by inhibiting this activity in a fashion targeted to cancerous cells, the ability of tumor cells to divide and replicate may be inhibited. Additionally, there are nucleotides which do not form nucleic acid molecules, but rather serve as energy stores (i.e., AMP) or as coenzymes (i.e., FAD and NAD). Several publications have described the use of these chemicals for these medical indications, by influencing purine and/or pyrimidine metabolism (e.g. Christopherson, R.I. and Lyons, S.D. (1990) "Potent inhibitors of de novo pyrimidine and purine biosynthesis as chemotherapeutic agents." Med. Res. Reviews 10: 505-548). Studies of enzymes involved in purine and pyrimidine metabolism have been focused on the development of new drugs which can be used, for example, as immunosuppressants or anti-proliferants (Smith, J.L., (1995) "Enzymes in nucleotide synthesis." Curr. Opin. Struct. Biol. 5: 752-757; (1995) Biochem Soc. Transact. 23: 877-902). However, purine and pyrimidine bases, nucleosides and nucleotides have other utilities: as intermediates in the biosynthesis of several fine chemicals (e.g., thiamine, S-adenosyl-methionine, folates, or riboflavin), as energy carriers for the cell (e.g., ATP or GTP), and for chemicals themselves, commonly used as flavor enhancers (e.g., IMP or GMP) or for several medicinal applications (see, for example, Kuninaka, A. (1996) Nucleotides and Related Compounds in Biotechnology vol. 6, Rehm et al, eds. VCH: Weinheim, p. 561- 612). Also, enzymes involved in purine, pyrimidine, nucleoside, or nucleotide metabolism are increasingly serving as targets against which chemicals for crop protection, including fungicides, herbicides and insecticides, are developed. The metabolism of these compounds in bacteria has been characterized (for reviews see, for example, Zalkin, H. and Dixon, J.E. (1992) de novo purine nucleotide biosynthesis", in: Progress in Nucleic Acid Research and Molecular Biology, vol. 42, Academic Press:, p. 259-287; and Michal, G. (1999) "Nucleotides and Nucleosides", Chapter 8 in: Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology, Wiley: New York). Purine metabolism has been the subject of intensive research, and is essential to the normal functioning of the cell. Impaired purine metabolism in higher animals can cause severe disease, such as gout. Purine nucleotides are synthesized from ribose-5-phosphate, in a series of steps through the intermediate compound inosine-5'- phosphate (IMP), resulting in the production of guanosine-5 '-monophosphate (GMP) or adenosine-5'-monophosphate (AMP), from which the triphosphate forms utilized as nucleotides are readily formed. These compounds are also utilized as energy stores, so their degradation provides energy for many different biochemical processes in the cell. Pyrimidine biosynthesis proceeds by the formation of uridine-5' -monophosphate (UMP) from ribose-5-phosphate. UMP, in turn, is converted to cytidine-5 '-triphosphate (CTP). The deoxy- forms of all of these nucleotides are produced in a one step reduction reaction from the diphosphate ribose form of the nucleotide to the diphosphate deoxyribose form of the nucleotide. Upon phosphorylation, these molecules are able to participate in DNA synthesis. D. Trehalose Metabolism and Uses Trehalose consists of two glucose molecules, bound in α, α-1,1 linkage. It is commonly used in the food industry as a sweetener, an additive for dried or frozen foods, and in beverages. However, it also has applications in the pharmaceutical, cosmetics and biotechnology industries (see, for example, Nishimoto et al, (1998) U.S. Patent No. 5,759,610; Singer, M.A. and Lindquist, S. (1998) Trends Biotech. 16: 460- 467; Paiva, C.L.A. and Panek, A.D. (1996) Biotech. Ann. Rev. 2: 293-314; and Shiosaka, M. (1997) J. Japan 172: 97-102). Trehalose is produced by enzymes from many microorganisms and is naturally released into the surrounding medium, from which it can be collected using methods known in the art. II. Maintenance of Homeostasis in C glutamicum and Environmental Adaptation The metabolic and other biochemical processes by which cells function are sensitive to environmental conditions such as temperature, pressure, solute concentration, and availability of oxygen. When one or more such environmental condition is perturbed or altered in a fashion that is incompatible with the normal functioning of these cellular processes, the cell must act to maintain an intracellular environment which will permit them to occur despite the hostile extracellular environment. Gram positive bacterial cells, such as C. glutamicum cells, have a number of mechanisms by which internal homeostasis may be maintained despite unfavorable extracellular conditions. These include a cell wall, proteins which are able to degrade possibly toxic aromatic and aliphatic compounds, mechanisms of proteolysis whereby misfolded or misregulated proteins may be rapidly destroyed, and catalysts which permit intracellular reactions to occur which would not normally take place under the conditions optimal for bacterial growth. Aside from merely surviving in a hostile environment, bacterial cells (e.g. C glutamicum cells) are also frequently able to adapt such that they are able to take advantage of such conditions. For example, cells in an environment lacking desired carbon sources may be able to adapt to growth on a less-suitable carbon source. Also, cells may be able to utilize less desirable inorganic compounds when the commonly utilized ones are unavailable. C glutamicum cells possess a number of genes which permit them to adapt to utilize inorganic and organic molecules which they would normally not encounter under optimal growth conditions as nutrients and precursors for metabolism. Aspects of cellular processes involved in homeostasis and adaptation are further explicated below. A. Modification and Degradation of Aromatic and Aliphatic Compounds Bacterial cells are routinely exposed to a variety of aromatic and aliphatic compounds in nature. Aromatic compounds are organic molecules having a cyclic ring structure, while aliphatic compounds are organic molecules having open chain structures rather than ring structures. Such compounds may arise as by-products of industrial processes (e.g., benzene or toluene), but may also be produced by certain microorganisms (e.g., alcohols). Many of these compounds are toxic to cells, particularly the aromatic compounds, which are highly reactive due to the high-energy ring structure. Thus, certain bacteria have developed mechanisms by which they are able to modify or degrade these compounds such that they are no longer hazardous to the cell. Cells may possess enzymes that are able to, for example, hydroxylate, isomerize, or methylate aromatic or aliphatic compounds such that they are either rendered less toxic, or such that the modified form is able to be processed by standard cellular waste and degradation pathways. Also, cells may possess enzymes which are able to specifically degrade one or more such potentially hazardous substance, thereby protecting the cell. Principles and examples of these types of modification and degradation processes in bacteria are described in several publications, e.g, Sahm, H. (1999) "Procaryotes in Industrial Production" in Lengeler, J.W. et al, eds. Biology of the Procaryotes, Thieme Verlag: Stuttgart; and Schlegel, H.G. (1992) Allgemeine Mikrobiologie, Thieme: Stuttgart). Aside from simply inactivating hazardous aromatic or aliphatic compounds, many bacteria have evolved to be able to utilize these compounds as carbon sources for continued metabolism when the preferred carbon sources of the cell are not available. For example, Pseudomonas strains able to utilize toluene, benzene, and 1,10-dichlorodecane as carbon sources are known (Chang, B.V. et al. (1997) Chemosphere 35(12): 2807-2815; Wischnak, C. et al (199S) App Environ. Microbiol. 64(9): 3507-3511; Churchill, S.A. et al. (1999) Appl Environ. Microbiol. 65(2): 549-552). There are similar examples from many other bacterial species which are known in the art. The ability of certain bacteria to modify or degrade aromatic and aliphatic compounds has begun to be exploited. Petroleum is a complex mixture of chemicals which includes aliphatic molecules and aromatic compounds. By applying bacteria having the ability to degrade or modify these toxic compounds to an oil spill, for example, it is possible to eliminate much of the environmental damage with high efficiency and low cost (see, for example, Smith, M.R. (1990) "The biodegradation of aromatic hydrocarbons by bacteria" Biodegradation 1(2-3): 191-206; and Suyama, T. et al. (1998) "Bacterial isolates degrading aliphatic polycarbonates," FEMS Microbiol Lett. 161(2): 255-261). B. Metabolism of Inorganic Compounds Cells (e.g., bacterial cells) contain large quantities of different molecules, such as water, inorganic ions, and organic substances (e.g., proteins, sugars, and other macromolecules). The bulk of the mass of a typical cell consists of only 4 types of atoms: carbon, oxygen, hydrogen, and nitrogen. Although they represent a smaller percentage of the content of a cell, inorganic substances are equally as important to the proper functioning of the cell. Such molecules include phosphorous, sulfur, calcium, magnesium, iron, zinc, manganese, copper, molybdenum, tungsten, and cobalt. Many of these compounds are critical for the construction of important molecules, such as nucleotides (phosphorous) and amino acids (nitrogen and sulfur). Others of these inorganic ions serve as cofactors for enzymic reactions or contribute to osmotic pressure. All such molecules must be taken up by the bacterium from the surrounding environment. For each of these inorganic compounds it is desirable for the bacterium to take up the form which can be most readily used by the standard metabolic machinery of the cell. However, the bacterium may encounter environments in which these preferred forms are not readily available. In order to survive under these circumstances, it is important for bacteria to have additional biochemical mechanisms which are able to convert less metabolically active but readily available forms of these inorganic compounds to ones which may be used in cellular metabolism. Bacteria frequently possess a number of genes encoding enzymes for this purpose, which are not expressed unless the desired inorganic species are not available. Thus, these genes for the metabolism of various inorganic compounds serve as another tool which bacteria may use to adapt to suboptimal environmental conditions. After carbon, the most important element in the cell is nitrogen. A typical bacterial cell contains between 12-15% nitrogen. It is a constituent of amino acids and nucleotides, as well as many other important molecules in the cell. Further, nitrogen may serve as a substitute for oxygen as a terminal electron acceptor in energy metabolism. Good sources of nitrogen include many organic and inorganic compounds, such ammonia gas or ammonia salts (e.g., NH C1, (NH 4 ) 2 SO 4 , or NH OH), nitrates, urea, amino acids, or complex nitrogen sources like corn steep liquor, soy bean flour, soy bean protein, yeast extract, meat extract, etc. Ammonia nitrogen is fixed by the action of particular enzymes: glutamate dehydrogenase, glutamine synthase, and glutamine-2-oxoglutarate aminotransferase. The transfer of amino-nitrogen from one organic molecule to another is accomplished by the aminotransferases, a class of enzymes which transfer one amino group from an alpha-amino acid to an alpha-keto acid. Nitrate may be reduced via nitrate reductase, nitrite reductase, and further redox enzymes until it is converted to molecular nitrogen or ammonia, which may be readily utilized by the cell in standard metabolic pathways. Phosphorous is typically found intracellularly in both organic and inorganic forms, and may be taken up by the cell in either of these forms as well, though most microorganisms preferentially take up inorganic phosphate. The conversion of organic phosphate to a form which the cell can utilize requires the action of phosphatases (e.g., phytases, which hydrolyze phyate-yielding phosphate and inositol derivatives). Phosphate is a key element in the synthesis of nucleic acids, and also has a significant role in cellular energy metabolism (e.g., in the synthesis of ATP, ADP, and AMP). Sulfur is a requirement for the synthesis of amino acids (e.g., methionine and cysteine), vitamins (e.g., thiamine, biotin, and lipoic acid) and iron sulfur proteins. Bacteria obtain sulfur primarily from inorganic sulfate, though thiosulfate, sulfite, and sulfide are also commonly utilized. Under conditions where these compounds may not be readily available, many bacteria express genes which enable them to utilize sulfonate compounds such as 2-aminosulfonate (taurine) (Kertesz, M.A. (1993) "Proteins induced by sulfate limitation in Escherichia coli, Pseudomonas putida, or Staphylococcus aureus " J. Bacteriol. 175: 1187-1190). Other inorganic atoms, e.g., metal or calcium ions, are also critical for the viability of cells. Iron, for example, plays a key role in redox reactions and is a cofactor of iron-sulfur proteins, heme proteins, and cytochromes. The uptake of iron into bacterial cells may be accomplished by the action of siderophores, chelating agents which bind extracellular iron ions and translocate them to the interior of the cell. For reference on the metabolism of iron and other inorganic compounds, see: Lengeler et al. (1999) Biology of Prokaryotes, Thieme Verlag: Stuttgart; Neidhardt, F.C. et al, eds. Escherichia coli and Salmonella. ASM Press: Washington, D.C.; Sonenshein, A.L. et al, eds. (199?) Bacillus subtilis and Other Gram-Positive Bacteria, ASM Press: Washington, D.C.; Voet, D. and Voet, J.G. (1992) Biochemie, VCH: Weinheim; Brock, T.D. and Madigan, M.T. (1991) Biology of Microorgansisms, 6 th ed. Prentice Hall: Englewood Cliffs, p. 267-269; Rhodes, P.M. and Stanbury, P.F. Applied Microbial Physiology - A Practical Approach, Oxford Univ. Press: Oxford. C. Enzymes and Proteolysis The intracellular conditions for which bacteria such as C. glutamicum are optimized are frequently not conditions under which many biochemical reactions would normally take place. In order to make such reactions proceed under physiological conditions, cells utilize enzymes. Enzymes are proteinaceous biological catalysts, spatially orienting reacting molecules or providing a specialized environment such that the energy barrier to a biochemical reaction is lowered. Different enzymes catalyze different reactions, and each enzyme may be the subject of transcriptional, translational, or posttranslational regulation such that the reaction will only take place under appropriate conditions and at specified times. Enzymes may contribute to the degradation (e.g., the proteases), synthesis (e.g., the synthases), or modification (e.g., transferases or isomerases) of compounds, all of which enable the production of necessary compounds within the cell. This, in turn, contributes to the maintenance of cellular homeostasis. However, the fact that enzymes are optimized for activity under the physiological conditions at which the bacterium is most viable means that when environmental conditions are perturbed, there is a significant possibility that enzyme activity will also be perturbed. For example, changes in temperature may result in aberrantly folded proteins, and the same is true for changes of pH - protein folding is largely dependent on electrostatic and hydrophobic interactions of amino acids within the polypeptide chain, so any alteration to the charges on individual amino acids (as might be brought about by a change in cellular pH) may have a profound effect on the ability of the protein to correctly fold. Changes in temperature effectively change the amount of kinetic energy that the polypeptide molecule possesses, which affects the ability of the polypeptide to settle into a correctly folded, energetically stable configuration. Misfolded proteins may be harmful to the cell for two reasons. First, the aberrantly folded protein may have a similarly aberrant activity, or no activity whatsoever. Second, misfolded proteins may lack the conformational regions necessary for proper regulation by other cellular systems and thus may continue to be active but in an uncontrolled fashion. The cell has a mechanism by which misfolded enzymes and regulatory proteins may be rapidly destroyed before any damage occurs to the cell: proteolysis. Proteins such as those of the la/Ion family and those of the Clp family specifically recognize and degrade misfolded proteins (see, e.g., Sherman, M.Y., Goldberg, A.L. (1999) EXS 77: 57-78 and references therein and Porankiewicz J. (1999) Molec. Microbiol. 32(3): 449- 58, and references therein; Neidhardt, F.C., et al. (1996) E. coli and Salmonella, ASM Press: Washington, D.C. and references therein; and Pritchard, G.G., and Coolbear, T. (1993) FEMS Microbiol. Rev. 12(1-3): 179-206 and references therein). These enzymes bind to misfolded or unfolded proteins and degrade them in an ATP-dependent manner. Proteolysis thus serves as an important mechanism employed by the cell to prevent damage to normal cellular functions upon environmental changes, and it further permits cells to survive under conditions and in environments which would otherwise be toxic due to misregulated and/or aberrant enzyme or regulatory activity. Proteolysis also has important functions in the cell under optimal environmental conditions. Within normal metabolic processes, proteases aid in the hydrolysis of peptide bonds, in the catabolism of complex molecules to provide necessary degradation products, and in protein modification. Secreted proteases play an important role in the catabolism of external nutrients even prior to the entry of these compounds into the cell. Further, proteolytic activity itself may serve regulatory functions; sporulation in B. subtilis and cell cycle progression in Caulobacter spp. are known to be regulated by key proteolytic events in each of these species (Gottesman, S. (1999) Curr. Opin. Microbiol. 2(2): 142-147). Thus, proteolytic processes are key for cellular survival under both suboptimal and optimal environmental conditions, and contribute to the overall maintenance of homeostasis in cells. D. Cell Wall Production and Rearrangements While the biochemical machinery of the cell may be able to readily adapt to different and possibly unfavorable environments, cells still require a general mechanism by which they may be protected from the environment. For many bacteria, the cell wall affords such protection, and also plays roles in adhesion, cell growth and division, and transport of desired solutes and waste materials. In order to function, cells require intracellular concentrations of metabolites and other molecules that are substantially higher than those of the surrounding media. Since these metabolites are largely prevented from leaving the cell due to the presence of the hydrophobic membrane, the tendency of the system is for water molecules to enter the cell from the external medium such that the interior concentrations of solutes match the exterior concentrations. Water molecules are readily able to cross the cellular membrane, and this membrane is not able to withstand the resulting swelling and pressure, which may lead to osmotic lysis of the cell. The rigidity of the cell wall greatly improves the ability of the cell to tolerate these pressures, and offers a further barrier to the unwanted diffusion of these metabolites and desired solutes from the cell. Similarly, the cell wall also serves to prevent unwanted material from entering the cell. The cell wall also participates in a number of other cellular processes, such as adhesion and cell growth and division. Due to the fact that the cell wall completely surrounds the cell, any interaction of the cell with its surroundings must be mediated by the cell wall. Thus, the cell wall must participate in any adherence of the cell to other cells and to desired surfaces. Further, the cell cannot grow or divide without concomitant changes in the cell wall. Since the protection that the wall affords requires its presence during growth, morphogenesis and multiplication, one of the key steps in cell division is cell wall synthesis within the cell such that a new cell divides from the old. Thus, frequently cell wall biosynthesis is regulated in tandem with cell growth and cell division (see, e.g., Sonenshein, A.L. et al, eds. (1993) Bacillus subtilis and Other Gram-Positive Bacteria, ASM: Washington, D.C.). The structure of the cell wall varies between gram-positive and gram-negative bacteria. However, in both types, the fundamental structural unit of the wall remains similar: an overlapping lattice of two polysaccharides, N-acetyl glucosamine (NAG) and N- acetyl muramic acid (NAM) which are cross-linked by amino acids (most commonly L- alanine, D-glutamate, diaminopimelic acid, and D-alanine), termed 'peptidoglycan'. The processes involved in the synthesis of the cell wall are known (see, e.g., Michal, G., ed. (1999) Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology, Wiley: New York). In gram-negative bacteria, the inner cellular membrane is coated by a single-layered peptidoglycan (approximately 10 nm thick), termed the murein-sacculus. This peptidoglycan structure is very rigid, and its structure determines the shape of the organism. The outer surface of the murein-sacculus is covered with an outer membrane, containing porins and other membrane proteins, phospholipids, and lipopolysaccharides. To maintain a tight association with the outer membrane, the gram-negative cell wall also has interspersed lipid molecules which serve to anchor it to the surrounding membrane. In gram-positive bacteria, such as Corynebacterium glutamicum, the cytoplasmic membrane is covered by a multi-layered peptidoglycan, which ranges from 20-80 nm in thickness (see, e.g., Lengeler et al. (1999) Biology of Prokaryotes Thieme Verlag: Stuttgart, p. 913-918, p. 875-899, and p. 88-109 and references therein). The gram-positive cell wall also contains teichoic acid, a polymer of glycerol or ribitol linked through phosphate groups. Teichoic acid is also able to associate with amino acids, and forms covalent bonds with muramic acid. Also present in the cell wall may be lipoteichoic acids and teichuronic acids. If present, cellular surface structures such as flagella or capsules will be anchored in this layer as well. III. Elements and Methods of the Invention The present invention is based, at least in part, on the discovery of novel molecules, referred to herein as HA nucleic acid and protein molecules, which participate in the maintenance of homeostasis in C. glutamicum, or which perform a function involved in the adaptation of this microorganism to different environmental conditions. In one embodiment, the HA molecules participate in C. glutamicum cell wall biosynthesis or rearrangements, in the metabolism of inorganic compounds, in the modification or degradation of aromatic or aliphatic compounds, or have an enzymatic or proteolytic activity. In a preferred embodiment, the activity of the HA molecules of the present invention with regard to C glutamicum cell wall biosynthesis or rearrangements, metabolism of inorganic compounds, modification or degradation of aromatic or aliphatic compounds, or enzymatic or proteolytic activity has an impact on the production of a desired fine chemical by this organism. In a particularly preferred embodiment, the HA molecules of the invention are modulated in activity, such that the C glutamicum cellular processes in which the HA molecules participate (e.g. , C glutamicum cell wall biosynthesis or rearrangements, metabolism of inorganic compounds, modification or degradation of aromatic or aliphatic compounds, or enzymatic or proteolytic activity) are also altered in activity, resulting either directly or indirectly in a modulation of the yield, production, and/or efficiency of production of a desired fine chemical by C glutamicum. The language, "HA protein" or "HA polypeptide" includes proteins which participate in a number of cellular processes related to C. glutamicum homeostasis or the ability of C glutamicum cells to adapt to unfavorable environmental conditions. For example, an HA protein may be involved in C glutamicum cell wall biosynthesis or rearrangements, in the metabolism of inorganic compounds in C. glutamicum, in the modification or degradation of aromatic or aliphatic compounds in C. glutamicum, or have a C. glutamicum enzymatic or proteolytic activity. Examples of HA proteins include those encoded by the HA genes set forth in Table 1 and by the odd-numbered SEQ ID NOs. The terms "HA gene" or "HA nucleic acid sequence" include nucleic acid sequences encoding an HA protein, which consist of a coding region and also corresponding untranslated 5' and 3' sequence regions. Examples of HA genes include those set forth in Table 1. The terms "production" or "productivity" are art-recognized and include the concentration of the fermentation product (for example, the desired fine chemical) formed within a given time and a given fermentation volume (e.g., kg product per hour per liter). The term "efficiency of production" includes the time required for a particular level of production to be achieved (for example, how long it takes for the cell to attain a particular rate of output of a fine chemical). The term "yield" or "product/carbon yield" is art-recognized and includes the efficiency of the conversion of the carbon source into the product (i.e., fine chemical). This is generally written as, for example, kg product per kg carbon source. By increasing the yield or production of the compound, the quantity of recovered molecules, or of useful recovered molecules of that compound in a given amount of culture over a given amount of time is increased. The terms "biosynthesis" or a "biosynthetic pathway" are art-recognized and include the synthesis of a compound, preferably an organic compound, by a cell from intermediate compounds in what may be a multistep and highly regulated process. The terms "degradation" or a "degradation pathway" are art-recognized and include the breakdown of a compound, preferably an organic compound, by a cell to degradation products (generally speaking, smaller or less complex molecules) in what may be a multistep and highly regulated process. The language "metabolism" is art-recognized and includes the totality of the biochemical reactions that take place in an organism. The metabolism of a particular compound, then, (e.g., the metabolism of an amino acid such as glycine) comprises the overall biosynthetic, modification, and degradation pathways in the cell related to this compound. The term "homeostasis" is art-recognized and includes all of the mechanisms utilized by a cell to maintain a constant intracellular environment despite the prevailing extracellular environmental conditions. A non- limiting example of such processes is the utilization of a cell wall to prevent osmotic lysis due to high intracellular solute concentrations. The term "adaptation" or "adaptation to an environmental condition" is art-recognized and includes mechanisms utilized by the cell to render the cell able to survive under nonpreferred environmental conditions (generally speaking, those environmental conditions in which one or more favored nutrients are absent, or in which an environmental condition such as temperature, pH, osmolarity, oxygen percentage and the like fall outside of the optimal survival range of the cell). Many cells, including C. glutamicum cells, possess genes encoding proteins which are expressed under such environmental conditions and which permit continued growth in such suboptimal conditions. In another embodiment, the HA molecules of the invention are capable of modulating the production of a desired molecule, such as a fine chemical, in a microorganism such as C. glutamicum. There are a number of mechanisms by which the alteration of an HA protein of the invention may directly affect the yield, production, and/or efficiency of production of a fine chemical from a C. glutamicum strain incorporating such an altered protein. For example, by engineering enzymes which modify or degrade aromatic or aliphatic compounds such that these enzymes are increased or decreased in activity or number, it may be possible to modulate the production of one or more fine chemicals which are the modification or degradation products of these compounds. Similarly, enzymes involved in the metabolism of inorganic compounds provide key molecules (e.g. phosphorous, sulfur, and nitrogen molecules) for the biosynthesis of such fine chemicals as amino acids, vitamins, and nucleic acids. By altering the activity or number of these enzymes in C. glutamicum, it may be possible to increase the conversion of these inorganic compounds (or to use alternate inorganic compounds) to thus permit improved rates of incorporation of inorganic atoms into these fine chemicals. Genetic engineering of C. glutamicum enzymes involved in general cellular processes may also directly improve fine chemical production, since many of these enzymes directly modify fine chemicals (e.g., amino acids) or the enzymes which are involved in fine chemical synthesis or secretion. Modulation of the activity or number of cellular proteases may also have a direct effect on fine chemical production, since many proteases may degrade fine chemicals or enzymes involved in fine chemical production or breakdown. Further, the aforementioned enzymes which participate in aromatic/aliphatic compound modification or degradation, general biocatalysis, inorganic compound metabolism or proteolysis are each themselves fine chemicals, desirable for their activity in various in vitro industrial applications. By altering the number of copies of the gene for one or more of these enzymes in C. glutamicum it may be possible to increase the number of these proteins produced by the cell, thereby increasing the potential yield or efficiency of production of these proteins from large-scale C. glutamicum or related bacterial cultures. The alteration of an HA protein of the invention may also indirectly affect the yield, production, and/or efficiency of production of a fine chemical from a C. glutamicum strain incorporating such an altered protein. For example, by modulating the activity and/or number of those proteins involved in the construction or rearrangement of the cell wall, it may be possible to modify the structure of the cell wall itself such that the cell is able to better withstand the mechanical and other stresses present during large-scale fermentative culture. Also, large-scale growth of C. glutamicum requires significant cell wall production. Modulation of the activity or number of cell wall biosynthetic or degradative enzymes may allow more rapid rates of cell wall biosynthesis, which in turn may permit increased growth rates of this microorganism in culture and thereby increase the number of cells producing the desired fine chemical. By modifying the HA enzymes of the invention, one may also indirectly impact the yield, production, or efficiency of production of one or more fine chemicals from C glutamicum. For example, many of the general enzymes in C. glutamicum may have a significant impact on global cellular processes (e.g., regulatory processes) which in turn have a significant effect on fine chemical metabolism. Similarly, proteases, enzymes which modify or degrade possibly toxic aromatic or aliphatic compounds, and enzymes which promote the metabolism of inorganic compounds all serve to increase the viability of C. glutamicum. The proteases aid in the selective removal of misfolded or misregulated proteins, such as those that might occur under the relatively stressful environmental conditions encountered during large-scale fermentor culture. By altering these proteins, it may be possible to further enhance this activity and to improve the viability of C glutamicum in culture. The aromatic/aliphatic modification or degradation proteins not only serve to detoxify these waste compounds (which may be encountered as impurities in culture medium or as waste products from cells themselves), but also to permit the cells to utilize alternate carbon sources if the optimal carbon source is limiting in the culture. By increasing their number and/or activity, the survival of C. glutamicum cells in culture may be enhanced. The inorganic metabolism proteins of the invention supply the cell with inorganic molecules required for all protein and nucleotide (among others) synthesis, and thus are critical for the overall viability of the cell. An increase in the number of viable cells producing one or more desired fine chemicals in large-scale culture should result in a concomitant increase in the yield, production, and/or efficiency of production of the fine chemical in the culture. The isolated nucleic acid sequences of the invention are contained within the genome of a Corynebacterium glutamicum strain available through the American Type Culture Collection, given designation ATCC 13032. The nucleotide sequence of the isolated C. glutamicum HA DNAs and the predicted amino acid sequences of the C. glutamicum HA proteins are shown in the Sequence Listing as odd-numbered SEQ ID NOs and even-numbered SEQ ID NOs, respectively, respectively. Computational analyses were performed which classified and/or identified these nucleotide sequences as sequences which encode proteins that participate in C. glutamicum cell wall biosynthesis or rearrangements, metabolism of inorganic compounds, modification or degradation of aromatic or aliphatic compounds, or that have a C. glutamicum enzymatic or proteolytic activity. The present invention also pertains to proteins which have an amino acid sequence which is substantially homologous to an amino acid sequence of the invention (e.g., the sequence of an even-numbered SEQ ID NO of the Sequence Listing). As used herein, a protein which has an amino acid sequence which is substantially homologous to a selected amino acid sequence is least about 50% homologous to the selected amino acid sequence, e.g., the entire selected amino acid sequence. A protein which has an amino acid sequence which is substantially homologous to a selected amino acid sequence can also be least about 50-60%, preferably at least about 60-70%, and more preferably at least about 70-80%, 80-90%, or 90-95%, and most preferably at least about 96%, 97%, 98%, 99% or more homologous to the selected amino acid sequence. The HA protein or a biologically active portion or fragment thereof of the invention can participate in the maintenance of homeostasis in C. glutamicum, or can perform a function involved in the adaptation of this microorganism to different environmental conditions, or have one or more of the activities set forth in Table 1. Various aspects of the invention are described in further detail in the following subsections. A. Isolated Nucleic Acid Molecules One aspect of the invention pertains to isolated nucleic acid molecules that encode HA polypeptides or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes or primers for the identification or amplification of HA-encoding nucleic acid (e.g., HA DNA). As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. This term also encompasses untranslated sequence located at both the 3' and 5' ends of the coding region of the gene: at least about 100 nucleotides of sequence upstream from the 5' end of the coding region and at least about 20 nucleotides of sequence downstream from the 3 'end of the coding region of the gene. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated HA nucleic acid molecule can contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived (e.g, a C glutamicum cell). Moreover, an "isolated" nucleic acid molecule, such as a DNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. A nucleic acid molecule of the present invention, e.g., a nucleic acid molecule having a nucleotide sequence of an odd-numbered SEQ ID NO of the Sequence Listing, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. For example, a C. glutamicum HA DNA can be isolated from a C glutamicum library using all or portion of one of the odd-numbered SEQ ID NO sequences of the Sequence Listing as a hybridization probe and standard hybridization techniques (e.g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). Moreover, a nucleic acid molecule encompassing all or a portion of one of the nucleic acid sequences of the invention (e.g., an odd-numbered SEQ ID NO:) can be isolated by the polymerase chain reaction using ohgonucleotide primers designed based upon this sequence (e.g., a nucleic acid molecule encompassing all or a portion of one of the nucleic acid sequences of the invention (e.g., an odd-numbered SEQ ID NO of the Sequence Listing) can be isolated by the polymerase chain reaction using ohgonucleotide primers designed based upon this same sequence). For example, mRNA can be isolated from normal endothelial cells (e.g., by the guanidinium-thiocyanate extraction procedure of Chirgwin et al (1979) Biochemistry 18: 5294-5299) and DNA can be prepared using reverse transcriptase (e.g., Moloney MLV reverse transcriptase, available from Gibco/BRL, Bethesda, MD; or AMV reverse transcriptase, available from Seikagaku America, Inc., St. Petersburg, FL). Synthetic ohgonucleotide primers for polymerase chain reaction amplification can be designed based upon one of the nucleotide sequences shown in the Sequence Listing. A nucleic acid of the invention can be amplified using cDNA or, alternatively, genomic DNA, as a template and appropriate ohgonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, ohgonucleotides corresponding to an HA nucleotide sequence can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer. In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises one of the nucleotide sequences shown in the Sequence Listing. The nucleic acid sequences of the invention, as set forth in the Sequence Listing, correspond to the Corynebacterium glutamicum HA DNAs of the invention. This DNA comprises sequences encoding HA proteins (i.e., the "coding region", indicated in each odd- numbered SEQ ID NO: sequence in the Sequence Listing), as well as 5' untranslated sequences and 3' untranslated sequences, also indicated in each odd-numbered SEQ ID NO: in the Sequence Listing. Alternatively, the nucleic acid molecule can comprise only the coding region of any of the sequences in nucleic acid sequences of the Sequence Listing For the purposes of this application, it will be understood that each of the nucleic acid and amino acid sequences set forth in the Sequence Listing has an identifying RXA, RXN, RXS, or RXC number having the designation "RXA," "RXN," "RXS, or "RXC" followed by 5 digits (i.e., RXA02458, RXN00249, RXS00153, or RXC00963). Each of the nucleic acid sequences comprises up to three parts: a 5' upstream region, a coding region, and a downstream region. Each of these three regions is identified by the same RXA, RXN, RXS, or RXC designation to eliminate confusion. The recitation "one of the odd-numbered sequences in of the Sequence Listing", then, refers to any of the nucleic acid sequences in the Sequence Listing, which may also be distinguished by their differing RXA, RXN, RXS, or RXC designations. The coding region of each of these sequences is translated into a corresponding amino acid sequence, which is also set forth in the Sequence Listing, as an even-numbered SEQ ID NO: immediately following the corresponding nucleic acid sequence . For example, the coding region for RXA02548 is set forth in SEQ ID NOT, while the amino acid sequence which it encodes is set forth as SEQ ID NO:2. The sequences of the nucleic acid molecules of the invention are identified by the same RXA, RXN, RXS, or RXC designations as the amino acid molecules which they encode, such that they can be readily correlated. For example, the amino acid sequences designated RXA02458, RXN00249, RXS00153, and RXC00963 are translations of the coding regions of the nucleotide sequences of nucleic acid molecules RXA02458, RXN00249, RXS00153, and RXC00963, respectively, of the correspondence between the RXA, RXN, RXS, and RXC nucleotide and amino acid sequences of the invention and their assigned SEQ ID NOs is set forth in Table 1. Several of the genes of the invention are "F-designated genes". An F-designated gene includes those genes set forth in Table 1 which have an 'F' in front of the RXA, RXN, RXS, or RXC designation. For example, SEQ ID NO:5, designated, as indicated on Table 1, as "F RXA00249", is an F-designated gene, as are SEQ ID NOs: 11, 15, and 33 (designated on Table 1 as "F RXA02264", "F RXA02274", and "F RXA00675", respectively). In one embodiment, the nucleic acid molecules of the present invention are not intended to include those compiled in Table 2. In the case of the dapD gene, a sequence for this gene was published in Wehrmann, A., et al. (1998) J Bacteriol. 180(12): 3159- 3165. However, the sequence obtained by the inventors of the present application is significantly longer than the published version. It is believed that the published version relied on an incorrect start codon, and thus represents only a fragment of the actual coding region. In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of one of the nucleotide sequences of the invention (e.g., a sequence of an odd-numbered SEQ ID NO: of the Sequence Listing), or a portion thereof. A nucleic acid molecule which is complementary to one of the nucleotide sequences of the invention is one which is sufficiently complementary to one of the nucleotide sequences the Sequence Listing (e.g., the sequence of an odd-numbered SEQ ID NO:) such that it can hybridize to one of the nucleotide sequences of the invention, thereby forming a stable duplex. In still another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%%, more preferably at least about 71 %, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to a nucleotide sequence of the invention (e.g., a sequence of an odd-numbered SEQ ID NO: of the Sequence Listing), or a portion thereof. Ranges and identity values intermediate to the above-recited ranges, (e.g., 70-90% identical or 80-95% identical) are also intended to be encompassed by the present invention. For example, ranges of identity values using a combination of any of the above values recited as upper and/or lower limits are intended to be included. In an additional preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to one of the nucleotide sequences of the invention, or a portion thereof. Moreover, the nucleic acid molecule of the invention can comprise only a portion of the coding region of the sequence of one of the odd-numbered SEQ ID NOs of the Sequence Listing, for example a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of an HA protein. The nucleotide sequences determined from the cloning of the HA genes from C. glutamicum allows for the generation of probes and primers designed for use in identifying and/or cloning HA homologues in other cell types and organisms, as well as HA homologues from other Corynebacteria or related species. The probe/primer typically comprises substantially purified ohgonucleotide. The ohgonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 40, 50 or 75 consecutive nucleotides of a sense strand of one of the nucleotide sequences of the invention (e.g., a sequence of one of the odd- numbered SEQ ID NOs of the Sequence Listing), an anti-sense sequence of one of these sequences , or naturally occurring mutants thereof. Primers based on a nucleotide sequence of the invention can be used in PCR reactions to clone HA homologues. Probes based on the HA nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In preferred embodiments, the probe further comprises a label group attached thereto, e.g. the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co- factor. Such probes can be used as a part of a diagnostic test kit for identifying cells which misexpress an HA protein, such as by measuring a level of an HA-encoding nucleic acid in a sample of cells, e.g., detecting HA mRNA levels or determining whether a genomic HA gene has been mutated or deleted. In one embodiment, the nucleic acid molecule of the invention encodes a protein or portion thereof which includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of the invention (e.g., a sequence of an even- numbered SEQ ID NO of the Sequence Listing) such that the protein or portion thereof maintains the ability to participate in the maintenance of homeostasis in C glutamicum, or to perform a function involved in the adaptation of this microorganism to different environmental conditions. As used herein, the language "sufficiently homologous" refers to proteins or portions thereof which have amino acid sequences which include a minimum number of identical or equivalent (e.g., an amino acid residue which has a similar side chain as an amino acid residue in a sequence of one of the even-numbered SEQ ID NOs of the Sequence Listing) amino acid residues to an amino acid sequence of the invention such that the protein or portion thereof is able to participate in the maintenance of homeostasis in C glutamicum, or to perform a function involved in the adaptation of this microorganism to different environmental conditions. Proteins involved in C. glutamicum cell wall biosynthesis or rearrangements, metabolism of inorganic compounds, modification or degradation of aromatic or aliphatic compounds, or that have a C. glutamicum enzymatic or proteolytic activity, as described herein, may play a role in the production and secretion of one or more fine chemicals. Examples of such activities are also described herein. Thus, "the function of an HA protein" contributes either directly or indirectly to the yield, production, and/or efficiency of production of one or more fine chemicals. Examples of HA protein activities are set forth in Table 1. In another embodiment, the protein is at least about 50-60%, preferably at least about 60-70%, and more preferably at least about 70-80%, 80-90%, 90-95%, and most preferably at least about 96%, 97%, 98%, 99% or more homologous to an entire amino acid sequence of the invention (e.g., a sequence of an even -numbered SEQ ID NO: of the Sequence Listing). Portions of proteins encoded by the HA nucleic acid molecules of the invention are preferably biologically active portions of one of the HA proteins. As used herein, the term "biologically active portion of an HA protein" is intended to include a portion, e.g., a domain/motif, of an HA protein that can participate in the maintenance of homeostasis in C. glutamicum, or that can perform a function involved in the adaptation of this microorganism to different environmental conditions, or has an activity as set forth in Table 1. To determine whether an HA protein or a biologically active portion thereof can participate in C. glutamicum cell wall biosynthesis or rearrangements, metabolism of inorganic compounds, modification or degradation of aromatic or aliphatic compounds, or has a C. glutamicum enzymatic or proteolytic activity, an assay of enzymatic activity may be performed. Such assay methods are well known to those of ordinary skill in the art, as detailed in Example 8 of the Exemplification. Additional nucleic acid fragments encoding biologically active portions of an HA protein can be prepared by isolating a portion of one of the s amino acid sequences in of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing), expressing the encoded portion of the HA protein or peptide (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of the HA protein or peptide. The invention further encompasses nucleic acid molecules that differ from one of the nucleotide sequences of the invention (e.g., a sequence of an odd-numbered SEQ ID NO: of the Sequence Listing) (and portions thereof) due to degeneracy of the genetic code and thus encode the same HA protein as that encoded by the nucleotide sequences shown in of the invention. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in the Sequence Listing (e.g., an even-numbered SEQ ID NO:). In a still further embodiment, the nucleic acid molecule of the invention encodes a full length C. glutamicum protein which is substantially homologous to an amino acid sequence of the invention (encoded by an open reading frame shown in an odd-numbered SEQ ID NO: of the Sequence Listing). It will be understood by one of ordinary skill in the art that in one embodiment the sequences of the invention are not meant to include the sequences of the prior art, such as those Genbank sequences set forth in Tables 2 or 4 which were available prior to the present invention. In one embodiment, the invention includes nucleotide and amino acid sequences having a percent identity to a nucleotide or amino acid sequence of the invention which is greater than that of a sequence of the prior art (e.g. , a Genbank sequence (or the protein encoded by such a sequence) set forth in Tables 2 or 4). For example, the invention includes a nucleotide sequence which is greater than and/or at least 39% identical to the nucleotide sequence designated RXA00471(SEQ ID NO:293), a nucleotide sequence which is greater than and/or at least 41% identical to the nucleotide sequence designated RXA00500 (SEQ ID NO: 143), and a nucleotide sequence which is greater than and/or at least 35% identical to the nucleotide sequence designated RXA00502(SEQ ID NO: 147). One of ordinary skill in the art would be able to calculate the lower threshold of percent identity for any given sequence of the invention by examining the GAP-calculated percent identity scores set forth in Table 4 for each of the three top hits for the given sequence, and by subtracting the highest GAP-calculated percent identity from 100 percent. One of ordinary skill in the art will also appreciate that nucleic acid and amino acid sequences having percent identities greater than the lower threshold so calculated (e.g., at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71 %, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more identical) are also encompassed by the invention. In addition to the C. glutamicum HA nucleotide set forth in the Sequence Listing as odd-numbered SEQ ID NOs, it will be appreciated by those of ordinary skill in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of HA proteins may exist within a population (e.g., the C. glutamicum population). Such genetic polymorphism in the HA gene may exist among individuals within a population due to natural variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding an HA protein, preferably a C. glutamicum HA protein. Such natural variations can typically result in 1-5% variance in the nucleotide sequence of the HA gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in HA that are the result of natural variation and that do not alter the functional activity of HA proteins are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural variants and non-C. glutamicum homologues of the C. glutamicum HA DNA of the invention can be isolated based on their homology to the C. glutamicum HA nucleic acid disclosed herein using the C. glutamicum DNA, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising a nucleotide sequence of an odd-numbered SEQ ID NO: of the Sequence Listing. In other embodiments, the nucleic acid is at least 30, 50, 100, 250 or more nucleotides in length. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other. Preferably, the conditions are such that sequences at least about 65%, more preferably at least about 70%, and even more preferably at least about 75% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those of ordinary skill in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to a nucleotide sequence of the invention corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein). In one embodiment, the nucleic acid encodes a natural C. glutamicum HA protein. In addition to naturally-occurring variants of the HA sequence that may exist in the population, one of ordinary skill in the art will further appreciate that changes can be introduced by mutation into a nucleotide sequence of the invention, thereby leading to changes in the amino acid sequence of the encoded HA protein, without altering the functional ability of the HA protein. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in a nucleotide sequence of the invention. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of one of the HA proteins (e.g., an even- numbered SEQ ID NO: of the Sequence Listing) without altering the activity of said HA protein, whereas an "essential" amino acid residue is required for HA protein activity. Other amino acid residues, however, (e.g. , those that are not conserved or only semi- conserved in the domain having HA activity) may not be essential for activity and thus are likely to be amenable to alteration without altering HA activity. Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding HA proteins that contain changes in amino acid residues that are not essential for HA activity. Such HA proteins differ in amino acid sequence from a sequence of an even-numbered SEQ ID NO: of the Sequence Listing yet retain at least one of the HA activities described herein. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 50% homologous to an amino acid sequence of the invention and is capable of participating in the maintenance of homeostasis in C. glutamicum, or of performing a function involved in the adaptation of this microorganism to different environmental conditions, or has one or more of the activities set forth in Table 1. Preferably, the protein encoded by the nucleic acid molecule is at least about 50-60% homologous to the amino acid sequence of one of the odd-numbered SEQ ID NOs of the Sequence Listing, more preferably at least about 60- 70% homologous to one of these sequences in, even more preferably at least about 70- 80%, 80-90%, 90-95% homologous to one of these sequences, and most preferably at least about 96%, 97%, 98%, or 99% homologous to one of the amino acid sequences of the invention To determine the percent homology of two amino acid sequences (e.g., one of the amino acid sequences of the invention and a mutant form thereof) or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of one protein or nucleic acid for optimal alignment with the other protein or nucleic acid). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in one sequence (e.g., one of the amino acid sequences of the invention) is occupied by the same amino acid residue or nucleotide as the corresponding position in the other sequence (e.g., a mutant form of the amino acid sequence), then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity"). The percent homology between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology = # of identical positions/total # of positions x 100). An isolated nucleic acid molecule encoding an HA protein homologous to a protein sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) can be created by introducing one or more nucleotide substitutions, additions or deletions into a nucleotide sequence of the invention such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into one of the nucleotide sequences of the invention by standard techniques, such as site-directed mutagenesis and PCR- mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g. , glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in an HA protein is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an HA coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for an HA activity described herein to identify mutants that retain HA activity. Following mutagenesis of the nucleotide sequence of one of the odd-numbered SEQ ID NOs of the Sequence Listing, the encoded protein can be expressed recombinantly and the activity of the protein can be determined using, for example, assays described herein (see Example 8 of the Exemplification). In addition to the nucleic acid molecules encoding HA proteins described above, another aspect of the invention pertains to isolated nucleic acid molecules which are antisense thereto. An "antisense" nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded DNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire HA coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding an HA protein. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (e.g., the entire coding region of SEQ ID NO. 3 (RXN00249) comprises nucleotides 1 to957). In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding HA. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (i.e. , also referred to as 5' and 3' untranslated regions). Given the coding strand sequences encoding HA disclosed herein (e.g., the sequences set forth as odd-numbered SEQ ID NOs in the Sequence Listing), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of HA mRNA, but more preferably is an ohgonucleotide which is antisense to only a portion of the coding or noncoding region of HA mRNA. For example, the antisense ohgonucleotide can be complementary to the region surrounding the translation start site of HA mRNA. An antisense ohgonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense ohgonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5- fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4- acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2- thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D- galactosylqueosine, inosine, N6-isopentenyladenine, 1 -methylguanine, 1 -methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5- methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5- methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'- methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5- methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5- oxyacetic acid methylester, uracil-5 -oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2- carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection). The antisense nucleic acid molecules of the invention are typically administered to a cell or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an HA protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. The antisense molecule can be modified such that it specifically binds to a receptor or an antigen expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecule to a peptide or an antibody which binds to a cell surface receptor or antigen. The antisense nucleic acid molecule can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong prokaryotic, viral, or eukaryotic promoter are preferred. In yet another embodiment, the antisense nucleic acid molecule of the invention is an α-anomeric nucleic acid molecule. An α-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β-units, the strands run parallel to each other (Gaultier et al (1987) Nucleic Acids. Res. 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o- methylribonucleotide (Inoue et al. (1987) Nucleic Acids Res. 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al (1987) FEBS Lett. 215:327-330). In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) Nature 334:585-591)) can be used to catalytically cleave HA mRNA transcripts to thereby inhibit translation of HA mRNA. A ribozyme having specificity for an HA-encoding nucleic acid can be designed based upon the nucleotide sequence of an HA DNA molecule disclosed herein (i.e., SEQ ID NO. 3 (RXN00249)). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an HA-encoding mRNA. See, e.g., Cech et al U.S. Patent No. 4,987,071 and Cech et al U.S. Patent No. 5,116,742. Alternatively, HA mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel, D. and Szostak, J.W. (1993) Science 261 :1411-1418. Alternatively, HA gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of an HA nucleotide sequence (e.g., an HA promoter and/or enhancers) to form triple helical structures that prevent transcription of an HA gene in target cells. See generally, Helene, C. (1991) Anticancer Drug Des. 6(6):569-84; Helene, C. et al. (1992) Ann. N Y. Acad. Sci. 660:27-36; and Maher, L.J. (1992) Bioassays 14(12):807-15. B. Recombinant Expression Vectors and Host Cells Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding an HA protein (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retro viruses, adeno viruses and adeno- associated viruses), which serve equivalent functions. The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which are operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., poly adenylation signals). Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells. Preferred regulatory sequences are, for example, promoters such as cos-, tac-, trp-, tet-, trp-tet-, lpp-, lac-, lpp-lac-, lacl q -, T7-, T5-, T3-, gal-, trc-, ara-, SP6-, arny, SPO2, λ-P R - or λ P , which are used preferably in bacteria. Additional regulatory sequences are, for example, promoters from yeasts and fungi, such as ADC1, MFα, AC, P-60, CYC1, GAPDH, TEF, rp28, ADH, promoters from plants such as CaMV/35S, SSU, OCS, lib4, usp, STLS1, B33, nos or ubiquitin- or phaseolin-promoters. It is also possible to use artificial promoters. It will be appreciated by those of ordinary skill in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., HA proteins, mutant forms of HA proteins, fusion proteins, etc.). The recombinant expression vectors of the invention can be designed for expression of HA proteins in prokaryotic or eukaryotic cells. For example, HA genes can be expressed in bacterial cells such as C. glutamicum, insect cells (using baculovirus expression vectors), yeast and other fungal cells (see Romanos, M.A. et al. (1992) "Foreign gene expression in yeast: a review", Yeast 8: 423-488; van den Hondel, C.A.M.J.J. et al. (1991) "Heterologous gene expression in filamentous fungi" in: More Gene Manipulations in Fungi, J.W. Bennet & L.L. Lasure, eds., p. 396-428: Academic Press: San Diego; and van den Hondel, C.A.M.J.J. & Punt, P.J. (1991) "Gene transfer systems and vector development for filamentous fungi, in: Applied Molecular Genetics of Fungi, Peberdy, J.F. et al, eds., p. 1-28, Cambridge University Press: Cambridge), algae and multicellular plant cells (see Schmidt, R. and Willmitzer, L. (1988) High efficiency Agrobacterium tumefaciens -mediated transformation of Arabidopsis thaliana leaf and cotyledon explants" Plant Cell Rep.: 583-586), or mammalian cells. Suitable host cells are discussed further in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase. Expression of proteins in prokaryotes is most often carried out with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein but also to the C-terminus or fused within suitable regions in the proteins. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) Gene 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. In one embodiment, the coding sequence of the HA protein is cloned into a pGEX expression vector to create a vector encoding a fusion protein comprising, from the N-terminus to the C-terminus, GST-thrombin cleavage site-X protein. The fusion protein can be purified by affinity chromatography using glutathione-agarose resin. Recombinant HA protein unfused to GST can be recovered by cleavage of the fusion protein with thrombin. Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al, (1988) Gene 69:301-315) pLG338, pACYC184, pBR322, pUC18, pUC19, pKC30, pRep4, pHSl, pHS2, pPLc236, pMBL24, pLG200, pUR290, pIN- III 113-B1, λgtl 1, pBdCl, and pET 1 Id (Studier et al, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 60-89 ; and Pouwels et al, eds. (1985) Cloning Vectors. Elsevier: New York IBSN 0 444 904018). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET l id vector relies on transcription from a T7 gnlO-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gnl). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident λ prophage harboring a T7 gnl gene under the transcriptional control of the lacUV 5 promoter. For transformation of other varieties of bacteria, appropriate vectors may be selected. For example, the plasmids pIJlOl, pIJ364, pIJ702 and pIJ361 are known to be useful in transforming Streptomyces, while plasmids pUBl 10, pC194, or pBD214 are suited for transformation of Bacillus species. Several plasmids of use in the transfer of genetic information into Corynebacterium include pHM1519, pBLl, pSA77, or pAJ667 (Pouwels et al, eds. (1985) Cloning Vectors. Elsevier: New York IBSN 0 444 904018). One strategy to maximize recombinant protein expression is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in the bacterium chosen for expression, such as C glutamicum (Wada et al. (1992) Nucleic Acids Res. 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques. In another embodiment, the HA protein expression vector is a yeast expression vector. Examples of vectors for expression in yeast S. cerevisiae include pYepSecl (Baldari, et al, (1987) Embo J. 6:229-234), 2 μ, pAG-1, Yep6, Yepl3, pEMBLYe23, pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al, (1987) Gene 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, CA). Vectors and methods for the construction of vectors appropriate for use in other fungi, such as the filamentous fungi, include those detailed in: van den Hondel, C.A.M.J.J. & Punt, P.J. (1991) "Gene transfer systems and vector development for filamentous fungi, in: Applied Molecular Genetics of Fungi, J.F. Peberdy, et al, eds., p. 1-28, Cambridge University Press: Cambridge, and Pouwels et al, eds. (1985) Cloning Vectors. Elsevier: New York (IBSN 0 444 904018). Alternatively, the HA proteins of the invention can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al (1983) Mol Cell Biol. 3:2156-2165) and the pVL series (Lucklow and Summers (1989) Virology 170:31-39). In another embodiment, the HA proteins of the invention may be expressed in unicellular plant cells (such as algae) or in plant cells from higher plants (e.g. , the spermatophytes, such as crop plants). Examples of plant expression vectors include those detailed in: Becker, D., Kemper, E., Schell, J. and Masterson, R. (1992) "New plant binary vectors with selectable markers located proximal to the left border", Plant Mol Biol 20: 1195-1197; and Bevan, M.W. (1984) "Binary Agrobacterium vectors for plant transformation", Nucl. Acid. Res. 12: 8711-8721, and include pLGV23, pGHlac+, pBIN19, pAK2004, and pDH51 (Pouwels et al, eds. (1985) Cloning Vectors. Elsevier: New York IBSN 0 444 904018). In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) Nature 329:840) and pMT2PC (Kaufman et al. (1987) EMBOJ. 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue- specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al. (1987) Genes Dev. 1 :268-277), lymphoid-specific promoters (Calame and Eaton (1988) Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) EMBO J. 8:729-733) and immunoglobulins (Banerji et al. (1983) Cell 33:729-740; Queen and Baltimore (1983) Cell 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) PNAS 86:5473-5477), pancreas-specific promoters (Edlund et al. (1985) Science 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) Science 249:374-379) and the α-fetoprotein promoter (Campes and Tilghman (1989) Genes Dev. 3:537-546). The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to HA mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. et al. , Antisense RNA as a molecular tool for genetic analysis, Reviews - Trends in Genetics, Vol. 1(1) (1986). Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein. A host cell can be any prokaryotic or eukaryotic cell. For example, an HA protein can be expressed in bacterial cells such as C. glutamicum, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those of ordinary skill in the art. Microorganisms related to Corynebacterium glutamicum which may be conveniently used as host cells for the nucleic acid and protein molecules of the invention are set forth in Table 3. Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection", "conjugation" and "transduction" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., linear DNA or RNA (e.g., a linearized vector or a gene construct alone without a vector) or nucleic acid in the form of a vector (e.g., a plasmid, phage, phasmid, phagemid, transposon or other DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, natural competence, chemical-mediated transfer, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals. For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding an HA protein or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by, for example, drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die). To create a homologous recombinant microorganism, a vector is prepared which contains at least a portion of an HA gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the HA gene. Preferably, this HA gene is a Corynebacterium glutamicum HA gene, but it can be a homologue from a related bacterium or even from a mammalian, yeast, or insect source. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous HA gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous HA gene is mutated or otherwise altered but still encodes functional protein (e.g. , the upstream regulatory region can be altered to thereby alter the expression of the endogenous HA protein). In the homologous recombination vector, the altered portion of the HA gene is flanked at its 5' and 3' ends by additional nucleic acid of the HA gene to allow for homologous recombination to occur between the exogenous HA gene carried by the vector and an endogenous HA gene in a microorganism. The additional flanking HA nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (see e.g. , Thomas, K.R., and Capecchi, M.R. (1987) Cell 51 : 503 for a description of homologous recombination vectors). The vector is introduced into a microorganism (e.g., by electroporation) and cells in which the introduced HA gene has homologously recombined with the endogenous HA gene are selected, using art-known techniques. In another embodiment, recombinant microorganisms can be produced which contain selected systems which allow for regulated expression of the introduced gene. For example, inclusion of an HA gene on a vector placing it under control of the lac operon permits expression of the HA gene only in the presence of IPTG. Such regulatory systems are well known in the art. In another embodiment, an endogenous HA gene in a host cell is disrupted (e.g., by homologous recombination or other genetic means known in the art) such that expression of its protein product does not occur. In another embodiment, an endogenous or introduced HA gene in a host cell has been altered by one or more point mutations, deletions, or inversions, but still encodes a functional HA protein. In still another embodiment, one or more of the regulatory regions (e.g., a promoter, repressor, or inducer) of an HA gene in a microorganism has been altered (e.g., by deletion, truncation, inversion, or point mutation) such that the expression of the HA gene is modulated. One of ordinary skill in the art will appreciate that host cells containing more than one of the described HA gene and protein modifications may be readily produced using the methods of the invention, and are meant to be included in the present invention. A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (/ ' . e. , express) an HA protein. Accordingly, the invention further provides methods for producing HA proteins using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding an HA protein has been introduced, or into which genome has been introduced a gene encoding a wild-type or altered HA protein) in a suitable medium until HA protein is produced. In another embodiment, the method further comprises isolating HA proteins from the medium or the host cell. C Isolated HA Proteins Another aspect of the invention pertains to isolated HA proteins, and biologically active portions thereof. An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of HA protein in which the protein is separated from cellular components of the cells in which it is naturally or recombinantly produced. In one embodiment, the language " substantially free of cellular material" includes preparations of HA protein having less than about 30% (by dry weight) of non-HA protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-HA protein, still more preferably less than about 10% of non-HA protein, and most preferably less than about 5% non-HA protein. When the HA protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation. The language "substantially free of chemical precursors or other chemicals" includes preparations of HA protein in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of HA protein having less than about 30% (by dry weight) of chemical precursors or non-HA chemicals, more preferably less than about 20% chemical precursors or non-HA chemicals, still more preferably less than about 10% chemical precursors or non-HA chemicals, and most preferably less than about 5% chemical precursors or non-HA chemicals. In preferred embodiments, isolated proteins or biologically active portions thereof lack contaminating proteins from the same organism from which the HA protein is derived. Typically, such proteins are produced by recombinant expression of, for example, a C. glutamicum HA protein in a microorganism such as C. glutamicum. An isolated HA protein or a portion thereof of the invention can participate in the repair or recombination of DNA, in the transposition of genetic material, in gene expression (i.e., the processes of transcription or translation), in protein folding, or in protein secretion in Corynebacterium glutamicum, or has one or more of the activities set forth in Table 1. In preferred embodiments, the protein or portion thereof comprises an amino acid sequence which is sufficiently homologous to an amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) such that the protein or portion thereof maintains the ability to participate in the maintenance of homeostasis in C. glutamicum, or to perform a function involved in the adaptation of this microorganism to different environmental conditions. The portion of the protein is preferably a biologically active portion as described herein. In another preferred embodiment, an HA protein of the invention has an amino acid sequence set forth as an even-numbered SEQ ID NO: of the Sequence Listing. In yet another preferred embodiment, the HA protein has an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, e.g. , hybridizes under stringent conditions, to a nucleotide sequence the invention (e.g., a sequence of an odd-numbered SEQ ID NO: of the Sequence Listing). In still another preferred embodiment, the HA protein has an amino acid sequence which is encoded by a nucleotide sequence that is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% % or more homologous to one of the nucleic acid sequences of the invention, or a portion thereof. Ranges and identity values intermediate to the above-recited values, (e.g., 70-90% identical or 80- 95% identical) are also intended to be encompassed by the present invention. For example, ranges of identity values using a combination of any of the above values recited as upper and/or lower limits are intended to be included. The preferred HA proteins of the present invention also preferably possess at least one of the HA activities described herein. For example, a preferred HA protein of the present invention includes an amino acid sequence encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to a nucleotide sequence of the invention, and which can participate in the maintenance of homeostasis in C. glutamicum, or can perform a function involved in the adaptation of this microorganism to different environmental conditions, or which has one or more of the activities set forth in Table 1. In other embodiments, the HA protein is substantially homologous to an amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) and retains the functional activity of the protein of one of the amino acid sequences of the invention yet differs in amino acid sequence due to natural variation or mutagenesis, as described in detail in subsection I above. Accordingly, in another embodiment, the HA protein is a protein which comprises an amino acid sequence which is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to an entire amino acid sequence of the invention and which has at least one of the HA activities described herein. Ranges and identity values intermediate to the above-recited values, (e.g., 70-90% identical or 80-95% identical) are also intended to be encompassed by the present invention. For example, ranges of identity values using a combination of any of the above values recited as upper and/or lower limits are intended to be included. In another embodiment, the invention pertains to a full length C. glutamicum protein which is substantially homologous to an entire amino acid sequence of the invention. Biologically active portions of an HA protein include peptides comprising amino acid sequences derived from the amino acid sequence of an HA protein, e.g., the amino acid sequence of an even-numbered SEQ ID NO: of the Sequence Listing, the amino acid sequence of a protein homologous to an HA protein, which include fewer amino acids than a full length HA protein or the full length protein which is homologous to an HA protein, and exhibit at least one activity of an HA protein. Typically, biologically active portions (peptides, e.g., peptides which are, for example, 5, 10, 15, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids in length) comprise a domain or motif with at least one activity of an HA protein. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the activities described herein. Preferably, the biologically active portions of an HA protein include one or more selected domains/motifs or portions thereof having biological activity. HA proteins are preferably produced by recombinant DNA techniques. For example, a nucleic acid molecule encoding the protein is cloned into an expression vector (as described above), the expression vector is introduced into a host cell (as described above) and the HA protein is expressed in the host cell. The HA protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Alternative to recombinant expression, an HA protein, polypeptide, or peptide can be synthesized chemically using standard peptide synthesis techniques. Moreover, native HA protein can be isolated from cells (e.g., endothelial cells), for example using an anti-HA antibody, which can be produced by standard techniques utilizing an HA protein or fragment thereof of this invention. The invention also provides HA chimeric or fusion proteins. As used herein, an HA "chimeric protein" or "fusion protein" comprises an HA polypeptide operatively linked to a non-HA polypeptide. An "HA polypeptide" refers to a polypeptide having an amino acid sequence corresponding to an HA protein, whereas a "non-HA polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the HA protein, e.g., a protein which is different from the HA protein and which is derived from the same or a different organism. Within the fusion protein, the term "operatively linked" is intended to indicate that the HA polypeptide and the non-HA polypeptide are fused in-frame to each other. The non-HA polypeptide can be fused to the N-terminus or C-terminus of the HA polypeptide. For example, in one embodiment the fusion protein is a GST-HA fusion protein in which the HA sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant HA proteins. In another embodiment, the fusion protein is an HA protein containing a heterologous signal sequence at its N- terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of an HA protein can be increased through use of a heterologous signal sequence. Preferably, an HA chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling- in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al. John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). An HA- encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the HA protein. Homologues of the HA protein can be generated by mutagenesis, e.g., discrete point mutation or truncation of the HA protein. As used herein, the term "homologue" refers to a variant form of the HA protein which acts as an agonist or antagonist of the activity of the HA protein. An agonist of the HA protein can retain substantially the same, or a subset, of the biological activities of the HA protein. An antagonist of the HA protein can inhibit one or more of the activities of the naturally occurring form of the HA protein, by, for example, competitively binding to a downstream or upstream member of a biochemical cascade which includes the HA protein, by binding to a target molecule with which the HA protein interacts, such that no functional interaction is possible, or by binding directly to the HA protein and inhibiting its normal activity. In an alternative embodiment, homologues of the HA protein can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the HA protein for HA protein agonist or antagonist activity. In one embodiment, a variegated library of HA variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of HA variants can be produced by, for example, enzymatically ligating a mixture of synthetic ohgonucleotides into gene sequences such that a degenerate set of potential HA sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of HA sequences therein. There are a variety of methods which can be used to produce libraries of potential HA homologues from a degenerate ohgonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential HA sequences. Methods for synthesizing degenerate ohgonucleotides are known in the art (see, e.g., Narang, S.A. (1983) Tetrahedron 39:3; Itakura et al (1984) Annu. Rev. Biochem. 53:323; Itakura et al (1984) Science 198:1056; Ike et al. (1983) Nucleic Acid Res. 11 :477. In addition, libraries of fragments of the HA protein coding can be used to generate a variegated population of HA fragments for screening and subsequent selection of homologues of an HA protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an HA coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S 1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the HA protein. Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of HA homologues. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify HA homologues (Arkin and Yourvan (1992) PNAS 59:7811-7815; Delgrave et al. (1993) Protein Engineering 6(3):327-331). In another embodiment, cell based assays can be exploited to analyze a variegated HA library, using methods well known in the art. D. Uses and Methods of the Invention The nucleic acid molecules, proteins, protein homologues, fusion proteins, primers, vectors, and host cells described herein can be used in one or more of the following methods: identification of C. glutamicum and related organisms; mapping of genomes of organisms related to C glutamicum; identification and localization of C. glutamicum sequences of interest; evolutionary studies; determination of HA protein regions required for function; modulation of an HA protein activity; modulation of the metabolism of one or more inorganic compounds; modulation of the modification or degradation of one or more aromatic or aliphatic compounds; modulation of cell wall synthesis or rearrangements; modulation of enzyme activity or proteolysis; and modulation of cellular production of a desired compound, such as a fine chemical. The HA nucleic acid molecules of the invention have a variety of uses. First, they may be used to identify an organism as being Corynebacterium glutamicum or a close relative thereof. Also, they may be used to identify the presence of C. glutamicum or a relative thereof in a mixed population of microorganisms. The invention provides the nucleic acid sequences of a number of C. glutamicum genes; by probing the extracted genomic DNA of a culture of a unique or mixed population of microorganisms under stringent conditions with a probe spanning a region of a C. glutamicum gene which is unique to this organism, one can ascertain whether this organism is present. Although Corynebacterium glutamicum itself is nonpathogenic, it is related to pathogenic species, such as Corynebacterium diphtheriae. Corynebacterium diphtheriae is the causative agent of diphtheria, a rapidly developing, acute, febrile infection which involves both local and systemic pathology. In this disease, a local lesion develops in the upper respiratory tract and involves necrotic injury to epithelial cells; the bacilli secrete toxin which is disseminated through this lesion to distal susceptible tissues of the body. Degenerative changes brought about by the inhibition of protein synthesis in these tissues, which include heart, muscle, peripheral nerves, adrenals, kidneys, liver and spleen, result in the systemic pathology of the disease. Diphtheria continues to have high incidence in many parts of the world, including Africa, Asia, Eastern Europe and the independent states of the former Soviet Union. An ongoing epidemic of diphtheria in the latter two regions has resulted in at least 5,000 deaths since 1990. In one embodiment, the invention provides a method of identifying the presence or activity of Cornyebacterium diphtheriae in a subject. This method includes detection of one or more of the nucleic acid or amino acid sequences of the invention (e.g., the sequences set forth in as odd-numbered or even-numbered SEQ ID NOs, respectively, in the Sequence Listing) in a subject, thereby detecting the presence or activity of Corynebacterium diphtheriae in the subject. C. glutamicum and C diphtheriae are related bacteria, and many of the nucleic acid and protein molecules in C. glutamicum are homologous to C. diphtheriae nucleic acid and protein molecules, and can therefore be used to detect C diphtheriae in a subject. The nucleic acid and protein molecules of the invention may also serve as markers for specific regions of the genome. This has utility not only in the mapping of the genome, but also for functional studies of C. glutamicum proteins. For example, to identify the region of the genome to which a particular C. glutamicum DNA-binding protein binds, the C. glutamicum genome could be digested, and the fragments incubated with the DNA-binding protein. Those which bind the protein may be additionally probed with the nucleic acid molecules of the invention, preferably with readily detectable labels; binding of such a nucleic acid molecule to the genome fragment enables the localization of the fragment to the genome map of C. glutamicum, and, when performed multiple times with different enzymes, facilitates a rapid determination of the nucleic acid sequence to which the protein binds. Further, the nucleic acid molecules of the invention may be sufficiently homologous to the sequences of related species such that these nucleic acid molecules may serve as markers for the construction of a genomic map in related bacteria, such as Brevibacterium lactofermentum. The HA nucleic acid molecules of the invention are also useful for evolutionary and protein structural studies. The processes involved in adaptation and the maintenance of homeostasis in which the molecules of the invention participate are utilized by a wide variety of species; by comparing the sequences of the nucleic acid molecules of the present invention to those encoding similar enzymes from other organisms, the evolutionary relatedness of the organisms can be assessed. Similarly, such a comparison permits an assessment of which regions of the sequence are conserved and which are not, which may aid in determining those regions of the protein which are essential for the functioning of the enzyme. This type of determination is of value for protein engineering studies and may give an indication of what the protein can tolerate in terms of mutagenesis without losing function. Manipulation of the HA nucleic acid molecules of the invention may result in the production of HA proteins having functional differences from the wild-type HA proteins. These proteins may be improved in efficiency or activity, may be present in greater numbers in the cell than is usual, or may be decreased in efficiency or activity. The invention provides methods for screening molecules which modulate the activity of an HA protein, either by interacting with the protein itself or a substrate or binding partner of the HA protein, or by modulating the transcription or translation of an HA nucleic acid molecule of the invention. In such methods, a microorganism expressing one or more HA proteins of the invention is contacted with one or more test compounds, and the effect of each test compound on the activity or level of expression of the HA protein is assessed. The modulation of activity or number of HA proteins involved in cell wall biosynthesis or rearrangements may impact the production, yield, and/or efficiency of production of one or more fine chemicals from C. glutamicum cells. For example, by altering the activity of these proteins, it may be possible to modulate the structure or thickness of the cell wall. The cell wall serves in large measure as a protective device against osmotic lysis and external sources of injury; by modifying the cell wall it may be possible to increase the ability of C. glutamicum to withstand the mechanical and shear force stresses encountered by this microorganism during large-scale fermentor culture. Further, each C. glutamicum cell is surrounded by a thick cell wall, and thus, a significant portion of the biomass present in large scale culture consists of cell wall. By increasing the rate at which the cell wall is synthesized or by activating cell wall synthesis (through genetic engineering of the HA cell wall proteins of the invention) it may be possible to improve the growth rate of the microorganism. Similarly, by decreasing the activity or number of proteins involved in the degradation of cell wall or by decreasing the repression of cell wall biosynthesis, an overall increase in cell wall production may be achieved. An increase in the number of viable C. glutamicum cells (as may be accomplished by any of the foregoing described protein alterations) should result in increased numbers of cells producing the desired fine chemical in large-scale fermentor culture, which should permit increased yields or efficiency of production of these compounds from the culture. The modulation of activity or number of C. glutamicum HA proteins that participate in the modification or degradation of aromatic or aliphatic compounds may also have direct or indirect impacts on the production of one or more fine chemicals from these cells. Certain aromatic or aliphatic modification or degradation products are desirable fine chemicals (e.g., organic acids or modified aromatic and aliphatic compounds); thus, by modifying the enzymes which perform these modifications (e.g., hydroxylation, methylation, or isomerization) or degradation reactions, it may be possible to increase the yields of these desired compounds. Similarly, by decreasing the activity or number of proteins involved in pathways which further degrade the modified or breakdown products of the aforementioned reactions it may be possible to improve the yields of these fine chemicals from C. glutamicum cells in culture. These aromatic and aliphatic modification and degradative enzymes are themselves fine chemicals. In purified form, these enzymes may be used to degrade aromatic and aliphatic compounds (e.g., toxic chemicals such as petroleum products), either for the bioremediation of polluted sites, for the engineered decomposition of wastes, or for the large-scale and economically feasible production of desired modified aromatic or aliphatic compounds or their breakdown products, some of which may be conveniently used as carbon or energy sources for other fine chemical-producing compounds in culture (see, e.g., Faber, K. (1995) Biotransformations in Organic Chemistry, Springer: Berlin and references therein; and Roberts, S.M., ed. (1992-1996) Preparative Biotransformations, Wiley: Chichester, and references therein). By genetically altering these proteins such that their regulation by other cellular mechanisms is lessened or abolished, it may be possible to increase the overall number or activity of these proteins, thereby improving not only the yield of these fine chemicals but also the activity of these harvested proteins. The modification of these aromatic and aliphatic modifying and degradation enzymes may also have an indirect effect on the production of one or more fine chemical. Many aromatic and aliphatic compounds (such as those that may be encountered as impurities in culture media or as waste products from cellular metabolism) are toxic to cells; by modifying and/or degrading these compounds such that they may be readily removed or destroyed, cellular viability should be increased. Further, these enzymes may modify or degrade these compounds in such a manner that the resulting products may enter the normal carbon metabolism pathways of the cell, thus rendering the cell able to use these compounds as alternate carbon or energy sources. In large-scale culture situations, when there may be limiting amounts of optimal carbon sources, these enzymes provide a method by which cells may continue to grow and divide using aromatic or aliphatic compounds as nutrients. In either case, the resulting increase in the number of C. glutamicum cells in the culture producing the desired fine chemical should in turn result in increased yields or efficiency of production of the fine chemical(s). Modifications in activity or number of HA proteins involved in the metabolism of inorganic compounds may also directly or indirectly affect the production of one or more fine chemicals from C. glutamicum or related bacterial cultures. For example, many desirable fine chemicals, such as nucleic acids, amino acids, cofactors and vitamins (e.g., thiamine, biotin, and lipoic acid) cannot be synthesized without inorganic molecules such as phosphorous, nitrate, sulfate, and iron. The inorganic metabolism proteins of the invention permit the cell to obtain these molecules from a variety of inorganic compounds and to divert them into various fine chemical biosynthetic pathways. Therefore, by increasing the activity or number of enzymes involved in the metabolism of these inorganic compounds, it may be possible to increase the supply of these possibly limiting inorganic molecules, thereby directly increasing the production or efficiency of production of various fine chemicals from C glutamicum cells containing such altered proteins. Modification of the activity or number of inorganic metabolism enzymes of the invention may also render C. glutamicum able to better utilize limited inorganic compound supplies, or to utilize nonoptimal inorganic compounds to synthesize amino acids, vitamins, cofactors, or nucleic acids, all of which are necessary for continued growth and replication of the cell. By improving the viability of these cells in large-scale culture, the number of C. glutamicum cells producing one or more fine chemicals in the culture may also be increased, in turn increasing the yields or efficiency of production of one or more fine chemicals. C. glutamicum enzymes for general processes are themselves desirable fine chemicals. The specific properties of enzymes (i.e., regio- and stereospecificity, among others) make them useful catalysts for chemical reactions in vitro. Either whole C glutamicum cells may be incubated with an appropriate substrate such that the desired product is produced by enzymes in the cell, or the desired enzymes may be overproduced and purified from C. glutamicum cultures (or those of a related bacterium) and subsequently utilized in in vitro reactions in an industrial setting (either in solution or immobilized on a suitable immobile phase). In either situation, the enzyme can either be a natural C. glutamicum protein, or it may be mutagenized to have an altered activity; typical industrial uses for such enzymes include as catalysts in the chemical industry (e.g. , for synthetic organic chemistry) as food additives, as feed components, for fruit processing, for leather preparation, in detergents, in analysis and medicine, and in the textile industry (see, e.g.,Yamada, H. (1993) "Microbial reactions for the production of useful organic compounds," Chimica 47: 5-10; Roberts, S.M. (1998) Preparative biotransformations: the employment of enzymes and whole-cells in synthetic chemistry," J. Chem. Soc. Perkin Trans. 1 : 157-169; Zaks, A. and Dodds, D.R. (1997) "Application of biocatalysis and biotransformations to the synthesis of pharmaceuticals," DDT 2: 513-531 ; Roberts, S.M. and Williamson, N.M. (1997) "The use of enzymes for the preparation of biologically active natural products and analogues in optically active form," Curr. Organ. Chemistry 1 : 1-20; Faber, K. (1995) Biotransformations in Organic Chemistry, Springer: Berlin; Roberts, S.M., ed. (1992- 96) Preparative Biotransformations, Wiley: Chichester; Cheetham, P.S.J. (1995) "The applications of enzymes in industry" in : Handbook of Enzyme Biotechnology, 3 rd ed., Wiseman, A., ed., Elis: Horwood, p. 419-552; and Ullmann's Encyclopedia of Industrial Chemistry (1987), vol. A9, Enzymes, p. 390-457). Thus, by increasing the activity or number of these enzymes, it may be possible to also increase the ability of the cell to convert supplied substrates to desired products, or to overproduce these enzymes for increased yields in large-scale culture. Further, by mutagenizing these proteins it may be possible to remove feedback inhibition or other repressive cellular regulatory controls such that greater numbers of these enzymes may be produced and activated by the cell, thereby leading to greater yields, production, or efficiency of production of these fine chemical proteins from large-scale cultures. Further, manipulation of these enzymes may alter the activity of one or more C. glutamicum metabolic pathways, such as those for the biosynthesis or secretion of one or more fine chemicals. Mutagenesis of the proteolytic enzymes of the invention such that they are altered in activity or number may also directly or indirectly affect the yield, production, and/or efficiency of production of one or more fine chemicals from C. glutamicum. For example, by increasing the activity or number of these proteins, it may be possible to increase the ability of the bacterium to survive in large-scale culture, due to an increased ability of the cell to rapidly degrade proteins misfolded in response to the high temperatures, nonoptimal pH, and other stresses encountered during fermentor culture. Increased numbers of cells in these cultures may result in increased yields or efficiency of production of one or more desired fine chemicals, due to the relatively larger number of cells producing these compounds in the culture. Also, C. glutamicum cells possess multiple cell-surface proteases which serve to break down external nutrients into molecules which may be more readily incorporated by the cells as carbon/energy sources or nutrients of other kinds. An increase in activity or number of these enzymes may improve this turnover and increase the levels of available nutrients, thereby improving cell growth or production. Thus, modifications of the proteases of the invention may indirectly impact C. glutamicum fine chemical production. A more direct impact on fine chemical production in response to the modification of one or more of the proteases of the invention may occur when these proteases are involved in the production or degradation of a desired fine chemical. By decreasing the activity of a protease which degrades a fine chemical or a protein involved in the synthesis of a fine chemical it may be possible to increase the levels of that fine chemical (due to the decreased degradation or increased synthesis of the compound). Similarly, by increasing the activity of a protease which degrades a compound to result in a fine chemical or a protein involved in the degradation of a fine chemical, a similar result should be achieved: increased levels of the desired fine chemical from C. glutamicum cells containing these engineered proteins. The aforementioned mutagenesis strategies for HA proteins to result in increased yields of a fine chemical from C glutamicum are not meant to be limiting; variations on these strategies will be readily apparent to one of ordinary skill in the art. Using such strategies, and incorporating the mechanisms disclosed herein, the nucleic acid and protein molecules of the invention may be utilized to generate C. glutamicum or related strains of bacteria expressing mutated HA nucleic acid and protein molecules such that the yield, production, and/or efficiency of production of a desired compound is improved. This desired compound may be any product produced by C. glutamicum, which includes the final products of biosynthesis pathways and intermediates of naturally-occurring metabolic pathways, as well as molecules which do not naturally occur in the metabolism of C glutamicum, but which are produced by a C glutamicum strain of the invention. This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patent applications, patents, published patent applications, Tables, and the sequence listing cited throughout this application are hereby incorporated by reference. Table 1: Genes in the Application Nucleic Acid Ammo Acid Identification Code Contig NT Start NT Stop Function SEQ ID NO SEQ ID NO RXA02548 GR00727 3 293 SULFATE ADENYLATE TRANSFERASE SUBUNIT 2 (EC 2 7 7 4) RXN00249 W0057 36825 35869 ADENYLYLSULFATE KINASE (EC 2 7 1 25) F RXA00249 GR00037 8837 7884 ADENYLYLSULFATE KINASE (EC 2 7 1 25) RXA01073 GR00300 1274 2104 NH(3)-DEPENDENT NAD(+) SYNTHETASE (EC 6 3 5 1) Urease Nucleic Acid Ammo Acid Identification Code Contig NT Start NT Stop Function SEQ ID NO SEQ ID NO 9 10 RXN02913 W0020 8998 8513 UREASE BETA SUBUNIT (EC 3515) 11 12 F RXA02264 GR00655 123 4 UREASE ALPHA SUBUNIT (EC 3515) 13 14 RXN02274 W0020 8509 6800 UREASE ALPHA SUBUNIT (EC 3515) 15 16 F RXA02274 GR00656 3 1604 UREASE ALPHA SUBUNIT (EC 3515) 17 18 RXA02265 GR00655 452 153 UREASE GAMMA SUBUNIT (EC 3515) 19 20 RXA02278 GR00656 3420 4268 UREASE OPERON URED PROTEIN 21 22 RXA02275 GR00656 1632 2102 UREASE ACCESSORY PROTEIN UREE 23 24 RXA02276 GR00656 2105 2782 UREASE ACCESSORY PROTEIN UREF 25 26 RXA02277 GR00656 2802 3416 UREASE ACCESSORY PROTEIN UREG 27 28 RXA02603 GR00742 7742 8737 4-HYDROXYBENZOATE OCTAPRENYLTRANSFERASE (EC 251 -) 29 30 RXA01385 GR00406 5320 3440 PHENOL 2 MONOOXYGENASE (EC 114137) Proteolysis Nucleic Acid Ammo Acid Identification Code Contig NT Start NT Stop Function SEQ ID NO SEQ ID NO 31 32 RXN00675 W0005 33258 34049 METHIONINE AMINOPEPTIDASE (EC 3 4 11 18) 33 34 F RXA00675 GR00178 2 484 METHIONINE AMINOPEPTIDASE (EC 3 4 1 1 18) 35 36 RXA01609 GR00449 2740 3612 METHIONINE AMINOPEPTIDASE (EC 3 4 1 1 18) 37 38 RXA01358 GR00393 5337 6857 ATP-DEPENDENT PROTEASE LA (EC 3 4 21 53) 39 40 RXA01458 GR00420 3225 2176 ATP-DEPENDENT PROTEASE LA (EC 3 4 21 53) 41 42 RXA01654 GR00459 986 1981 (AL022121 ) putative alkaline serine protease [Mycobactenum tuberculosis] 43 44 RXN01868 W0127 9980 11905 ZINC METALLOPROTEASE (EC 3 4 24 -) 45 46 F RXA01868 GR00534 1640 30 ZINC METALLOPROTEASE (EC 3 4 24 -) 47 48 F RXA01869 GR00534 1954 1652 ZINC METALLOPROTEASE (EC 3 4 24 -) 49 50 RXN03028 W0008 41156 43930 ATP-DEPENDENT CLP PROTEASE ATP-BINDING SUBUNIT CLPA 51 52 F RXA02470 GR00715 2216 3196 ATP-DEPENDENT CLP PROTEASE ATP-BINDING SUBUNIT CLPA Table 1 (continued) Nucleic Acid Ammo Acid Identification Code Contig NT Start NT Stop Function SEQ ID NO SEQ ID NO 53 54 F RXA02471 GR00715 3159 4991 ATP-DEPENDENT CLP PROTEASE ATP-BINDING SUBUNIT CLPA 55 56 RXA02630 GR00748 2654 1332 (AL021999) putative serine protease [Mycobactenum tuberculosis] 57 58 RXA02834 GR00823 3 497 ATPases with chaperone activity, ATP-dependent protease subunit 59 60 RXA00112 GR00016 3687 2497 PROBABLE PERIPLASMIC SERINE PROTEASE DO-LIKE PRECURSOR 61 62 RXA00566 GR00152 742 137 ATP-DEPENDENT CLP PROTEASE PROTEOLYTIC SUBUNIT (EC 34 21 92) 63 64 RXA00567 GR00152 1388 798 ATP-DEPENDENT CLP PROTEASE PROTEOLYTIC SUBUNIT (EC 3 4 21 92) 65 66 RXN03094 W0057 1794 43 CLPB PROTEIN 67 68 F RXA01668 GR00464 2205 3920 CLPB PROTEIN 69 70 RXN01120 W0182 5678 4401 ATP-DEPENDENT CLP PROTEASE ATP-BINDING SUBUNIT CLPX 71 72 F RXA01120 GR00310 2349 1072 ATP-DEPENDENT CLP PROTEASE ATP-BINDING SUBUNIT CLPX 73 74 RXA00744 GR00202 10722 9781 Peπplasmic serine proteases 75 76 RXA00844 GR00228 3620 4453 Hypothetical Secretory Serine Protease (EC 3 4 21 -) 77 78 RXA01151 GR00324 862 5 ATP-dependent Zn proteases 79 80 RXA02317 GR00665 9664 9053 PEPTIDASE E (EC 3 4 - -) 81 82 RXA02644 GR00751 767 117 XAA-PRO DIPEPTIDASE (EC 3 4 13 9) 83 84 RXN02820 W0131 4799 6109 GAMMA-GLUTAMYLTRANSPEPTIDASE (EC 2 3 2 2) 85 86 F RXA02820 GR00801 1 507 GAMMA-GLUTAMYLTRANSPEPTIDASE (EC 2 3 2 2) 87 88 F RXA02000 GR00589 3430 3933 GAMMA-GLUTAMYLTRANSPEPTIDASE (EC 2 3 2 2) 89 90 RXN03178 W0334 921 121 PENICILLIN-BINDING PROTEIN 5* PRECURSOR (D-ALANYL-D-ALANINE CARBOXYPEPTIDASE) (EC 34 16 4) 91 92 F RXA02859 GR10005 846 121 PENICILLIN-BINDING PROTEIN 5 * PRECURSOR (D-ALANYL-D-ALANINE CARBOXYPEPTIDASE) (EC 3 4 16 4) 93 94 RXA00137 GR00022 738 1826 XAA-PRO AMINOPEPTIDASE (EC 3 4 11 9) 95 96 RXN00499 W0086 8158 9438 PROLINE IMINOPEPTIDASE (EC 3 4 11 5) o 97 98 F RXA00499 GR00125 3 959 PROLINE IMINOPEPTIDASE 99 100 RXN00877 W0099 2221 3885 PEPTIDYL-DIPEPTIDASE DCP (EC 3 4 15 5) 101 102 F RXA00877 GR00242 3 1067 PEPTIDYL-DIPEPTIDASE DCP (EC 3 4 15 5) 103 104 RXN01014 W0209 13328 10728 AMINOPEPTIDASE N (EC 3 4 11 2) 105 106 F RXA01014 GR00289 3 1580 AMINOPEPTIDASE N (EC 3 4 11 2) 107 108 F RXA01018 GR00290 2289 3152 AMINOPEPTIDASE N (EC 3 4 11 2) 109 110 RXA01147 GR00323 1353 94 VACUOLAR AMINOPEPTIDASE I PRECURSOR (EC 3 4 11 1) 111 112 RXA01161 GR00329 1253 117 XAA-PRO AMINOPEPTIDASE (EC 3 4 11 9) 113 114 RXN01181 W0065 1 957 AMINOPEPTIDASE A I (EC 34 11 1) 115 116 F RXA01181 GR00337 1 957 AMINOPEPTIDASE 117 118 RXN01277 W0009 32155 34158 PROLYL ENDOPEPTIDASE (EC 3 4 21 26) 119 120 F RXA01277 GR00368 1738 50 PROLYL ENDOPEPTIDASE (EC 3 4 21 26) 121 122 RXA01914 GR00548 125 550 AMINOPEPTIDASE 123 124 RXA02048 GR00624 207 1580 AMINOPEPTIDASE N (EC 3 4 11 2) 125 126 RXN00621 W0135 5853 5071 PROTEASE II (EC 3 4 21 83) 127 128 F RXA00621 GR00163 4075 4857 PTRB penplasmic protease 129 130 RXN00622 W0135 5150 3735 PROTEASE II (EC 3 4 21 83) 131 132 F RXA00622 GR00163 4778 6193 PTRB penplasmic protease 133 134 RXN00982 W0149 7596 6091 (L42758) protemase [Streptomyces hvidans] 135 136 F RXA00977 GR00275 1647 2660 (L42758) protemase [Streptomyces hvidans] 137 138 F RXA00982 GR00276 5194 4949 (L42758) protemase [Streptomyces hvidans] 139 140 RXA00152 GR00023 7175 5880 HFLC PROTEIN (EC 3 4 - -) 141 142 RXA02558 GR00731 4939 3965 HFLC PROTEIN (EC 3 4 - -) Table 1 (continued) Nucleic Acid Ammo Acid Identification Code Contig NT Start NT Stop Function SEQ ID NO SEQ ID NO 143 144 RXA00500 GR00125 969 1643 O-SIALOGLYCOPROTEIN ENDOPEPTIDASE (EC 3 4 24 57) 145 146 RXA00501 GR00125 1643 2149 O-SIALOGLYCOPROTEIN ENDOPEPTIDASE (EC 3 4 24 57) 147 148 RXA00502 GR00125 2156 3187 O-SIALOGLYCOPROTEIN ENDOPEPTIDASE (EC 3 4 24 57) Enzymes in general Nucleic Acid Ammo Acid Identification Code Contig NT Start NT Stop Function SEQ ID NO SEQ ID NO 149 150 RXN02589 W0098 16346 17110 Hypothetical Methyltransferase (EC 2 1 1 -) 151 152 F RXA02589 GR00741 13804 13040 Predicted S-adenosylmethiomne-dependent methyltransferase 153 154 RXA00226 GR00032 26836 26012 SAM-dependent methyltransferases 155 156 RXN01885 W0184 2004 2804 Hypothetical Methyltransferase (EC 2 1 1 -) 157 158 F RXA01885 GR00539 1589 2389 SAM-dependent methyltransferases 159 160 RXA02592 GR00741 18477 17707 SAM-dependent methyltransferases 161 162 RXN01795 W0093 722 1318 MODIFIKATION METHYLASE (EC 2 1 1 73) 163 164 F RXA01795 GR00507 706 1140 MODIFICATION METHYLASE (EC 2 1 1 73) 165 166 RXA01214 GR00351 1640 3130 LACCASE 1 PRECURSOR (EC 1 10 3 2) 167 168 RXA01250 GR00364 592 5 LACCASE 1 PRECURSOR (EC 1 10 3 2) 169 170 RXA02477 GR00715 10581 11201 CARBONIC ANHYDRASE (EC 4 2 1 1 ) 171 172 RXN00833 GR00225 374 6 THIOL PEROXIDASE (EC 1 11 1 -) 173 174 F RXA00833 GR00225 374 6 THIOL PEROXIDASE (EC 1 11 1 -) 175 176 RXA01224 GR00354 4186 5208 2-NITROPROPANE DIOXYGENASE (EC 1 13 11 32) 177 178 RXA01182 GR00337 1363 971 Hypothetical Oxidoreductase 179 180 RXA02531 GR00726 1226 1936 Hypothetical Oxidoreductase 181 182 RXN00689 W0005 22416 20926 BETAINE-ALDEHYDE DEHYDROGENASE PRECURSOR (EC 1 2 1 8) 183 184 F RXA00689 GR00180 1401 775 BETAINE-ALDEHYDE DEHYDROGENASE PRECURSOR (EC 1 2 1 8) 185 186 RXN03128 W0120 3 857 MORPHINE 6-DEHYDROGENASE (EC 1 1 1 218) 187 188 F RXA02192 GR00643 2 523 MORPHINE 6-DEHYDROGENASE (EC 1 1 1 218) 189 190 RXA02351 GR00679 132 1070 NITRILOTRIACETATE MONOOXYGENASE COMPONENT A (EC 1 14 13 -) 191 192 RXN00905 W0238 8075 8875 N-ACYL-L-AMINO ACID AMIDOHYDROLASE (EC 3 5 1 14) 193 194 F RXA00905 GR00247 2 694 N-ACYL-L-AMINO ACID AMIDOHYDROLASE (EC 3 5 1 14) 195 196 RXA00906 GR00247 630 1133 N-ACYL-L-AMINO ACID AMIDOHYDROLASE (EC 3 5 1 14) 197 198 RXA00907 GR00247 1143 1265 N-ACYL-L-AMINO ACID AMIDOHYDROLASE (EC 3 5 1 14) 199 200 RXA02101 GR00631 3104 1842 N-ACYL-L-AMINO ACID AMIDOHYDROLASE (EC 3 5 1 14) 201 202 RXN02565 W0154 14299 13034 N-ACYL-L-AMINO ACID AMIDOHYDROLASE (EC 3 5 1 14) 203 204 F RXA02565 GR00733 1 342 N-ACYL-L-AMINO ACID AMIDOHYDROLASE (EC 3 5 1 14) 205 206 F RXA02567 GR00734 3 740 N-ACYL-L-AMINO ACID AMIDOHYDROLASE (EC 3 5 1 14) 207 208 RXN03077 W0043 1729 2913 N-ACYL-L-AMINO ACID AMIDOHYDROLASE (EC 3 5 1 14) 209 210 F RXA02855 GR10002 1693 2877 N-ACYL-L-AMINO ACID AMIDOHYDROLASE (EC 3 5 1 14), hippurate hydrolase 211 212 RXA00026 GR00003 3657 5042 Hypothetical Amidohydrolase (EC 3 5 1 -) 213 214 RXA01971 GR00569 963 133 Hypothetical Metal-Dependent Hydrolase 215 216 RXA01802 GR00509 3461 4291 Predicted hydrolases (HAD superfamily) 217 218 RXN00866 W0258 3557 4522 Predicted Zn-dependent hydrolases 219 220 F RXA00866 GR00236 3555 4499 Predicted Zn-dependent hydrolases 221 222 RXA02410 GR00703 792 127 Predicted Zn-dependent hydrolases Table 1 (continued) Nucleic Acid Ammo Acid Identification Code Contig NT Start NT Stop Function SEQ ID NO SEQ ID NO 223 224 RXA00961 GR00267 2 433 SALICYLATE HYDROXYLASE (EC 1 14 13 1 ) 225 226 RXA00111 GR00016 930 1922 SOLUBLE EPOXIDE HYDROLASE (SEH) (EC 3 3 2 3) 227 228 RXA01932 GR00555 6479 5583 ACETYL-HYDROLASE (EC 3 1 1 -) 229 230 RXA02574 GR00739 833 1840 PUTATIVE SECRETED HYDROLASE 231 232 RXN00983 W0231 1796 321 SIALIDASE PRECURSOR (EC 3 2 1 18) 233 234 F RXA00983 GR00278 1200 4 SIALIDASE PRECURSOR (EC 3 2 1 18) 235 236 RXA00984 GR00278 1716 1300 SIALIDASE PRECURSOR (EC 3 2 1 18) 237 238 RXN02513 W0193 737 6 SIALIDASE PRECURSOR (EC 3 2 1 18) 239 240 F RXA02513 GR00722 93 824 SIALIDASE PRECURSOR (EC 3 2 1 18) 241 242 RXA00903 GR00246 637 5 Putative epimerase 243 244 RXA01224 GR00354 4186 5208 2-NITROPROPANE DIOXYGENASE (EC 1 13 11 32) 245 246 RXA01571 GR00438 1360 1959 ALCOHOL DEHYDROGENASE (EC 1 1 1 1) 247 248 RXN02478 W0119 7564 6350 SIALIDASE PRECURSOR (EC 3 2 1 18) 249 250 RXN00343 W0125 1118 6 3-OXOSTEROID 1-DEHYDROGENASE (EC 1 3 99 4) 251 252 RXN01555 W0135 29820 28861 3-OXOSTEROID 1-DEHYDROGENASE (EC 1 3 99 4) 253 254 RXN01166 W0117 18142 16838 EXTRACELLULAR LIPASE PRECURSOR (EC 3 1 1 3) 255 256 RXN02001 W0326 630 1787 N-ACYL-L-AMINO ACID AMIDOHYDROLASE (EC 3 5 1 14) 257 258 RXN03145 W0142 7561 7115 4-OXALOCROTONATE TAUTOMERASE (EC 5 3 2 -) 259 260 RXN01466 W0019 7050 6091 ARYLESTERASE (EC 3 1 1 2) 261 262 RXN01145 W0077 7538 6525 KETOL-ACID REDUCTOISOMERASE (EC 1 1 1 86) 263 264 RXN03088 W0052 3431 3817 Hypothetical Methyltransferase (EC 2 1 1 -) 265 266 RXN02952 W0320 1032 1547 PUTATIVE REDUCTASE 267 268 RXN00513 W0092 1573 653 CARBOXYVINYL-CARBOXYPHOSPHONATE PHOSPHORYLMUTASE (EC 2 7 8 23) 269 270 RXN01152 W0136 1740 907 PROTEIN-L-ISOASPARTATE 0-METHYLTRANSFERASE (EC 2 1 1 77) 271 272 RXN00787 W0321 3736 5637 D-AMINO ACID DEHYDROGENASE LARGE SUBUNIT (EC 1 4 99 1) N-metabolism Nucleic Acid Ammo Acid Identification Code Contig NT Start NT Stop Function SEQ ID NO SEQ ID NO 273 274 RXN01302 W0148 2837 2385 NITRATE REDUCTASE ALPHA CHAIN (EC 1 7 99 4) 275 276 F RXA01302 GR00376 370 5 NITRATE REDUCTASE ALPHA CHAIN (EC 1 7 994) 277 278 RXN01308 W0148 2406 4 NITRATE REDUCTASE ALPHA CHAIN (EC 1 7 99 4) 279 280 F RXA01307 GR00377 686 6 NITRATE REDUCTASE ALPHA CHAIN (EC 1 7 99 4) 281 282 F RXA01308 GR00378 1211 6 NITRATE REDUCTASE ALPHA CHAIN (EC 1 7 99 4) 283 284 RXN01309 W0158 1 801 NITRATE REDUCTASE ALPHA CHAIN (EC 1 7 99 4) 285 286 F RXA01309 GR00379 719 51 NITRATE REDUCTASE ALPHA CHAIN (EC 1 7 99 4) 287 288 RXA02017 GR00610 1731 1048 NITRATE REDUCTASE ALPHA CHAIN (EC 1 7 99 4) 289 290 RXA02018 GR00610 2788 1739 NITRATE REDUCTASE BETA CHAIN (EC 1 7 99 4) 291 292 RXA02016 GR00610 1036 260 NITRATE REDUCTASE GAMMA CHAIN (EC 1 7 99 4) 293 294 RXA00471 GR00119 2997 3686 NITRATE/NITRITE RESPONSE REGULATOR PROTEIN NARL 295 296 RXA00133 GR00021 201 1013 NITRATE/NITRITE RESPONSE REGULATOR PROTEIN NARP 297 298 RXA00650 GR00169 4017 3382 NITRATE/NITRITE RESPONSE REGULATOR PROTEIN NARP Table 1 (continued) Nucleic Acid Ammo Acid Identification Code Contig NT Start NT Stop Function SEQ ID NO SEQ ID NO 299 300 RXA01189 GR00339 2545 1937 NITRATE/NITRITE RESPONSE REGULATOR PROTEIN NARP 301 302 RXA01607 GR00449 123 752 NITRATE/NITRITE RESPONSE REGULATOR PROTEIN NARP 303 304 RXN00470 W0086 27401 28669 NITRATE NITRITE SENSOR PROTEIN NARX (EC 2 7 3 -) 305 306 F RXA00470 GR00119 1752 2951 NITRATE/NITRITE SENSOR PROTEIN NARX (EC 2 7 3 -) 307 308 RXA00756 GR00203 2932 1937 N UTILIZATION SUBSTANCE PROTEIN A 309 310 RXA00139 GR00022 2514 3224 N UTILIZATION SUBSTANCE PROTEIN B 311 312 RXA01303 GR00376 1724 390 NITRITE EXTRUSION PROTEIN 313 314 RXA01412 GR00412 620 417 NITROGEN FIXATION PROTEIN FIXI (PROBABLE E1-E2 TYPE CATION ATPASE) (EC 3 6 1 -) 315 316 RXA00773 GR00205 3208 4350 NITROGEN REGULATION PROTEIN NIFR3 317 318 RXA02746 GR00764 1 267 NITROGEN REGULATORY PROTEIN P-ll 319 320 RXA02745 GR00763 15350 14472 NODULATION ATP-BINDING PROTEIN I 321 322 RXN00820 W0054 19455 19817 NODULATION PROTEIN N 323 324 F RXA00820 GR00221 1007 1369 NODULATION PROTEIN N 325 326 RXA01059 GR00296 8782 9390 OXYGEN-INSENSITIVE NAD(P)H NITROREDUCTASE (EC 1 - - -) 327 328 RXN01386 W0008 39246 38317 NITRILASE REGULATOR 329 330 RXN00073 W0154 2369 687 FERREDOXIN--NITRITE REDUCTASE (EC 1 7 7 1 ) 331 332 RXN03131 W0127 276 4 RHIZOPINE CATABOLISM PROTEIN MOCC 333 334 RXS00153 W0167 4195 4620 NODULATION PROTEIN Urease Nucleic Acid Ammo Acid Identification Code Contig NT Start NT Stop Function SEQ ID NO SEQ ID NO Phosphate and Phosphonate metabolism Nucleic Acid Ammo Acid Identification Code Contig NT Start NT Stop Function SEQ ID NO SEQ ID NO 335 336 RXN01716 W0319 3259 2774 EXOPOLYPHOSPHATASE (EC 3 6 1 11 ) 337 338 RXN02972 W0319 2763 2353 EXOPOLYPHOSPHATASE (EC 36 1 11) 339 340 RXN00663 W0142 10120 11493 PHOH PROTEIN HOMOLOG 341 342 RXN00778 W0103 18126 19250 PHOSPHATE-BINDING PERIPLASMIC PROTEIN PRECURSOR 343 344 RXN00250 W0189 286 1032 DEDA PROTEIN - ALKALINE PHOSPHATASE LIKE PROTEIN Sulfate metabolism Nucleic Acid Ammo Acid Identification Code Contig NT Start NT Stop Function SEQ ID NO SEQ ID NO 345 346 RXA00072 GR00012 446 6 PHOSPHOADENOSINE PHOSPHOSULFATE REDUCTASE (EC 1 8 99 4) 347 348 RXA00793 GR00211 1469 2644 SULFATE STARVATION-INDUCED PROTEIN 6 349 350 RXA01192 GR00342 161 733 SULFATE STARVATION-INDUCED PROTEIN 6 Table 1 (continued) Nucleic Acid Ammo Acid Identification Code Contig NT Start NT Stop Function SEQ ID NO SEQ ID NO 351 352 RXA00715 GR00188 2120 2914 THIOSULFATE SULFURTRANSFERASE (EC 2 8 1 1 ) 353 354 RXA01664 GR00463 1306 485 THIOSULFATE SULFURTRANSFERASE (EC 2 8 1 1) 355 356 RXN02334 W0141 7939 7217 THIOSULFATE SULFURTRANSFERASE (EC 2 8 1 1) 357 358 F RXA02334 GR00672 2 355 THIOSULFATE SULFURTRANSFERASE (EC 2 8 1 1) Fe-Metabolism Nucleic Acid Ammo Acid Identification Code Contig NT Start NT Stop Function SEQ ID NO SEQ ID NO 359 360 RXN01499 W0008 7034 3213 ENTEROBACTIN SYNTHETASE COMPONENT F 361 362 RXN01997 W0084 33308 33793 FERRITIN Mg Metabolism Nucleic Acid Ammo Acid Identification Code Contig NT Start NT Stop Function SEQ ID NO SEQ ID NO 363 364 RXA01848 GR00524 1532 789 MAGNESIUM-CHELATASE SUBUNIT CHLI 365 366 RXN01849 W0139 16415 17515 MAGNESIUM-CHELATASE SUBUNIT CHLI 367 368 F RXA01849 GR00524 2004 1555 MAGNESIUM-CHELATASE SUBUNIT CHLI 369 370 F RXA01691 GR00474 570 4 MAGNESIUM-CHELATASE SUBUNIT CHLI 371 372 RXN00665 W0252 135 635 MG2+/CITRATE COMPLEX SECONDARY TRANSPORTER t Modification and degradation of aromatic compounds Nucleic Acid Ammo Acid Identification Code Contig NT Start NT Stop Function SEQ ID NO SEQ ID NO 373 374 RXN03026 W0007 28635 28901 3-DEHYDROQUINATE DEHYDRATASE (EC 4 2 1 10) 375 376 RXN02908 W0025 8507 8247 O-SUCCINYLBENZOIC ACID-COA LIGASE (EC 6 2 1 26) 377 378 RXN03000 W0235 570 4 SALICYLATE HYDROXYLASE (EC 1 14 13 1) 379 380 RXN03036 W0014 671 6 PROTOCATECHUATE 3,4-DIOXYGENASE BETA CHAIN (EC 1 13 11 3) 381 382 RXN02974 W0229 12631 12437 4-NITROPHENYLPHOSPHATASE (EC 3 1 3 41 ) 383 384 RXN00393 W0025 7241 6348 1 ,4-DIHYDROXY-2-NAPHTHOATE OCTAPRENYLTRANSFERASE (EC 2 5 - -) 385 386 RXN00948 W0107 4266 5384 12-oxophytodιenoate reductase (EC 1 3 1 42) 387 388 RXN01923 W0020 3384 4133 2-HYDROXY-6-OXO-6-PHENYLHEXA-2.4-DIENOATE HYDROLASE (EC 3 7 1 -) 389 390 RXN00398 W0025 14633 13884 2-PYRONE-4.6-DICARBOXYLATE LACTONASE (EC 3 1 1 57) 391 392 RXN02813 W0128 13120 14118 3-CARBOXY-CIS,CIS-MUCONATE CYCLOISOMERASE HOMOLOG (EC 5 5 1 2) 393 394 RXN00136 W0134 13373 14467 3-DEHYDROQUINATE SYNTHASE (EC 4 6 1 3) 395 396 RXN02508 W0007 26733 28586 3-DEHYDROSHIKIMATE DEHYDRATASE (EC 4 2 1 -) 397 398 RXN02839 W0362 3 449 4-HYDROXYBENZOATE OCTAPRENYLTRANSFERASE (EC 2 5 1 -) 399 400 RXN00639 W0128 7858 8712 CATECHOL 1 ,2-DIOXYGENASE (EC 1 13 11 1) 401 402 RXN02530 W0057 5469 6125 DIMETHYLANILINE MONOOXYGENASE (N-OXIDE FORMING) 1 (EC 1 14 13 8) 403 404 RXN00434 W0112 12078 11212 QUINONE OXIDOREDUCTASE (EC 1 6 5 5) 405 406 RXN01619 W0050 24649 23675 QUINONE OXIDOREDUCTASE (EC 1 6 5 5) 407 408 RXN01842 W0234 1615 2532 QUINONE OXIDOREDUCTASE (EC 1 6 5 5) Table 1 (continued) Nucleic Acid Ammo Acid Identification Code Contig NT Start NT Stop Function SEQ ID NO SEQ ID NO 409 410 RXN00641 W0128 7440 5950 TOLUATE 1 ,2-DIOXYGENASE ALPHA SUBUNIT (EC 1 14 12 -) 411 412 RXN01993 W0182 16 1143 VANILLATE DEMETHYLASE (EC 1 14 - -) 413 414 RXN00658 W0083 15705 16397 PHENOL 2-MONOOXYGENASE (EC 1 14 13 7) 415 416 RXN00178 W0174 14670 15554 hydroxyqu ol 1 ,2-dιoxygenase (EC 1 13 11 37) 417 418 RXN01461 W0128 12414 13025 PROTOCATECHUATE 3,4-DIOXYGENASE ALPHA CHAIN (EC 1 13 11 3) 419 420 RXN01653 W0321 12867 11407 DIBENZOTHIOPHENE DESULFURIZATION ENZYME A 421 422 RXN02053 W0009 39448 40026 DRGA PROTEIN 423 424 RXN00177 W0174 13589 14656 MALEYLACETATE REDUCTASE (EC 1 3 1 32) 425 426 RXC00963 W0249 1816 2652 PROTEIN involved in degradation of aromatic compounds Modification and degradation of aliphatic compounds Nucleic Acid Ammo Acid Identification Code Contig NT Start NT Stop Function - SEQ ID NO SEQ ID NO 427 428 RXN00299 W0176 43379 42402 ALKANAL MONOOXYGENASE ALPHA CHAIN (EC 1 14 14 3) 429 430 F RXA00299 GR00048 7376 6633 ALKANAL MONOOXYGENASE ALPHA CHAIN (EC 1 14 14 3) 431 432 RXA00332 GR00057 16086 15385 ALKANAL MONOOXYGENASE ALPHA CHAIN (EC 1 14 14 3) 433 434 RXA01838 GR00519 2 820 ALKANAL MONOOXYGENASE ALPHA CHAIN (EC 1 14 14 3) 435 436 RXA02643 GR00750 1603 560 ALKANAL MONOOXYGENASE ALPHA CHAIN (EC 1 14 14 3) 437 438 RXA01933 GR00555 6590 7192 2-HALOALKANOIC ACID DEHALOGENASE I (EC 3 8 1 2) 439 440 RXA02351 GR00679 132 1070 NITRILOTRIACETATE MONOOXYGENASE COMPONENT A (EC 1 14 13 -) TABLE 3 : Corynebacterium and Brevibacterium Strains Which May be Used in the Practice of the Invention ATCC: American Type Culture Collection, Rockville, MD, USA FERM: Fermentation Research Institute, Chiba, Japan NRRL: ARS Culture Collection, Northern Regional Research Laboratory, Peoria, IL, USA CECT: Coleccion Espanola de Cultivos Tipo, Valencia, Spain NCIMB: National Collection of Industrial and Marine Bacteria Ltd., Aberdeen, UK CBS: Centraalbureau voor Schimmelcultures, Baarn, NL NCTC: National Collection of Type Cultures, London, UK DSMZ: Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany For reference see Sugawara, H. et al. (1993) World directory of collections of cultures of microorganisms: Bacteria, fungi and yeasts (4 th edn), World federation for culture collections world data center on microorganisms, Saimata, Japen. Table 4: Alignment Results ID # length Genbank Hit Length Accession Name of Genbank Hit Source of Genbank Hit % homology Date of (NT) (GAP) Deposit rxa00026 1509 GB_RO MMHC310M6 158405 AF 109906 Mus musculus MHC class III region RD gene, partial eds, Bf, C2, Mus musculus 38,003 10-DEC-1998 G9A, NG22, G9, HSP70, HSP70, HSC70t, and smRNP genes, complete eds, G7A gene, partial eds, and unknown genes GB_HTG2 AC007029 119007 AC007029 Homo sapiens clone DJ0855F16, *** SEQUENCING IN PROGR! Homo sapiens 37,943 7-Apr-99 ** * , 1 unordered pieces GBJHTG2 AC007029 119007 AC007029 Homo sapiens clone DJ0855F16, * * * SEQUENCING IN PROGRESS H Hoommoo ssaappiieennss 37,943 7-Apr-99 ** * , 1 unordered pieces rxa00072 rxaOOm 1116 GB_BA1 SAUSIGA 2748 M94370 Stigmatella aurantiaca sigma factor (sigA) gene, complete eds Stigmatella aurantiaca 40,435 16-Aug-94 GB_BA1 SC5B8 28500 AL022374 Streptomyces coelicolor cosmid 5B8 Streptomyces coelicolor 40,090 22-Apr-98 GB_BA2 AE001767 9086 AE001767 Thermotoga maπtima section 79 of 136 of the complete genome Thermotoga maπtima 35,091 2-Jun-99 rxa00112 1314 GB_EST35 AU075536 418 AU075536 AU075536 Rice shoot Oryza sativa cDNA clone S0028_2Z, mRNA Oryza sativa 39,423 7-Jul-99 sequence GB_GSS9 AQ157585 647 AQ157585 nbxb0009B16r CUGI Rice BAC Library Oryza sativa genomic clone Oryza sativa 40,867 12-Sep-98 nbxb0009B16r, genomic survey sequence GB_GSS14 AQ510314 542 AQ510314 nbxb0095O05f CUGI Rice BAC Library Oryza sativa genomic clone Oryza sativa 39,372 04-MAY-1999 nbxb0095O05f, genomic survey sequence rxa00133 936 GB_BA1 SC2G5 38404 AL035478 Streptomyces coelicolor cosmid 2G5 Streptomyces coelicolor 41 ,170 11-Jun-99 j GB_EST7 W64291 515 W64291 md98h12 r1 Soares mouse embryo NbME13 5 14 5 Mus musculus Mus musculus 35,306 10-Jun-96 cDNA clone IMAGE 386087 5' similar to gb L26528 Mus musculus Rab11b mRNA, complete eds (MOUSE),, mRNA sequence GB PR3 AC005624 39594 AC005624 Homo sapiens chromosome 19, cosmid R30017, complete sequence Homo sapiens 39,054 6-Sep-98 rxa00137 1212 GB_BA2 AF124600 4115 AF124600 Corynebacterium glutamicum choπsmate synthase (aroC), shikimate Corynebacterium 99,867 04-MAY-199 kinase (aroK), and 3-dehydroquιnate synthase (aroB) genes, glutamicum complete eds, and putative cytoplasmic peptidase (pepQ) gene, partial eds GB_BA1 MTCY159 33818 Z83863 Mycobacterium tuberculosis H37Rv complete genome, segment Mycobacterium 40,959 17-Jun-98 111/162 tuberculosis GB_BA1 MT3DEHQ 3437 X59509 M tuberculosis, genes for 3-dehydroquιnate synthase and 3- Mycobacterium 52,583 30-Jun-93 dehydroqumase tuberculosis rxa00139 834 GB_BA1 BLELONP 738 X99289 B lactofermentum gene encoding elongation factor P Corynebacterium 100,000 1-Nov-97 glutamicum GB PL1 SPAC24C9 38666 Z98601 S po be chromosome I cosmid c24C9 Schizosaccharomyces 35,230 24-Feb-99 pombe GB HTG1 CEY102A5 1110000 Z99711 Caenorhabditis elegans chromosome V clone Y102A5, *** Caenorhabditis elegans 37,775 Z99711 SEQUENCING IN PROGRESS * * *, in unordered pieces Table 4 (continued) rxa00152 1419 GB_BA1 MTCY277 38300 Z79701 Mycobacterium tuberculosis H37Rv complete genome, segment Mycobactenum 5 588,,550000 1 177--JJuunn--9988 65/162 tuberculosis GB_BA1 MSGY456 37316 AD000001 Mycobacterium tuberculosis sequence from clone y456 Mycobacterium 38,913 03-DEC-1996 tuberculosis GB_BA2 AF002133 15437 AF002133 Mycobacterium avium strain GIR10 transcnptional regulator (mav81) Mycobacterium avium 64,009 26-MAR-199 gene, partial eds, aconitase (acn), invasm 1 (ιnv1), mvasin 2 (ιnv2), transcnptional regulator (moxR), ketoacyl-reductase (fabG), enoyl- reductase (inhA) and ferrochelatase (mav272) genes, complete eds rxa00226 948 GB_PR3 AC005756 43299 AC005756 Homo sapiens chromosome 19, fosmid 39347, complete sequence Homo sapiens 36,209 02-OCT-1998 GB_GSS5 AQ818463 413 AQ818463 HS_5250_A2_B08_SP6E RPCI-11 Human Male BAC Library Homo Homo sapiens 37,288 26-Aug-99 sapiens genomic clone Plate=826 Col=16 Row=C, genomic survey sequence GB_GSS5 AQ782337 832 AQ782337 HS_3184_B1_H12_T7C CIT Approved Human Genomic Sperm Homo sapiens 35,917 2-Aug-99 Library D Homo sapiens genomic clone Plate=3184 Col=23 Row=P, genomic survey sequence rxa00249 980 GB_BA2 AF035608 3614 AF035608 Pseudomonas aeruginosa ATP sulfurylase small subunit (cysD) and Pseudomonas aeruginosa 50,205 1-Jun-98 ATP sulfurylase GTP-binding subunit APS kinase (cysN) genes, complete eds GB_BA1 AB017641 17101 AB017641 Micromonospora gnseorubida gene for polyketide synthase, complete Micromonospora 40,266 2-Apr-99 eds gnseorubida GB_BA2 AF002133 15437 AF002133 Mycobacterium avium strain GIR10 transcnptional regulator (mav81) Mycobacterium avium 38,429 26-MAR-199 gene, partial eds, aconitase (acn), invasm 1 (ιnv1), invasm 2 (ιnv2), transcnptional regulator (moxR), ketoacyl-reductase (fabG), enoyl- reductase (inhA) and ferrochelatase (mav272) genes, complete eds rxa00299 1101 GB_BA2 CORCSLYS 2821 M89931 Corynebacterium glutamicum beta C-S lyase (aecD) and branched- Corynebacterium 100,000 4-Jun-98 chain ammo acid uptake carrier (brnQ) genes, complete eds, and glutamicum hypothetical protein Yhbw (yhbw) gene, partial eds GB_BA1 CGECTP 2719 AJ001436 Corynebacterium glutamicum ectP gene Corynebacterium 41 ,143 20-Nov-98 glutamicum GB_BA2 AF181035 5922 AF181035 Rhodobacter sphaeroides glycogen utilization operon, complete Rhodobacter sphaeroides 36,701 7-Sep-99 sequence rxa00332 825 GB_BA1 CGTHRC 3120 X56037 Corynebacterium glutamicum thrC gene for threonine synthase (EC Corynebacterium 37,730 17-Jun-97 42 992) glutamicum GB_PAT I09078 3146 I09078 Sequence 4 from Patent WO 8809819 Unknown 38,700 02-DEC-199 GB_PR3 HSJ333B15 73666 AL109954 Human DNA sequence from clone 333B15 on chromosome 20, Homo sapiens 37,203 23-NOV-99 complete sequence rxa00470 1392 GB PL2 DCPCNAM 865 X62977 D carota mRNA for proliferating cell nuclear antigen (PCNA) Daucus carota 37,914 30-Sep-99 Table 4 (continued) GB_PL2 AC006267 101644 AC006267 Arabidopsis thaliana BAC F9M13 from chromosome IV near 21 5 cM, Arabidopsis thaliana 36,158 27-Apr-99 complete sequence GB_BA1 TT10SARNA 721 Y15063 Thermus thermophilus 10Sa RNA gene Thermus thermophilus 39,494 18-Aug-98 rxa00471 813 GB_BA1 SERERYAA 11219 M63676 S erythraea first ORF of eryA gene, complete eds Saccharopolyspora 38,781 26-Apr-93 erythraea GB_PAT AR049367 11219 AR049367 Sequence 1 from patent US 5824513 Unknown 38,781 29-Sep-99 GB_BA1 SERERYAA 11219 M63676 S erythraea first ORF of eryA gene, complete eds Saccharopolyspora 38,205 26-Apr-93 erythraea rxa00499 1404 GB_PR4 AC007206 42732 AC007206 Homo sapiens chromosome 19, cosmid R27370, complete sequence Homo sapiens 34,982 4-Apr-99 GB EST26 Al 344735 462 AI344735 qp05a10 x1 NCI_CGAP_Kιd5 Homo sapiens cDNA clone Homo sapiens 42,675 2-Feb-99 IMAGE 1917114 3' similar to gb M15800 T-LYMPHOCYTE MATURATION-ASSOCIATED PROTEIN (HUMAN),, mRNA sequence GB_PR4 AC006479 161837 AC006479 Homo sapiens clone DJ1051J04, complete sequence Homo sapiens 38,462 11-NOV-99 rxa00500 798 GB_PR4 AC006111 190825 AC006111 Homo sapiens chromosome 16 clone RPC1-11_461A8, complete Homo sapiens 40,736 3-Jul-99 sequence GB HTG2 AF128834 196589 AF128834 Homo sapiens chromosome 8 clone BAC 57G24 map 8p12, *** Homo sapiens 34,062 28-Feb-99 SEQUENCING IN PROGRESS *** , in unordered pieces GB_HTG2 AF128834 196589 AF128834 Homo sapiens chromosome 8 clone BAC 57G24 map 8p12, *** Homo sapiens 34,062 28-Feb-99 SEQUENCING IN PROGRESS * **, in unordered pieces rxa00501 630 GB_BA1 D86429 5925 D86429 Saccharopolyspora rectivirgula gene for beta-galactosidase, Saccharopolyspora 53,871 09-DEC-199 complete eds rectivirgula GB_HTG1 HS1099D15 1301 AL035456 Homo sapiens chromosome 20 clone RP5-1099D15, *** Homo sapiens 33,546 23-Nov-99 SEQUENCING IN PROGRESS *", in unordered pieces GB_HTG1 HS1099D15 1301 AL035456 Homo sapiens chromosome 20 clone RP5-1099D15, *** Homo sapiens 33,546 23-Nov-99 SEQUENCING IN PROGRESS ** * , in unordered pieces rxa00502 1155 GB_BA2 U00015 42325 U00015 Mycobacteπum leprae cosmid B1620 Mycobacterium leprae 34,783 01-MAR-199 GB_BA1 U00020 36947 U00020 Mycobacterium leprae cosmid B229 Mycobacterium leprae 34,900 01-MAR-199 GBJHTG1 HS179I15 210672 Z84464 Homo sapiens chromosome 13 clone 179115, *** SEQUENCING IN Homo sapiens 32,898 22-Jan-97 PROGRESS ***, in unordered pieces rxa00566 729 GB_BA1 MTV008 63033 AL021246 Mycobacterium tuberculosis H37Rv complete genome, segment Mycobacteπum 37,011 17-Jun-98 108/162 tuberculosis GB BA2 AF071885 2188 AF0 1885 Streptomyces coelicolor ATP-dependent Clp protease proteolytic Streptomyces coelicolor 62,963 29-Jun-99 subunit 1 (clpP1) and ATP-dependent Clp protease proteolytic subunit 2 (clpP2) genes, complete eds, and ATP-dependent Clp protease ATP-binding subunit Clpx (clpX) gene, partial eds GB BA2 AF013216 15742 AF013216 Myxocoecus xanthus Dog (dog), isocitrate lyase (id), Mis (mis), Ufo Myxocoecus xanthus 54,683 28-Jan-98 (ufo), fumarate hydratase (fhy), and proteosome major subunit (clpP) genes, complete eds, and acyl-CoA oxidase (aco) gene, partial eds Table 4 (continued) rxa00567 714 GB_BA1 MTV008 63033 AL021246 Mycobacterium tuberculosis H37Rv complete genome, segment Mycobacterium 42,090 17-Jun-98 108/162 tuberculosis GB_BA1 CGBPHI16 962 Y12472 C glutamicum DNA, attachment site bacteπophage Phι-16 Corynebacterium 40,000 05-MAR-1999 glutamicum GB_BA1 ECOCLPPA 1236 J05534 Escherichia coli ATP-dependent dp protease proteolytic component Escherichia coli 52,119 26-Apr-93 (clpP) gene, complete eds rxa00621 906 GB_EST1 D36491 360 D36491 CELK033GYF Yuji Kohara unpublished cDNA Caenorhabditis Caenorhabditis elegans 40,390 8-Aug-94 elegans cDNA clone yk33g11 5', mRNA sequence GBJN2 CELC16A3 34968 U41534 Caenorhabditis elegans cosmid C16A3 Caenorhabditis elegans 35,477 18-MAY-1999 GB HTG3 AC009311 160198 AC009311 Homo sapiens clone NH0311 L03, *** SEQUENCING IN PROGRESS Homo sapiens 38,636 13-Aug-99 ***, 3 unordered pieces rxa00622 1539 GB_BA1 AB004795 3039 AABB000044779955 Pseudomonas sp gene for dipeptidyl aminopeptidase, complete eds Pseudomonas sp 54,721 5-Feb-99 GB_BA1 MBOPII 2392 D38405 Moraxella lacunata gene for protease II, complete eds Moraxella lacunata 50,167 8-Feb-99 GBJN2 AF078916 2960 AF078916 Trypanosoma brucei brucei oligopeptidase B (opb) gene, complete Trypanosoma brucei 48,076 08-OCT-1999 eds brucei rxa00650 759 GB_BA2 AF161327 2021 AF161327 Corynebacterium diphtheriae histidine kinase ChrS (chrS) and Corynebacterium 51 ,319 9-Sep-99 response regulator ChrA (chrA) genes, complete eds diphtheriae GB_PL2 ATAC006533 99188 AC006533 Arabidopsis thaliana chromosome II BAC F20M17 genomic Arabidopsis thaliana 38,051 26-MAY-1999 sequence, complete sequence GB_PL2 ATAC006533 99188 AC006533 Arabidopsis thaliana chromosome II BAC F20M17 genomic Arabidopsis thaliana 35,403 26-MAY-1999 sequence, complete sequence rxa00675 915 GB_BA1 SC3C8 33095 AL023861 Streptomyces coelicolor cosmid 3C8 Streptomyces coelicolor 36,836 15-Jan-99 GB_PR3 AC005736 215441 AC005736 Homo sapiens chromosome 16, BAC clone 462G18 (LANL), Homo sapiens 42,027 01-OCT-1998 complete sequence GBJN2 AC005719 188357 AC005719 Drosophila melanogaster, chromosome 2L, region 38A5-38B4, BAC Drosophila melanogaster 35,531 27-OCT-1999 clone BACR48M05, complete sequence rxa00689 1614 GB_PAT E07294 2975 E07294 genomic DNA encoding dehydrogenase of Bacillus Bacillus 45,677 29-Sep-97 stearothermophilus stearothermophilus GB_BA1 BACALDHT 1975 D 13846 B stearothermophilus aldhT gene for aldehyde dehydrogenase, Bacillus 45,677 20-Feb-99 complete eds I stearothermophilus GB BA2 PPU96338 5276 U96338 Pseudomonas putida NCIMB 9866 plasmid pRA4000 p-cresol Pseudomonas putida 44,317 13-MAY-1999 degradative pathway genes, p-hydroxybenzaldehyde dehydrogenase (pchA), p-cresol methylhydroxylase, cytochrome subunit precursor (pchC), unknown (pchX) and p-cresol methylhydroxylase, flavoprotein subunit (pchF) genes, complete eds rxa00715 918 GB_EST30 AI647104 218 AI647104 vn15c01 y1 Stratagene mouse heart (#937316) Mus musculus cDNA Mus musculus 58,511 29-Apr-99 clone IMAGE 1021248 5', mRNA sequence GB EST17 AA636159 447 AA636159 vn15c01 r1 Stratagene mouse heart (#937316) Mus musculus cDNA Mus musculus 41 ,195 22-OCT-1997 clone IMAGE 1021248 5', mRNA sequence Table 4 (continued) GB EST10 AA184468 583 AA184468 mt52h05 r1 Stratagene mouse embryonic carcinoma (#937317) Mus Mus musculus 40,426 12-Feb-97 musculus cDNA clone IMAGE 633561 5' similar to gb D10918 Mouse mRNA for ubiquitin like protein, partial sequence (MOUSE),, mRNA sequence rxa00744 1065 GB_HTG3 AC009855 167592 AC009855 Homo sapiens clone 1_C_5, * * * SEQUENCING IN PROGRESS " * , Homo sapiens 36,673 3-Sep-99 13 unordered pieces GB_HTG3 AC009855 167592 AC009855 Homo sapiens clone 1_C_5, * ** SEQUENCING IN PROGRESS * ", Homo sapiens 36,673 3-Sep-99 13 unordered pieces GB_PR4 AC005082 169739 AC005082 Homo sapiens clone RG271 G13, complete sequence Homo sapiens 39,557 8-Sep-99 rxa00756 1119 GB_BA1 MLCB596 38426 AL035472 Mycobacteπum leprae cosmid B596 Mycobacterium leprae 54,562 27-Aug-99 GB_GSS12 AQ368028 652 AQ368028 toxbOOOI N11 r CUGI Tomato BAC Library Lycopersicon esculentum Lycopersicon esculentum 42,657 5-Feb-99 genomic clone toxbOOOI N11 r, genomic survey sequence GB_HTG3 AC008067 151242 AC008067 Homo sapiens clone NH0303I04, * ** SEQUENCING IN PROGRESS Homo sapiens 37,239 8-Sep-99 ***, 2 unordered pieces rxa00773 1266 GB_BA1 MLU15182 40123 U15182 Mycobacterium leprae cosmid B2266 Mycobacterium leprae 36,616 09-MAR-1995 GB_BA1 MSGL611CS 37769 L78822 Mycobacterium leprae cosmid L611 DNA sequence Mycobacterium leprae 35,714 15-Jun-96 GB_GSS14 AQ578181 728 AQ578181 nbxb0083P08r CUGI Rice BAC Library Oryza sativa genomic clone Oryza sativa 39,246 2-Jun-99 nbxb0083P08r, genomic survey sequence rxa00793 1299 GB_GSS5 AQ769737 519 AQ769737 HS_3160_A2_G04_T7C CIT Approved Human Genomic Sperm Homo sapiens 37,765 28-Jul-99 Library D Homo sapiens genomic clone Plate=3160 Col=8 Row=M, genomic survey sequence GB_BA1 RTU08434 2400 U08434 Rhizobium tπfolii orotate phosphoribosyltransferase (pyrE) and Rhizobium tπfolii 40,700 16-Apr-97 fructokinase (frk) genes, complete eds GB_EST31 F33810 243 F33810 HSPD27491 HM3 Homo sapiens cDNA clone S3000041 E12, mRNA Homo sapiens 41 ,564 13-MAY-1999 sequence rxa00820 486 GB_PR4 AC005868 96180 AC005868 Homo sapiens 12q24 2 PAC RPCI5-944M2 (Roswell Park Cancer Homo sapiens 32,298 27-Feb-99 Institute Human PAC Library) complete sequence GB_EST8 AA000903 396 AA000903 mg38b04 r1 Soares mouse embryo NbME13 5 14 5 Mus musculus Mus musculus 42,045 18-Jul-96 cDNA clone IMAGE 426031 5', mRNA sequence GB_EST25 AI317789 696 AI317789 uj20g09 y1 Sugano mouse embryo mewa Mus musculus cDNA clone Mus musculus 38,557 17-DEC-1998 IMAGE 1920544 5' similar to WP C13C4 5 CE08130 SUGAR TRANSPORTER ,, mRNA sequence rxa00833 618 GB_PH BPH6589 41489 AJ006589 Bacteπophage phι-C31 complete genome Bacteπophage phι-C31 41 ,806 29-Apr-99 GB_HTG2 AC006887 215801 AC006887 Caenorhabditis elegans clone Y59H11 , *** SEQUENCING IN Caenorhabditis elegans 35,798 24-Feb-99 PROGRESS ** * , 3 unordered pieces GB_HTG2 AC006887 215801 AC006887 Caenorhabditis elegans clone Y59H11 , *** SEQUENCING IN Caenorhabditis elegans 35,798 24-Feb-99 PROGRESS ***, 3 unordered pieces rxa00844 957 GB_GSS15 AQ605195 459 AQ605195 HS_2136_B1_C12_T7C CIT Approved Human Genomic Sperm Homo sapiens 38,074 10-Jun-99 Library D Homo sapiens genomic clone Plate=2136 Col=23 Row=F, genomic survey sequence Table 4 (continued) GB_HTG1 CNS00M8S 214599 AL079302 Homo sapiens chromosome 14 clone R-1089B7, * SEQUENCING Homo sapiens 38,120 15-OCT-1999 IN PROGRESS ** *, in ordered pieces GB_HTG1 CNS00M8S 214599 AL079302 Homo sapiens chromosome 14 clone R-1089B7, * SEQUENCING Homo sapiens 38,120 15-OCT-1999 IN PROGRESS ***, in ordered pieces rxa00866 1066 GB_BA1 CGORF4GEN 2398 X95649 C glutamicum ORF4 gene Corynebacterium 99,273 10-MAR-1998 glutamicum GB_BA1 BLDAPAB 3572 Z21502 B lactofermentum dapA and dapB genes for dihydrodipicolinate Corynebacterium 99,301 16-Aug-93 synthase and dihydrodipicolinate reductase glutamicum GB_PAT E14517 1411 E14517 DNA encoding Brevibacterium dihydrodipicolinic acid reductase Corynebacterium 99,659 28-Jul-99 glutamicum rxa00877 1788 GB_PAT I92050 567 I92050 Sequence 17 from patent US 5726299 Unknown 62,787 01-DEC-1998 GB_PAT I78760 567 I78760 Sequence 16 from patent US 5693781 Unknown 62,787 3-Apr-98 GB BA2 AE000426 10240 AE000426 Escherichia coli K-12 MG1655 section 316 of 400 of the complete Escherichia coli 36,456 12-NOV-98 genome rxa00903 733 GB BA2 AE001598 11136 AE001598 Chlamydia pneumoniae section 14 of 103 of the complete genome Chlamydophila 32,782 08-MAR-1999 pneumoniae GB_PL2 AF079370 2897 AF079370 Kluyveromyces lactis invertase (INV1) gene, complete eds Kluyveromyces lactis 35,849 4-Aug-99 GB_BA2 AE001598 11136 AE001598 Chlamydia pneumoniae section 14 of 103 of the complete genome Chlamydophila 40,138 08-MAR-1999 pneumoniae rxa00905 924 GB_PR2 HSQ15C24 73192 AJ239325 Homo sapiens chromosome 21 from cosmids LLNLc116 1C16 and Homo sapiens 35,076 28-Sep-99 LLNLcl 16 15C24 map 21q22 3 region D21S171-LA161 , complete sequence GB_GSS4 AQ691923 446 AQ691923 HS_5400_B2_G04_SP6E RPCI-11 Human Male BAC Library Homo Homo sapiens 33,500 6-Jul-99 sapiens genomic clone Plate=976 Col=8 Row=N, genomic survey sequence GB_EST37 AI967802 479 AI967802 Ljιrnpest12-930-d6 Ljirnp Lambda HybπZap two-hybrid library Lotus Lotus japonicus 41 ,127 24-Aug-99 japonicus cDNA clone LP930-12-d6 5' similar to 60S ribosomal protein L7A, mRNA sequence rxa00906 627 GB_PAT I78750 588 I78750 Sequence 6 from patent US 5693781 Unknown 97,071 3-Apr-98 GB_PAT I92039 588 I92039 Sequence 6 from patent US 5726299 Unknown 97,071 01-DEC-1998 GB_PR3 HS929C8 139190 AL020994 Human DNA sequence from clone 929C8 on chromosome 22q12 1- Homo sapiens 39,016 23-Nov-99 12 3 Contains CA repeat, GSS, STS, complete sequence rxa00907 246 GB_PAT I78750 588 I78750 Sequence 6 from patent US 5693781 Unknown 97,561 3-Apr-98 GB_PAT I92039 588 I92039 Sequence 6 from patent US 5726299 Unknown 97,561 01-DEC-1998 GB_PAT I78750 588 I78750 Sequence 6 from patent US 5693781 Unknown 37,222 3-Apr-98 rxa00961 455 GB_BA1 AB032799 9077 AB032799 Chromobacteπum violaceum violacein biosynthetic gene cluster (vio Chromobactenum 39,868 02-OCT-1999 A, vio B, vio C, vio D), complete eds violaceum GB_BA2 AF172851 10094 AF172851 Chromobacteπum violaceum violacein biosynthetic gene cluster, Chromobactenum 42,760 30-Aug-99 complete sequence violaceum GB BA1 AB032799 9077 AB032799 Chromobacteπum violaceum violacein biosynthetic gene cluster (vio Chromobactenum 39,551 02-OCT-1999 A, vio B, vio C, vio D), complete eds violaceum Table 4 (continued) rxa00982 1629 GB_BA1 BLARGS 2501 Z21501 B lactofermentum argS and lysA genes for arginyl-tRNA synthetase Corynebacterium 39,003 28-DEC-199 and diaminopimelate decarboxylase (partial) glutamicum GB_BA1 CGXLYSA 2344 X54740 Corynebacterium glutamicum argS-lysA operon gene for the Corynebacterium 41 ,435 30-Jun-93 upstream region of the arginyl-tRNA synthetase and diaminopimelate glutamicum decarboxylase (EC 4 1 1 20) GB_PAT E14508 3579 E14508 DNA encoding Brevibacterium diaminopimelic acid decarboxylase Corynebacterium 40,566 28-Jul-99 and arginyl-tRNA synthase glutamicum rxa00983 1599 GB_HTG2 AC008152 24000 AC008152 Leishmania major chromosome 35 clone L7936 strain Fπedlin, *** Leishmania major 38,658 28-Jul-99 SEQUENCING IN PROGRESS ***, 4 unordered pieces GB_HTG2 AC008152 24000 AC008152 Leishmania major chromosome 35 clone L7936 strain Fπedlin, * ** Leishmania major 38,658 28-Jul-99 SEQUENCING IN PROGRESS *", 4 unordered pieces GBJHTG3 AC008648 87249 AC008648 Homo sapiens chromosome 5 clone CIT978SKB 86E14, *** Homo sapiens 36,102 3-Aug-99 SEQUENCING IN PROGRESS ***, 22 unordered pieces rxa00984 440 GB_BA1 MVINED 3098 D01045 Micromonospora viπdifaciens DNA for nedR protein and Micromonospora 59,226 2-Feb-99 neuramimdase, complete eds viπdifaciens GB_PAT E02375 1881 E02375 Neuramimdase gene Micromonospora 59,226 29-Sep-97 viπdifaciens GB_PR4 HUAC004513 101311 AC004513 Homo sapiens Chromosome 16 BAC clone CIT987SK-A-926E7, Homo sapiens 41 ,204 23-Nov-99 complete sequence rxa01014 2724 GB_BA1 MTV008 63033 AL021246 Mycobacterium tuberculosis H37Rv complete genome, segment Mycobacterium 56,167 17-Jun-98 108/162 tuberculosis GB_BA1 STMAMPEPN 2849 L23172 Streptomyces hvidans aminopeptidase N gene, complete eds Streptomyces hvidans 57,067 18-MAY-199 GB_BA1 SC7H2 42655 AL109732 Streptomyces coelicolor cosmid 7H2 Streptomyces coelicolor 37,551 2-Aug-99 A3(2) rxa01059 732 GB_HTG3 AC008154 172241 AC008154 Homo sapiens chromosome 7, * ** SEQUENCING IN PROGRESS Homo sapiens 39,499 8-Sep-99 ***, 26 unordered pieces GB_HTG3 AC008154 172241 AC008154 Homo sapiens chromosome 7, *" SEQUENCING IN PROGRESS Homo sapiens 39,499 8-Sep-99 ***, 26 unordered pieces GB_EST32 AI756574 299 AI756574 ea02f10 y1 Eimeπa M5-6 Merozoite stage Eimeπa tenella cDNA 5', Eimeπa tenella 37,793 23-Jun-99 mRNA sequence rxa01073 954 GB_BA1 BACOUTB 1004 M15811 Bacillus subti s outB gene encoding a sporulation protein, complete Bacillus subtilis 53,723 26-Apr-93 eds GB_PR4 AC007938 167237 AC007938 Homo sapiens clone UWGC djs201 from 7q31 , complete sequence Homo sapiens 34,322 1-Jul-99 GB_PL2 ATAC006282 92577 AC006282 Arabidopsis thaliana chromosome II BAC F13K3 genomic sequence, Arabidopsis thaliana 36,181 13-MAR-199 complete sequence rxa01120 1401 GB_BA1 MTV008 63033 AL021246 Mycobacteπum tuberculosis H37Rv complete genome, segment Mycobacteπum 36,715 17-Jun-98 108/162 tuberculosis GB_BA1 CAJ10321 6710 AJ010321 Caulobacter crescentus partial tig gene and clpP, cicA, clpX, Ion Caulobacter crescentus 63,311 01-OCT-199 genes Table 4 (continued) GB BA2 AF150957 4440 AF150957 Azospiπllum brasilense trigger factor (tig), heat-shock protein ClpP Azospiπllum brasilense 60,613 7-Jun-99 (clpP), and heat-shock protein ClpX (clpX) genes, complete eds, and Lon protease (Ion) gene, partial eds rxa01147 1383 GB PR3 HS408N23 97916 Z98048 Human DNA sequence from PAC 408N23 on chromosome 22q13 Homo sapiens 34,567 23-Nov-99 Contains HIP, HSC70-INTERACTING PROTEIN (PROGESTERONE RECEPTOR-ASSOCIATED P48 PROTEIN), ESTs and STS GB_BA2 AE001227 26849 AE001227 Treponema palhdum section 43 of 87 of the complete genome Treponema pal dum 37,564 16-Jul-98 GB_PR3 HS408N23 97916 Z98048 Human DNA sequence from PAC 408N23 on chromosome 22q13 Homo sapiens 34,911 23-Nov-99 Contains HIP, HSC70-INTERACTING PROTEIN (PROGESTERONE RECEPTOR-ASSOCIATED P48 PROTEIN), ESTs and STS rxa01151 958 GB_BA1 MTCY261 27322 Z97559 Mycobacterium tuberculosis H37Rv complete genome, segment Mycobacterium 38,789 17-Jun-98 95/162 tuberculosis GB_HTG4 AC009849 114993 AC009849 Drosophila melanogaster chromosome 2 clone BACR07H08 (D864) Drosophila melanogaster 39,213 25-OCT-1999 RPCI-9807 H 8 map 31 B-31C strain y, en bw sp, *** SEQUENCING IN PROGRESS "*, 55 unordered pieces GB_HTG4 AC009849 114993 AC009849 Drosophila melanogaster chromosome 2 clone BACR07H08 (D864) Drosophila melanogaster 39,213 25-OCT-1999 RPCI-98 07 H 8 map 31 B-31C strain y, en bw sp, " * SEQUENCING IN PROGRESS " * , 55 unordered pieces rxa01161 1260 GB_BA2 AF176799 2943 AF176799 Lactobacillus pentosus PepQ (pepQ) and catabohte control protein A Lactobacillus pentosus 37,043 5-Sep-99 (ccpA) genes, complete eds GB_BA2 AF012084 3082 AF012084 Lactobacillus helveticus pro dase (pepQ) gene, complete eds Lactobacillus helveticus 46,796 l-Jul-98 GB_EST32 AI728955 611 AI728955 BNLGHι12114 Six-day Cotton fiber Gossypium hirsutum cDNA 5' Gossypium hirsutum 37,647 11-Jun-99 similar to (AC004481) putative permease [Arabidopsis thaliana], mRNA sequence rxa01181 980 GB_BA1 MLCB22 40281 Z98741 Mycobacterium leprae cosmid B22 Mycobacterium leprae 61 ,570 22-Aug-97 GB_BA1 MTCY190 34150 Z70283 Mycobacterium tuberculosis H37Rv complete genome, segment Mycobacterium 60,434 17-Jun-98 98/162 tuberculosis GB_BA1 SC5F7 40024 AL096872 Streptomyces coelicolor cosmid 5F7 Streptomyces coelicolor 57,011 22-Jul-99 A3(2) rxa01182 516 GB_HTG1 CEY116A8. .2110000 Z98858 Caenorhabditis elegans chromosome IV clone Y116A8, *** Caenorhabditis elegans 34,843 26-Oct-99 SEQUENCING IN PROGRESS ***, in unordered pieces GB_HTG1 CEY116A8. .2110000 Z98858 Caenorhabditis elegans chromosome IV clone Y116A8, *** Caenorhabditis elegans 34,843 26-Oct-99 SEQUENCING IN PROGRESS ***, in unordered pieces GBJN1 CEY116A8C 260341 AL117204 Caenorhabditis elegans cosmid Y116A8C, complete sequence Caenorhabditis elegans 34,843 19-NOV-99 rxa01189 732 GB BA1 D90915 130001 D90915 Synechocystis sp PCC6803 complete genome, 17/27, 2137259- Synechocystis sp 36,538 7-Feb-99 2267259 GB BA1 D90915 130001 D90915 Synechocystis sp PCC6803 complete genome, 17/27, 2137259- Synechocystis sp 34,512 7-Feb-99 2267259 Table 4 (continued) GB_HTG3 AC010515 41038 AC010515 Homo sapiens chromosome 19 clone LLNL-R_249H9, * * * Homo sapiens 33,564 15-Sep-99 SEQUENCING IN PROGRESS ***, 31 unordered pieces rxa01192 681 GBJO CFP180RRC 5425 X87224 Cams famihaπs mRNA for πbosome receptor, p180 Cams famihans 41 ,229 22-Jan-99 GB_OM CFP180RRC 5425 X87224 Cams familiaπs mRNA for πbosome receptor, p180 Cams famihans 38,187 22-Jan-99 rxa01214 1614 GBJN1 CEY47D3A 199814 AL117202 Caenorhabditis elegans cosmid Y47D3A, complete sequence Caenorhabditis elegans 36,604 19-Nov-99 GB_PR4 AC006039 176257 AC006039 Homo sapiens clone NH0319F03, complete sequence Homo sapiens 34,984 05-MAY-199 GB_PR4 AC006039 176257 AC006039 Homo sapiens clone NH0319F03, complete sequence Homo sapiens 35,951 05-MAY-199 rxa01224 1146 GB_EST22 AI070047 479 AI070047 UI-R-C1-ln-f-08-0-UI s1 UI-R-C1 Rattus norvegicus cDNA clone Ul-R- ■ Rattus norvegicus 36,975 5-Jul-99 C1-ln-f-08-0-UI 3', mRNA sequence GB_RO S75965 625 S75965 THP=Tamm-Horsfall protein {promoter} [rats, Genomic, 625 nt] Rattus sp 34,400 27-Jul-95 GB_EST5 H96951 459 H96951 yu01g03 r1 Soares_pιneal_gland_N3HPG Homo sapiens cDNA Homo sapiens 32,969 11-DEC-199 clone IMAGE 232564 5', mRNA sequence rxa01250 588 GB_PL1 NEULCCB 2656 M 18334 N crassa (strain TS) laccase gene, complete eds Neurospora crassa 44,330 03-MAY-199 GB_OV MTRACOMPL 16714 Y16884 Rhea ameπcana complete mitochondnal genome Mitochondrion Rhea 35,094 19-Jul-99 amencana GB_OV AF090339 16704 AF090339 Rhea ameπcana mitochondrion, complete genome Mitochondrion Rhea 35,094 27-MAY-199 amencana rxa01277 2127 GB_PL2 AF111709 52684 AF111709 Oryza sativa subsp indica Retrosat 1 retrotransposon and Ty3- Oryza sativa subsp indica 37,410 26-Apr-99 Gypsy type Retrosat 2 retrotransposon, complete sequences, and unknown genes GBJN1 CELZC250 34372 AF003383 Caenorhabditis elegans cosmid ZC250 Caenorhabditis elegans 35,506 14-MAY-199 GB_EST1 Z14808 331 Z14808 CEL5E4 Chris Martin sorted cDNA library Caenorhabditis elegans Caenorhabditis elegans 36,890 19-Jun-97 cDNA clone cm5e4 5', mRNA sequence rxa01302 576 GB_BA1 MTCI65 34331 Z95584 Mycobacterium tuberculosis H37Rv complete genome, segment Mycobacterium 59,298 17-Jun-98 50/162 tuberculosis GB_BA1 MSGY348 40056 AD000020 Mycobacterium tuberculosis sequence from clone y348 Mycobacterium 59,227 10-DEC-199 tuberculosis GB_BA1 SC5C7 41906 AL031515 Streptomyces coelicolor cosmid 5C7 Streptomyces coelicolor 39,261 7-Sep-98 rxa01303 1458 GB_BA1 TTAJ5043 837 AJ225043 Thermus thermophilus partial narK gene Thermus thermophilus 55,245 18-Jun-98 GB_PL2 AC010675 84723 AC010675 Arabidopsis thaliana chromosome I BAC T17F3 genomic sequence, Arabidopsis thaliana 37,058 H-Nov-99 complete sequence GB_GSS9 AQ170862 518 AQ 170862 HS_3165_B2_F03_T7 CIT Approved Human Genomic Sperm Library Homo sapiens 38,610 17-OCT- 99 D Homo sapiens genomic clone Plate=3165 Col=6 Row=L, genomic survey sequence rxa01308 2503 GB_BA1 D90757 17621 D90757 Escherichia coli genomic DNA (27 3 - 27 7 mm) Escherichia coli 55,445 7-Feb-99 GB_BA1 D90787 15942 D90787 E coli genomic DNA, Kohara clone #276(33 0-33 3 mm ) Escherichia coli 36,815 29-MAY-199 GB_BA1 D90758 13860 D90758 Escherichia coli genomic DNA (27 6 - 27 9 mm) Escherichia coli 54,942 7-Feb-99 rxa01309 824 GB BA1 SCJ12 35302 AL109989 Streptomyces coelicolor cosmid J12 Streptomyces coelicolor 62,423 24-Aug-99 A3(2) GB_BA1 BSNARYWI 12450 Z49884 B subtihs nar[G,H,l,J,K], ywι[C,D,E] and argS genes Bacillus subtihs 57,447 24-Jun-98 Table 4 (continued) GB_BA1 BSUB0020 212150 Z99123 Bacillus subtihs complete genome (section 20 of 21 ) from 3798401 to Bacillus subtihs 37,129 26-Nov-97 4010550 rxa01358 1644 GB_GSS11 AQ260413 453 AQ260413 CITBI-E1-2510B12 TF CITBI-E1 Homo sapiens genomic clone Homo sapiens 41 ,531 24-OCT-1998 2510B12, genomic survey sequence GB EST20 AA840582 326 AA840582 vw77h07 r1 Stratagene mouse heart (#937316) Mus musculus cDNA Mus musculus 42,901 27-Feb-98 clone IMAGE 1261021 5' similar to gb J04181 Mouse A-X actin mRNA, complete eds (MOUSE),, mRNA sequence GB_PAT A39944 3836 A39944 Sequence 1 from Patent W09421807 unidentified 38,764 05-MAR-1997 rxa01385 2004 GB BA1 FVBPENTA 2519 M98557 Flavobacteπum sp pentachlorophenol 4-monooxygenase gene, Flavobacteπum sp 40,855 26-Apr-93 complete mRNA GB_PAT 119994 2516 119994 Sequence 2 from patent US 5512478 Unknown 40,855 07-OCT-1996 GB BA2 AF059680 2410 AF059680 Sphingomonas sp UG30 pentachlorophenol 4-monooxygenase Sphingomonas sp UG30 42,993 27-Apr-99 (pcpB) gene, complete eds, and pentachlorophenol 4- monooxygenase reductase (pcpD) gene, partial eds rxa01412 327 GB_GSS12 AQ332469 459 AQ332469 HS_5003_A1_H08_SP6E RPCI11 Human Male BAC Library Homo Homo sapiens 38,208 06-MAR-1999 sapiens genomic clone Plate=579 Col=15 Row=0, genomic survey sequence GB_EST27 AA998532 453 AA998532 UI-R-CO-ιc-d-11-0-UI s1 UI-R-C0 Rattus norvegicus cDNA clone Ul- Rattus norvegicus 39,336 09-MAR-1999 R-C0-ιc-d-11-0-UI 3', mRNA sequence GB_HTG1 HSA342D11 178183 AL121748 Homo sapiens chromosome 10 clone RP11-342D11 , ** * Homo sapiens 40,550 23-Nov-99 SEQUENCING IN PROGRESS ***, in unordered pieces rxa01458 1173 GB_BA2 AE000745 15085 AE000745 Aquifex aeohcus section 77 of 109 of the complete genome Aquifex aeohcus 37,694 25-MAR-1998 GB BA2 AE000745 15085 AE000745 Aquifex aeohcus section 77 of 109 of the complete genome Aquifex aeohcus 35,567 25-MAR-1998 rxa01571 723 GB_BA1 AB011413 12070 AB011413 Streptomyces griseus genes for Orf2, Orf3, Orf4, Orf5, AfsA, Orfβ, Streptomyces griseus 57,500 7-Aug-98 partial and complete eds GB_BA1 AB011413 12070 AB011413 Streptomyces griseus genes for Orf2, Orf3, Orf4, Orf5, AfsA, Orf8, Streptomyces griseus 35,655 7-Aug-98 partial and complete eds rxa01607 753 GB_PR4 AC005005 133893 AC005005 Homo sapiens PAC clone DJ412A9 from 22, complete sequence Homo sapiens 38,399 02-MAR-1999 GB_HTG3 AC008257 109187 AC008257 Drosophila melanogaster chromosome 2 clone BACR08A11 (D916) Drosophila melanogaster 33,741 08-OCT-1999 RPCI-98 08 A 11 map 42A-42A strain y, en bw sp, *** SEQUENCING IN PROGRESS * ** , 93 unordered pieces GB_HTG3 AC008257 109187 AC008257 Drosophila melanogaster chromosome 2 clone BACR08A11 (D916) Drosophila melanogaster 33,741 08-OCT-1999 RPCI-98 08 A 11 map 42A-42A strain y, en bw sp, * " SEQUENCING IN PROGRESS * * *, 93 unordered pieces rxa01609 996 GB_BA1 MTV003 13246 AL008883 Mycobacterium tuberculosis H37Rv complete genome, segment Mycobacterium 39,369 17-Jun-98 125/162 tuberculosis GB_BA1 MSGB1529CS 36985 L78824 Mycobacterium leprae cosmid B1529 DNA sequence Mycobacterium leprae 60,624 15-Jun-96 GB BA1 AB024601 14807 AB024601 Pseudomonas aeruginosa dapD gene for tetrahydrodipico nate N- Pseudomonas aeruginosa 41 ,603 12-MAR-1999 succinyletransferase, complete eds, strain PA01 Table 4 (continued) rxa01654 1119 GB_GSS4 AQ704352 532 AQ704352 HS_2147_A2_H04_MR CIT Approved Human Genomic Sperm Homo sapiens 37,838 7-Jul-99 Library D Homo sapiens genomic clone Plate=2147 Col=8 Row=0, genomic survey sequence GB_RO MMAE000663 250611 AE000663 Mus musculus TCR beta locus from bases 1 to 250611 (section 1 of Mus musculus 35,799 4-Sep-97 3) of the complete sequence GB_EST23 AH 58428 511 AH 58428 ud24f12 r1 Soares 2NbMT Mus musculus cDNA clone Mus musculus 41 ,337 30-Sep-98 IMAGE 1446863 5', mRNA sequence rxa01664 945 GB OV AF026198 63155 AF026198 Fugu rubnpes neural cell adhesion molecule L1 homolog (L1-CAM) Fugu rubnpes 35,187 02-MAY-1998 gene, complete eds, putative protein 1 (PUT1) gene, partial eds, mitosis-specific chromosome segregation protein SMC1 homolog (SMC1 ) gene, complete eds, and calcium channel alpha-1 subunit homolog (CCA1 ) and putative protein 2 (PUT2) genes, partial eds, complete sequence GB_PR3 AC004466 122186 AC004466 Homo sapiens 12q13 1 PAC RPCI5-1057I20 (Roswell Park Cancer Homo sapiens 37,382 17-Sep-98 Institute Human PAC library) complete sequence GB_PR3 AC004466 122186 AC004466 Homo sapiens 12q13 1 PAC RPCI5-1057I20 (Roswell Park Cancer Homo sapiens 37,325 17-Sep-98 Institute Human PAC library) complete sequence rxa01795 720 GB_BA2 CGU13922 4412 U13922 Corynebacterium glutamicum putative type II 5-cytosoιne Corynebacterium 99,444 3-Feb-98 methyltransferase (cgllM) and putative type II restriction glutamicum endonuclease (cgllR) and putative type I or type III restriction endonuclease (clgllR) genes, complete eds GB_BA1 S86113 1044 S86113 ORF 1 [Neisseπa gonorrhoeae, Genomic, 1044 nt] Neisseπa gonorrhoeae 58,320 07-MAY-1993 GB_PAT I22080 850 I22080 Sequence 1 from patent US 5525717 Unknown 57,722 07-OCT-1996 rxa01802 954 GB_BA2 AE001519 14062 AE001519 Hehcobacter pylori, strain J99 section 80 of 132 of the complete Hehcobacter pylori J99 33,510 20-Jan-99 genome GB_GSS5 AQ774071 552 AQ774071 HS_2269_B1_C10_T7C CIT Approved Human Genomic Sperm Homo sapiens 37,967 29-Jul-99 Library D Homo sapiens genomic clone Plate=2269 Col=19 Row=F, genomic survey sequence GB_PR4 AC007459 40907 AC007459 Homo sapiens chromosome 16 clone 306C6, complete sequence Homo sapiens 39,140 04-MAY-1999 rxa01838 842 GB_BA1 SCE15 26440 AL049707 Streptomyces coelicolor cosmid E15 Streptomyces coelicolor 36,297 22-Apr-99 GB_HTG3 AC009545 165042 AC009545 Homo sapiens chromosome 11 clone 131_J_04 map 11 , *** Homo sapiens 37,651 01-OCT-1999 SEQUENCING IN PROGRESS *** , 8 unordered pieces G B_HTG3 AC009545 165042 AC009545 Homo sapiens chromosome 11 clone 131_J_04 map 11 , *** Homo sapiens 37,651 01-OCT-1999 SEQUENCING IN PROGRESS ***, 8 unordered pieces rxa01848 867 GB_BA1 MTCY24A1 20270 Z95207 Mycobacterium tuberculosis H37Rv complete genome, segment Mycobacterium 38,270 17-Jun-98 124/162 tuberculosis GB_EST21 C89252 587 C89252 C89252 Mouse early blastocyst cDNA Mus musculus cDNA clone Mus musculus 37,219 28-MAY-1998 01 B00061JC08, mRNA sequence GB EST14 AA423340 457 AA423340 ve39d04 r1 Soares mouse mammary gland NbMMG Mus musculus Mus musculus 38,377 16-OCT-1997 cDNA clone IMAGE 820519 5', mRNA sequence Table 4 (continued) rxa01849 1224 GB_BA1 MTCY24A1 20270 Z95207 Mycobactenum tuberculosis H37Rv complete genome, segment Mycobacterium 39,950 17-Jun-98 124/162 tuberculosis GB_BA2 RCPHSYNG 45959 Z11165 R capsulatus complete photosynthesis gene cluster Rhodobacter capsulatus 37,344 2-Sep-99 GB_BA1 RSP010302 40707 AJ010302 Rhodobacter sphaeroides photosynthetic gene cluster Rhodobacter sphaeroides 40,898 27-Aug-99 rxa01868 2049 GB_BA1 MTV033 21620 AL021928 Mycobacterium tuberculosis H37Rv complete genome, segment Mycobacteπum 38,679 17-Jun-98 11/162 tuberculosis GB_BA1 MLCL622 42498 Z95398 Mycobacterium leprae cosmid L622 Mycobacterium leprae 38,911 24-Jun-97 GB_BA1 MSGB983CS 36788 L78828 Mycobacterium leprae cosmid B983 DNA sequence Mycobacterium leprae 38,933 15-Jun-96 rxa01885 924 G GBB_ BBAA11 MMTTCCYY11AA1100 2 255994499 Z Z9955338877 Mycobacterium tuberculosis H37Rv complete genome, segment Mycobacterium 51 ,094 17-Jun-98 117/162 tuberculosis GB_PR3 HSU220B11 41247 Z69908 Human DNA sequence from cosmid cU220B11 , between markers Homo sapiens 39,038 23-Nov-99 DXS6791 and DXS8038 on chromosome X GB_BA1 PDU 17435 993 U 17435 Paracoccus denitπficans Fnr- ke transcnptiona 1 activator (nnr) gene, Paracoccus denitπficans 39,390 19-Jul-95 complete eds rxa01914 526 G GBB_ PPRR33 AACC000055779966 4 433884433 A ACC0000557796 Homo sapiens chromosome 19, cosmid R31408, complete sequence Homo sapiens 34,961 06-OCT-199 GB PR3 HS390C10 1 11144223311 A ALL000088772:1 Homo sapiens DNA sequence from BAC 390C10 on chromosome Homo sapiens 39,600 23-Nov-99 22q11 21-12 1 Contains an Immunoglobulin LIKE gene and a pseudogene similar to Beta Crystalhn Contains ESTs, STSs, GSSs and taga and tat repeat polymorphisms, complete sequence GB_PR3 AC005796 43843 AC005796 Homo sapiens chromosome 19, cosmid R31408, complete sequence Homo sapiens 37,725 06-OCT-199 rxa01932 1020 GB_PR3 AC003025 112309 AC003025 Human Chromosome 11 p12 2 PAC clone pDJ466a11 , complete Homo sapiens 35,585 23-Jul-98 sequence GB_GSS3 B78728 312 B78728 CIT-HSP-431 E3 TV CIT-HSP Homo sapiens genomic clone 431 E3, Homo sapiens 38,907 25-Jun-98 genomic survey sequence GB_PR3 AC003025 112309 AC003025 Human Chromosome 11 p12 2 PAC clone pDJ466a11 , complete Homo sapiens 35,859 23-Jul-98 sequence rxa01933 726 GBJHTG1 HS74016 169401 AL110119 Homo sapiens chromosome 21 clone RPCIP704O1674 map 21q21 , Homo sapiens 35,302 27-Aug-99 *** SEQUENCING IN PROGRESS ** * , in unordered pieces GBJHTG1 HS74016 169401 AL110119 Homo sapiens chromosome 21 clone RPCIP704O1674 map 21 q21 , Homo sapiens 35,302 27-Aug-99 ' SEQUENCING IN PROGRESS *** , in unordered pieces GB_PR4 AC006032 170282 AC006032 Homo sapiens BAC clone NH0115E20 from Y, complete sequence Homo sapiens 37,640 27-Feb-99 rxa01971 954 GBJHTG3 AC008230 108469 AC008230 Drosophila melanogaster chromosome 2 clone BACR17117 (D934) Drosophila melanogaster 35,466 10-Aug-99 RPCI-98 17 1 17 map 53A-53C strain y, cn bw sp, *** SEQUENCING IN PROGRESS ***, 108 unordered pieces GB_HTG3 AC008230 108469 AC008230 Drosophila melanogaster chromosome 2 clone BACR17I17 (D934) Drosophila melanogaster 35,466 10-Aug-99 RPCI-98 17 I 17 map 53A-53C strain y, cn bw sp, *** SEQUENCING IN PROGRESS *** , 108 unordered pieces Table 4 (continued) GB_PR3 AF064860 165382 AF064860 Homo sapiens chromosome 21q22 3 PAC 70I24, complete Homo sapiens 39,716 2-Jun-98 sequence rxa02016 900 GB_EST2 D48846 459 D48846 RICS15292A Rice green shoot Oryza sativa cDNA, mRNA Oryza sativa 37,118 2-Aug-95 sequence GB_GSS10 AQ195886 595 AQ195886 RPCI11 -66013 TJ RPCI-11 Homo sapiens genomic clone RPCI-11 - Homo sapiens 41 ,000 20-Apr-99 66013, genomic survey sequence GB_GSS10 AQ195886 595 AQ195886 RPCI11-66013 TJ RPCI-11 Homo sapiens genomic clone RPCI-11- Homo sapiens 34,790 20-Apr-99 66013, genomic survey sequence rxa02017 807 GB_EST20 AA855266 406 AA855266 vw70b08 r1 Stratagene mouse heart (#937316) Mus musculus cDNA Mus musculus 42,638 06-MAR-1998 clone IMAGE 1260279 5', mRNA sequence GB EST20 AA855266 406 AA855266 vw70b08 r1 Stratagene mouse heart (#937316) Mus musculus cDNA Mus musculus 37,183 06-MAR-1998 clone IMAGE 1260279 5', mRNA sequence rxa02018 1073 GB_BA1 SC5C7 41906 AL031515 Streptomyces coelicolor cosmid 5C7 Streptomyces coelicolor 41 ,732 7-Sep-98 GB_BA1 MTCI65 34331 Z95584 Mycobacterium tuberculosis H37Rv complete genome, segment Mycobacterium 62,395 17-Jun-98 50/162 tuberculosis GB_BA1 SCJ12 35302 AL 109989 Streptomyces coelicolor cosmid J12 Streptomyces coelicolor 61 ,603 24-Aug-99 A3(2) rxa02048 1497 GB_PAT E15823 2323 E 15823 DNA encoding cell surface protein from Corynebacterium Corynebacterium 53,942 28-Jul-99 ammoniagenes ammoniagenes GB_OM SSAMPTDN 3387 Z29522 S scrofa mRNA for aminopeptidase N Sus scrofa 42,672 26-Sep-94 GB_OV D87992, 3181 D87992 Gallus gallus mRNA for aminopeptidase Ey, complete eds Gallus gallus 41 ,554 5-Jun-99 rxa02101 1386 GB_BA1 AP000064 247695 AP000064 Aeropyrum permx genomic DNA, section 7/7 Aeropyrum per x 39,882 22-Jun-99 GB_PL2 ATAC0O6587 79262 AC006587 Arabidopsis thaliana chromosome II BAC T17D12 genomic Arabidopsis thaliana 38,490 23-MAR-1999 sequence, complete sequence GB_PL2 ATAC006587 79262 AC006587 Arabidopsis thaliana chromosome II BAC T17D12 genomic Arabidopsis thaliana 34,863 23-MAR-1999 sequence, complete sequence rxa02265 423 GB_BA2 AF120718 4137 AF120718 Lactobacillus fermentum urease operon, partial sequence Lactobacillus fermentum 56,265 31-MAR-1999 GB_PAT E03531 2896 E03531 DNA sequence coding for acid urease Lactobacillus fermentum 56,265 29-Sep-97 GB_BA1 LBAAURE 2896 D10605 L fermentum gene for acid urease Lactobacillus fermentum 56,265 2-Feb-99 rxa02276 801 GB_GSS10 AQ242920 451 AQ242920 HS_2061_A1_E08_MR CIT Approved Human Genomic Sperm Homo sapiens 37,916 03-OCT-1998 Library D Homo sapiens genomic clone Plate=2061 Col=15 Row=l, genomic survey sequence GBJN1 SLMMTPMF 14503 D29637 Physarum polycephalum mitochondπal DNA Mitochondrion Physarum 40,335 12-MAY-1999 polycephalum r GB IN2 AF012249 5542 AF012249 Physarum polycephalum strain aux2-S region of mitochondria derived Mitochondrion Physarum 40,335 08-MAY-1998 from mF plasmid, including URFA', URFC, URFD, URFE, URFF, and polycephalum URFG genes, complete eds, and URFH gene, partial eds rxa02277 738 GB BA2 AF048784 681 AF048784 Actinomyces naeslundn urease accessory protein (ureG) gene, Actinomyces naeslundn 66,814 9-Feb-99 complete eds Table 4 (continued) GB BA2 AF056321 5482 AF056321 Actinomyces naeslundn urease gamma subunit UreA (ureA), urease Actinomyces naeslundn 63,686 9-Feb-99 beta subunit UreB (ureB), urease alpha subunit UreC (ureC), urease accessory protein UreE (ureE), urease accessory protein UreF (ureF), urease accessory protein UreG (ureG), and urease accessory protein UreD (ureD) genes, complete eds GB BA2 SSU35248 5773 U35248 Streptococcus salivaπus ure cluster nickel transporter homolog (urel) Streptococcus salivaπus 61 ,931 26-Jan-96 gene, partial eds, and urease beta subunit (ureA), gamma subunit (ureB), alpha subunit (ureC), and accessory proteins (ureE), (ureF), (ureG), and (ureD) genes, complete eds rxa02278 972 GB GSS3 B49054 543 B49054 RPCI11 -4113 TV RPCI-11 Homo sapiens genomic clone RPCI-11 - Homo sapiens 39,161 8-Apr-99 4113, genomic survey sequence GB_PL1 PMCMSGI 3363 L27092 Pneumocystis carinii B-cell receptor (msgl) gene, 3' end Pneumocystis caπnii 39,819 26-Sep-94 GB_PL2 AF038556 12792 AF038556 Pneumocystis carinii f sp hominis variant regions of major surface Pneumocystis caπnii f sp 33,832 10-Sep-98 glycoprotems (msgl , msg3, msg4) genes, partial eds hominis rxa02317 735 GB_GSS8 AQ051031 914 AQ051031 nbxb0004dG10r CUGI Rice BAC Library Oryza sativa genomic clone Oryza sativa 32,299 24-MAR-199 nbxb0004N20r, genomic survey sequence GB_GSS8 AQ051031 914 AQ051031 nbxb0004dG10r CUGI Rice BAC Library Oryza sativa genomic clone Oryza sativa 34,573 24-MAR-199 nbxb0004N20r, genomic survey sequence rxa02334 746 GB BA1 CGU35023 3195 U35023 Corynebacterium glutamicum thiosulfate sulfurtransferase (thtR) Corynebacterium 100,000 16-Jan-97 gene, partial eds, acyl CoA carboxylase (accBC) gene, complete eds glutamicum GB_BA1 MTCY71 42729 Z92771 Mycobacterium tuberculosis H37Rv complete genome, segment Mycobactenum 60,380 10-Feb-99 141/162 tuberculosis GB_BA1 U00012 33312 U00012 Mycobacterium leprae cosmid B1308 Mycobacterium leprae 37,660 30-Jan-96 rxa02351 1039 GB_HTG2 HS225E12 126464 AL031772 Homo sapiens chromosome 6 clone RP1-225E12 map q24, * * * Homo sapiens 35,973 03-DEC-199 SEQUENCING IN PROGRESS ***, in unordered pieces GB HTG2 HS225E12 126464 AL031772 Homo sapiens chromosome 6 clone RP1-225E12 map q24, *** Homo sapiens 35,973 03-DEC-199 SEQUENCING IN PROGRESS ***, in unordered pieces GB_HTG2 HS225E12 126464 AL031772 Homo sapiens chromosome 6 clone RP1-225E12 map q24, *** Homo sapiens 36,992 03-DEC-199 SEQUENCING IN PROGRESS ** * , in unordered pieces rxa02410 789 GB_BA1 AB020624 1605 AB020624 Corynebacterium glutamicum murl gene for D-glutamate racemase, Corynebacterium 99,227 24-Jul-99 complete eds glutamicum GB_EST4 H51527 294 H51527 yo33b09 s1 Soares adult brain N2b4HB55Y Homo sapiens cDNA Homo sapiens 40,411 18-Sep-95 clone IMAGE 179705 3', mRNA sequence GB GSS1 CNS003CM 1101 AL064136 Drosophila melanogaster genome survey sequence T7 end of BAC # Drosophila melanogaster 37,674 3-Jun-99 BACR08C19 of RPCI-98 library from Drosophila melanogaster (fruit fly), genomic survey sequence Table 4 (continued) rxa02477 744 GB_HTG4 AC010054 130191 ACO 10054 Drosophila melanogaster chromosome 3L/74E2 clone RPCI98- Drosophila melanogaster 37,466 16-OCT-1999 15E10, * * * SEQUENCING IN PROGRESS * **, 70 unordered pieces GB_HTG4 AC010054 130191 AC010054 Drosophila melanogaster chromosome 3L/74E2 clone RPCI98- Drosophila melanogaster 37,466 16-OCT-1999 15E10, *** SEQUENCING IN PROGRESS "*, 70 unordered pieces GB_HTG4 AC009375 137069 AC009375 Drosophila melanogaster chromosome 3L/75A1 clone RPCI98- Drosophila melanogaster 39,118 16-OCT-1999 44L18, *** SEQUENCING IN PROGRESS ***, 59 unordered pieces rxa02513 832 GB_BA1 MTER260 373 X92572 M terrae gene for 32 kDa protein (partial) Mycobacterium terrae 42,895 15-Jan-98 GB_PL1 AB019229 84294 AB019229 Arabidopsis thaliana genomic DNA, chromosome 3, P1 clone Arabidopsis thaliana 36,084 20-Nov-99 MDC16, complete sequence GB_PL1 AB019229 84294 AB019229 Arabidopsis thaliana genomic DNA, chromosome 3, P1 clone Arabidopsis thaliana 35,244 20-Nov-99 MDC16, complete sequence rxa02531 834 GB BA1 CGLATTB 271 X89850 C glutamicum DNA for attB region Corynebacterium 40,590 8-Aug-96 glutamicum GB EST11 AA239557 423 AA239557 mv25f04 r1 GuayWoodford Beier mouse kidney day 0 Mus musculus Mus musculus 38,760 12-MAR-1997 cDNA clone IMAGE 656095 5' similar to gb X52634 Muπne tl oncogene for tlm protein (MOUSE),, mRNA sequence GB BA1 RSPYPPCL 6500 AJ002398 Rhodobacter sphaeroides pyp and pel genes, and orfA, orfB, orfC, Rhodobacter sphaeroides 3 377,,009911 17-DEC-1998 orfD, orfE, orfF rxa02548 314 GB BA2 AF127374 63734 AF 127374 Streptomyces lavendulae LinA homolog, cytochrome P450 Streptomyces lavendulae 6 666,,224422 27-MAY-1999 hydroxylase ORF4, cytochrome P450 hydroxylase ORF3, MitT (mitT), MitS (mitS), MitR (mitR), MitQ (mitQ), MitP (mitP), MitO (mitO), MitN (mitN), MitM (mitM), MitL (mitL), MitK (mitK), MitJ (mitJ), Mitl (mitl), MitH (mitH), MitG (mitG), MitF (mitF), MitE (mitE), MitD (mitD), MitC (mitC), MitB (mitB), MitA (mitA), MmcA (mmcA), MmcB (mmcB), MmcC (mmcC), M cD (mmcD), MmcE (mmcE), MmcF (mmcF), MmcG (mmcG), MmcH (mmcH), Mmcl (mmcl), MmcJ (mmcJ), MmcK (mmcK), MmcL (mmcL), M cM (mmcM), MmcN (mmcN), MmcO (mmcO), Mrd (mrd), MmcP (mmcP), MmcQ (mmcQ) MmcR (mmcR), MmcS (mmcS), MmcT (mmcT), MmcU (mmcU), MmcV (mmcV), Met (met), MmcW (mmcW) MmcX (mmcX), and MmcY (mmcY) genes, complete eds, and unknown genes Table 4 (continued) GB BA2 AF127374 63734 AF127374 Streptomyces lavendulae LinA homolog, cytochrome P450 Streptomyces lavendulae 38,411 27-MAY-1999 hydroxylase ORF4, cytochrome P450 hydroxylase ORF3, MitT (mitT), MitS (mitS), MitR (mitR), MitQ (mitQ), MitP (mitP), MitO (mitO), MitN (mitN), MitM (mitM), MitL (mitL), MitK (mitK), MitJ (mitJ), Mitl (mitl), MitH (mitH), MitG (mitG), MitF (mitF), MitE (mitE), MitD (mitD), MitC (mitC), MitB (mitB), MitA (mitA), MmcA (mmcA), MmcB (mmcB), MmcC (mmcC), MmcD (mmcD), MmcE (mmcE), MmcF (mmcF), MmcG (mmcG), MmcH (mmcH), Mmcl (mmcl), MmcJ (mmcJ), MmcK (mmcK), MmcL (mmcL), MmcM (mmcM), MmcN (mmcN), MmcO (mmcO), Mrd (mrd), MmcP (mmcP), MmcQ (mmcQ), MmcR (mmcR), MmcS (mmcS), MmcT (mmcT), MmcU (mmcU), MmcV (mmcV), Met (met), MmcW (mmcW), MmcX (mmcX), and MmcY (mmcY) genes, complete eds, and unknown genes GB GSS4 AQ741886 742 AQ741886 HS_5569_B2_B02_SP6 RPCI-11 Human Male BAC Library Homo Homo sapiens 38,907 16-Jul-99 sapiens genomic clone Plate=1145 Col=4 Row=D, genomic survey sequence rxa02558 1098 GB EST18 AA567307 741 AA567307 HL01004 5pπme HL Drosophila melanogaster head BlueScπpt Drosophila melanogaster 38,736 28-Nov-98 Drosophila melanogaster cDNA clone HL01004 5prιme, mRNA sequence GB EST27 AI402394 630 AI402394 GH21610 5prιme GH Drosophila melanogaster head pOT2 Drosophila melanogaster 41 ,308 8-Feb-99 Drosophila melanogaster cDNA clone GH21610 5pπme, mRNA sequence GB GSS10 AQ237646 715 AQ237646 RPCI11-6119 TJB RPCI-11 Homo sapiens genomic clone RPCI-11- Homo sapiens 44,340 21-Apr-99 6119, genomic survey sequence rxa02565 1389 GB EST32 AI726448 562 AI726448 BNLGHι5854 Six-day Cotton fiber Gossypium hirsutum cDNA 5' Gossypium hirsutum 37,003 11-Jun-99 similar to (U53418) UDP-glucose dehydrogenase [Glycine max], mRNA sequence GB EST32 AI726198 608 AI726198 BNLGHι5243 Six-day Cotton fiber Gossypium hirsutum cDNA 5' Gossypium hirsutum 40,925 11-Jun-99 similar to (U53418) UDP-glucose dehydrogenase [Glycine max], mRNA sequence GB PR4 AC002992 154848 AC002992 Homo sapiens chromosome Y, clone 203M13, complete sequence Homo sapiens 38,039 13-OCT-1999 rxa02574 1131 GB EST4 H29653 415 H29653 ym58f01 r1 Soares infant brain 1 NIB Homo sapiens cDNA clone Homo sapiens 39,036 17-Jul-95 IMAGE 52678 5' similar to SP OXDD_BOVIN P31228 D- ASPARTATE OXIDASE „ mRNA sequence GB PR3 HSDJ261 K5 131974 AL050350 Human DNA sequence from clone 261 K5 on chromosome 6q21- Homo sapiens 35,957 23-Nov-99 22 1 Contains the 3' part of the gene for a novel organic cation transporter (BAC ORF RG331 P03), the DDO gene for D-aspartate oxidase (EC 1 4 3 1 ), ESTs, STSs, GSSs and two putative CpG islands, complete sequence Table 4 (continued) GB EST2 R20147 494 R20147 yg18h02 r1 Soares infant brain 1 NIB Homo sapiens cDNA clone Homo sapiens 36,437 17-Apr-95 IMAGE 32866 5' similar to SP OXDD_BOVIN P31228 D- ASPARTATE OXIDASE,, mRNA sequence rxa02589 888 GB_HTG1 CEY6E2 186306 Z96799 Caenorhabditis elegans chromosome V clone Y6E2, * ** Caenorhabditis elegans 37,979 02-OCT-1997 SEQUENCING IN PROGRESS *** , in unordered pieces GB_HTG1 CEY6E2 186306 Z96799 Caenorhabditis elegans chromosome V clone Y6E2, *** Caenorhabditis elegans 37,979 02-OCT-1997 SEQUENCING IN PROGRESS ** *, in unordered pieces G B_HTG3 AC011690 72277 AC011690 Homo sapiens clone 17_E_13, LOW-PASS SEQUENCE Homo sapiens 35,814 10-OCT-1999 SAMPLING rxa02592 894 GB_BA1 MSGB983CS 36788 L78828 Mycobacterium leprae cosmid B983 DNA sequence Mycobacterium leprae 53,235 15-Jun-96 GB_GSS9 AQ170723 487 AQ170723 HS_2270_B2_F05_MR CIT Approved Human Genomic Sperm Homo sapiens 39,666 16-OCT-1998 Library D Homo sapiens genomic clone Plate=2270 Col=10 Row=L, genomic survey sequence GB_GSS12 AQ349397 791 AQ349397 RPCI11-118H16 TJ RPCI-11 Homo sapiens genomic clone RPCI-11- Homo sapiens 34,204 07-MAY-1999 118H16, genomic survey sequence rxa02603 1119 GB_BA1 MTV026 23740 AL022076 Mycobacterium tuberculosis H37Rv complete genome, segment Mycobacterium 37,975 24-Jun-99 157/162 tuberculosis GBJN2 AC005714 177740 AC005714 Drosophila melanogaster, chromosome 2R, region 58D4-58E2, BAC Drosophila melanogaster 41 ,226 01-MAY-1999 clone BACR48M13, complete sequence GB EST19 AA775050 218 AA775050 ac76e10 s1 Stratagene lung (#937210) Homo sapiens cDNA clone Homo sapiens 40,826 5-Feb-98 IMAGE 868554 3' similar to gb Y00371_rna1 HEAT SHOCK COGNATE 71 KD PROTEIN (HUMAN),, mRNA sequence rxa02630 1446 GB_BA1 MLCL373 37304 AL035500 Mycobacterium leprae cosmid L373 Mycobacterium leprae 49,015 27-Aug-99 GB_BA1 MTV044 16150 AL021999 Mycobacterium tuberculosis H37Rv complete genome, segment Mycobacterium 49,192 17-Jun-98 45/162 tuberculosis GB_BA1 MLU15180 38675 U15180 Mycobacterium leprae cosmid B1756 Mycobacterium leprae 45,621 09-MAR-1995 rxa02643 1167 GB_EST37 AI950576 308 AI950576 wx52e08 x1 NCI_CGAP_Lu28 Homo sapiens cDNA clone Homo sapiens 40,909 6-Sep-99 IMAGE 2547302 3', mRNA sequence GB EST37 AI950576 308 AI950576 wx52e08 x1 NCI_CGAP_Lu28 Homo sapiens cDNA clone Homo sapiens 40,288 6-Sep-99 IMAGE 2547302 3', mRNA sequence rxa02644 774 GB EST34 AV149547 302 AV149547 AV149547 Mus musculus C57BL/6J 10-11 day embryo Mus Mus musculus 38,627 5-Jul-99 musculus cDNA clone 2810489D03, mRNA sequence GB EST35 AV156221 271 AV156221 AV156221 Mus musculus head C57BL/6J 12-day embryo Mus Mus musculus 33,990 7-Jul-99 musculus cDNA clone 3000001 C24, mRNA sequence GB EST32 AV054919 274 AV054919 AV054919 Mus musculus pancreas C57BL/6J adult Mus musculus Mus musculus 36,585 23-Jun-99 cDNA clone 1810033C08, mRNA sequence rxa02745 902 GB BA1 MTV007 32806 AL021184 Mycobacterium tuberculosis H37Rv complete genome, segment Mycobacterium 39,298 17-Jun-98 64/162 tuberculosis Table 4 (continued) GB BA2 AF027770 30683 AF027770 Mycobactenum smegmatis FxbA (fxbA) gene, partial eds, FxbB Mycobacterium smegmatis 55,125 03-DEC-1998 (fxbB), FxbC (fxbC), and FxuD (fxtD) genes, complete eds, and unknown genes GB BA2 SAU43537 3938 U43537 Streptomyces argillaceus mithramycm resistance determinant, ATP- Streptomyces argillaceus 46,868 5-Sep-96 binding protein (mtrA) and membrane protein (mtrB) genes, complete eds rxa02746 290 GB_BA1 CAJ10319 5368 AJ010319 Corynebacterium glutamicum amtP, glnB, glnD genes and partial ftsY Corynebacterium 100,000 14-MAY-199 and srp genes glutamicum GB_BA1 MTCY338 29372 Z74697 Mycobacterium tuberculosis H37Rv complete genome, segment Mycobacteπum 39,785 17-Jun-98 127/162 tuberculosis GB_HTG3 AC008733 216140 AC008733 Homo sapiens chromosome 19 clone CITB-E1_2525J15, ** * Homo sapiens 35,688 3-Aug-99 SEQUENCING IN PROGRESS *** , 72 unordered pieces rxa02820 1411 GB BA1 BFU64514 3837 U64514 Bacillus firmus dppABC operon, dipeptide transporter protein dppA Bacillus firmus 36,859 1-Feb-97 gene, partial eds, and dipeptide transporter proteins dppB and dppC genes, complete eds GBJN1 CET04C10 20958 Z69885 Caenorhabditis elegans cosmid T04C10, complete sequence Caenorhabditis elegans 35,934 2-Sep-99 GB EST35 AI823090 720 AI823090 L30-944T3 Ice plant Lambda Uni-Zap XR expression library, 30 Mesembryanthemum 35,770 21-Jul-99 hours NaCI treatment Mesembryanthemum crystalhnum cDNA clone crystalhnum L30-944 5' similar to 60S ribosomal protein L36 (AC004684)[Arabιdopsιs thaliana], mRNA sequence rxa02834 518 GB_BA1 CJY13333 3315 Y13333 Campylobacter jejuni clpB gene Campylobacter jejuni 53,400 12-Apr-99 GB_BA2 AF065404 181654 AF065404 Bacillus anthraαs virulence plasmid PX01 , complete sequence Bacillus anthracis 45,168 20-OCT-199 GB PL2 AC006601 110684 AC006601 Arabidopsis thaliana chromosome V map near 60 5 cM, complete Arabidopsis thaliana 36,680 22-Feb-99 sequence Exemplification Example 1 : Preparation of total genomic DNA of Corynebacterium glutamicum ATCC 13032 A culture of Corynebacterium glutamicum (ATCC 13032) was grown overnight at 30°C with vigorous shaking in BHI medium (Difco). The cells were harvested by centrifugation, the supernatant was discarded and the cells were resuspended in 5 ml buffer-I (5% of the original volume of the culture — all indicated volumes have been calculated for 100 ml of culture volume). Composition of buffer-I: 140.34 g/1 sucrose, 2.46 g/1 MgSO, x 7H 2 O, 10 ml/1 KH 2 PO 4 solution (100 g/1, adjusted to pH 6.7 with KOH), 50 ml/1 Ml 2 concentrate (10 g/1 (NH 4 ) 2 SO 4 , 1 g/1 NaCl, 2 g/1 MgSO 4 x 7H 2 O, 0.2 g/1 CaCl 2 , 0.5 g/1 yeast extract (Difco), 10 ml/1 trace-elements-mix (200 mg/1 FeSO 4 x H 2 O, 10 mg/1 ZnSO 4 x 7 H 2 O, 3 mg/1 MnCl 2 x 4 H 2 O, 30 mg/1 H 3 BO 3 20 mg/1 CoCl 2 x 6 H 2 O, 1 mg/1 NiCl 2 x 6 H 2 O, 3 mg/1 Na 2 MoO 4 x 2 H 2 O, 500 mg/1 complexing agent (EDTA or critic acid), 100 ml/1 vitamins-mix (0.2 mg/1 biotin, 0.2 mg/1 folic acid, 20 mg/1 p-amino benzoic acid, 20 mg/1 riboflavin, 40 mg/1 ca-panthothenate, 140 mg/1 nicotinic acid, 40 mg/1 pyridoxole hydrochloride, 200 mg/1 myo-inositol). Lysozyme was added to the suspension to a final concentration of 2.5 mg/ml. After an approximately 4 h incubation at 37°C, the cell wall was degraded and the resulting protoplasts are harvested by centrifugation. The pellet was washed once with 5 ml buffer-I and once with 5 ml TE-buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8). The pellet was resuspended in 4 ml TE-buffer and 0.5 ml SDS solution (10%) and 0.5 ml NaCl solution (5 M) are added. After adding of proteinase K to a final concentration of 200 μg/ml, the suspension is incubated for ca.18 h at 37°C. The DNA was purified by extraction with phenol, phenol-chloroform-isoamylalcohol and chloroform- isoamylalcohol using standard procedures. Then, the DNA was precipitated by adding 1/50 volume of 3 M sodium acetate and 2 volumes of ethanol, followed by a 30 min incubation at -20°C and a 30 min centrifugation at 12,000 rpm in a high speed centrifuge using a SS34 rotor (Sorvall). The DNA was dissolved in 1 ml TE-buffer containing 20 μg/ml RNaseA and dialysed at 4°C against 1000 ml TE-buffer for at least 3 hours. During this time, the buffer was exchanged 3 times. To aliquots of 0.4 ml of the dialysed DNA solution, 0.4 ml of 2 M LiCl and 0.8 ml of ethanol are added. After a 30 min incubation at -20°C, the DNA was collected by centrifugation (13,000 rpm, Biofuge Fresco, Heraeus, Hanau, Germany). The DNA pellet was dissolved in TE-buffer. DNA prepared by this procedure could be used for all purposes, including southern blotting or construction of genomic libraries. Example 2: Construction of genomic libraries in Escherichia coli of Corynebacterium glutamicum ATCC13032. Using DNA prepared as described in Example 1 , cosmid and plasmid libraries were constructed according to known and well established methods (see e.g., Sambrook, J. et al. (1989) "Molecular Cloning : A Laboratory Manual", Cold Spring Harbor Laboratory Press, or Ausubel, F.M. et al. (1994) "Current Protocols in Molecular Biology", John Wiley & Sons.) Any plasmid or cosmid could be used. Of particular use were the plasmids pBR322 (Sutcliffe, J.G. (1979) Proc. Natl Acad. Sci. USA, 75:3737-3741); pACYC177 (Change & Cohen (1978) J. Bacteriol 134:1 141-1156), plasmids of the pBS series (pBSSK+, pBSSK- and others; Stratagene, LaJolla, USA), or cosmids as SuperCosl (Stratagene, LaJolla, USA) or Loristό (Gibson, T.J., Rosenthal A. and Waterson, R.H. (1987) Gene 53:283-286. Gene libraries specifically for use in C. glutamicum may be constructed using plasmid pSL109 (Lee, H.-S. and A. J. Sinskey (1994) J Microbiol. Biotechnol. 4: 256-263). Example 3: DNA Sequencing and Computational Functional Analysis Genomic libraries as described in Example 2 were used for DNA sequencing according to standard methods, in particular by the chain termination method using ABI377 sequencing machines (see e.g., Fleischman, R.D. et al (1995) "Whole-genome Random Sequencing and Assembly of Haemophilus Influenzae Rd., Science, 269:496- 512). Sequencing primers with the following nucleotide sequences were used: 5'- GGAAACAGTATGACCATG-3' or 5'-GTAAAACGACGGCCAGT-3\ Example 4: In vivo Mutagenesis In vivo mutagenesis of Corynebacterium glutamicum can be performed by passage of plasmid (or other vector) DNA through E. coli or other microorganisms (e.g. Bacillus spp. or yeasts such as Saccharomyces cerevisiae) which are impaired in their capabilities to maintain the integrity of their genetic information. Typical mutator strains have mutations in the genes for the DNA repair system (e.g., mutHLS, mutD, mutT, etc.; for reference, see Rupp, W.D. (1996) DNA repair mechanisms, in: Escherichia coli and Salmonella, p. 2277-2294, ASM: Washington.) Such strains are well known to those of ordinary skill in the art. The use of such strains is illustrated, for example, in Greener, A. and Callahan, M. (1994) Strategies 7: 32-34. Example 5: DNA Transfer Between Escherichia coli and Corynebacterium glutamicum Several Corynebacterium and Brevibacterium species contain endogenous plasmids (as e.g. , pHM 1519 or pBL 1 ) which replicate autonomously (for review see, e.g. , Martin, J.F. et al. (1987) Biotechnology, 5:137-146). Shuttle vectors for Escherichia coli and Corynebacterium glutamicum can be readily constructed by using standard vectors for E. coli (Sambrook, J. et al. (1989), "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor Laboratory Press or Ausubel, F.M. et al. (1994) "Current Protocols in Molecular Biology", John Wiley & Sons) to which a origin or replication for and a suitable marker from Corynebacterium glutamicum is added. Such origins of replication are preferably taken from endogenous plasmids isolated from Corynebacterium and Brevibacterium species. Of particular use as transformation markers for these species are genes for kanamycin resistance (such as those derived from the Tn5 or Tn903 transposons) or chloramphenicol (Winnacker, E.L. (1987) "From Genes to Clones — Introduction to Gene Technology, VCH, Weinheim). There are numerous examples in the literature of the construction of a wide variety of shuttle vectors which replicate in both E. coli and C glutamicum, and which can be used for several purposes, including gene over- expression (for reference, see e.g., Yoshihama, M. et al (1985) J. Bacteriol. 162:591-597, Martin J.F. et al (1987) Biotechnology, 5:137-146 and Eikmanns, B.J. et al. (1991) Gene, 102:93-98). Using standard methods, it is possible to clone a gene of interest into one of the shuttle vectors described above and to introduce such a hybrid vectors into strains of Corynebacterium glutamicum. Transformation of C glutamicum can be achieved by protoplast transformation (Kastsumata, R. et al. (1984) J. Bacteriol. 159306-31 1), electroporation (Liebl, E. et al. (1989) FEMS Microbiol. Letters, 53:399-303) and in cases where special vectors are used, also by conjugation (as described e.g. in Schafer, A et al. (1990) J. Bacteriol. 172:1663-1666). It is also possible to transfer the shuttle vectors for C. glutamicum to E. coli by preparing plasmid DNA from C. glutamicum (using standard methods well-known in the art) and transforming it into E. coli. This transformation step can be performed using standard methods, but it is advantageous to use an Mcr-deficient E. coli strain, such as NM522 (Gough & Murray (1983) J. Mol. Biol. 166:1-19). Genes may be overexpressed in C. glutamicum strains using plasmids which comprise pCGl (U.S. Patent No. 4,617,267) or fragments thereof, and optionally the gene for kanamycin resistance from TN903 (Grindley, N.D. and Joyce, CM. (1980) Proc. Natl Acad. Sci. USA 77(12): 7176-7180). In addition, genes may be overexpressed in C. glutamicum strains using plasmid pSL109 (Lee, H.-S. and A. J. Sinskey (1994) J. Microbiol. Biotechnol. 4: 256-263). Aside from the use of replicative plasmids, gene overexpression can also be achieved by integration into the genome. Genomic integration in C glutamicum or other Corynebacterium or Brevibacterium species may be accomplished by well-known methods, such as homologous recombination with genomic region(s), restriction endonuclease mediated integration (REMI) (see, e.g., DE Patent 19823834), or through the use of transposons. It is also possible to modulate the activity of a gene of interest by modifying the regulatory regions (e.g., a promoter, a repressor, and/or an enhancer) by sequence modification, insertion, or deletion using site-directed methods (such as homologous recombination) or methods based on random events (such as transposon mutagenesis or REMI). Nucleic acid sequences which function as transcriptional terminators may also be inserted 3' to the coding region of one or more genes of the invention; such terminators are well-known in the art and are described, for example, in Winnacker, E.L. (1987) From Genes to Clones - Introduction to Gene Technology. VCH: Weinheim. Example 6: Assessment of the Expression of the Mutant Protein Observations of the activity of a mutated protein in a transformed host cell rely on the fact that the mutant protein is expressed in a similar fashion and in a similar quantity to that of the wild-type protein. A useful method to ascertain the level of transcription of the mutant gene (an indicator of the amount of mRNA available for translation to the gene product) is to perform a Northern blot (for reference see, for example, Ausubel et al (1988) Current Protocols in Molecular Biology, Wiley: New York), in which a primer designed to bind to the gene of interest is labeled with a detectable tag (usually radioactive or chemiluminescent), such that when the total RNA of a culture of the organism is extracted, run on gel, transferred to a stable matrix and incubated with this probe, the binding and quantity of binding of the probe indicates the presence and also the quantity of mRNA for this gene. This information is evidence of the degree of transcription of the mutant gene. Total cellular RNA can be prepared from Corynebacterium glutamicum by several methods, all well-known in the art, such as that described in Bormann, E.R. et al. (1992) Mol Microbiol. 6: 317-326. To assess the presence or relative quantity of protein translated from this mRNA, standard techniques, such as a Western blot, may be employed (see, for example, Ausubel et al. (1988) Current Protocols in Molecular Biology, Wiley: New York). In this process, total cellular proteins are extracted, separated by gel electrophoresis, transferred to a matrix such as nitrocellulose, and incubated with a probe, such as an antibody, which specifically binds to the desired protein. This probe is generally tagged with a chemiluminescent or colorimetric label which may be readily detected. The presence and quantity of label observed indicates the presence and quantity of the desired mutant protein present in the cell. Example 7: Growth of Genetically Modified Corynebacterium glutamicum — Media and Culture Conditions Genetically modified Corynebacteria are cultured in synthetic or natural growth media. A number of different growth media for Corynebacteria are both well-known and readily available (Lieb et al (1989) Appl. Microbiol. Biotechnol., 32:205-210; von der Osten et al. (1998) Biotechnology Letters, 11 :11-16; Patent DE 4,120,867; Liebl (1992) "The Genus Corynebacterium, in: The Procaryotes, Volume II, Balows, A. et al, eds. Springer- Verlag). These media consist of one or more carbon sources, nitrogen sources, inorganic salts, vitamins and trace elements. Preferred carbon sources are sugars, such as mono-, di-, or polysaccharides. For example, glucose, fructose, mannose, galactose, ribose, sorbose, ribulose, lactose, maltose, sucrose, raffinose, starch or cellulose serve as very good carbon sources. It is also possible to supply sugar to the media via complex compounds such as molasses or other by-products from sugar refinement. It can also be advantageous to supply mixtures of different carbon sources. Other possible carbon sources are alcohols and organic acids, such as methanol, ethanol, acetic acid or lactic acid. Nitrogen sources are usually organic or inorganic nitrogen compounds, or materials which contain these compounds. Exemplary nitrogen sources include ammonia gas or ammonia salts, such as NH 4 C1 or (NH 4 ) 2 SO 4 , NH 4 OH, nitrates, urea, amino acids or complex nitrogen sources like corn steep liquor, soy bean flour, soy bean protein, yeast extract, meat extract and others. Inorganic salt compounds which may be included in the media include the chloride-, phosphorous- or sulfate- salts of calcium, magnesium, sodium, cobalt, molybdenum, potassium, manganese, zinc, copper and iron. Chelating compounds can be added to the medium to keep the metal ions in solution. Particularly useful chelating compounds include dihydroxyphenols, like catechol or protocatechuate, or organic acids, such as citric acid. It is typical for the media to also contain other growth factors, such as vitamins or growth promoters, examples of which include biotin, riboflavin, thiamin, folic acid, nicotinic acid, pantothenate and pyridoxin. Growth factors and salts frequently originate from complex media components such as yeast extract, molasses, corn steep liquor and others. The exact composition of the media compounds depends strongly on the immediate experiment and is individually decided for each specific case. Information about media optimization is available in the textbook "Applied Microbiol. Physiology, A Practical Approach (eds. P.M. Rhodes, P.F. Stanbury, IRL Press (1997) pp. 53-73, ISBN 0 19 963577 3). It is also possible to select growth media from commercial suppliers, like standard 1 (Merck) or BHI (grain heart infusion, DIFCO) or others. All medium components are sterilized, either by heat (20 minutes at 1.5 bar and 121°C) or by sterile filtration. The components can either be sterilized together or, if necessary, separately. All media components can be present at the beginning of growth, or they can optionally be added continuously or batchwise. Culture conditions are defined separately for each experiment. The temperature should be in a range between 15°C and 45°C. The temperature can be kept constant or can be altered during the experiment. The pH of the medium should be in the range of 5 to 8.5, preferably around 7.0, and can be maintained by the addition of buffers to the media. An exemplary buffer for this purpose is a potassium phosphate buffer. Synthetic buffers such as MOPS, HEPES, ACES and others can alternatively or simultaneously be used. It is also possible to maintain a constant culture pH through the addition of NaOH or NH 4 OH during growth. If complex medium components such as yeast extract are utilized, the necessity for additional buffers may be reduced, due to the fact that many complex compounds have high buffer capacities. If a fermentor is utilized for culturing the micro- organisms, the pH can also be controlled using gaseous ammonia. The incubation time is usually in a range from several hours to several days. This time is selected in order to permit the maximal amount of product to accumulate in the broth. The disclosed growth experiments can be carried out in a variety of vessels, such as microtiter plates, glass tubes, glass flasks or glass or metal fermentors of different sizes. For screening a large number of clones, the microorganisms should be cultured in microtiter plates, glass tubes or shake flasks, either with or without baffles. Preferably 100 ml shake flasks are used, filled with 10% (by volume) of the required growth medium. The flasks should be shaken on a rotary shaker (amplitude 25 mm) using a speed-range of 100 - 300 rpm. Evaporation losses can be diminished by the maintenance of a humid atmosphere; alternatively, a mathematical correction for evaporation losses should be performed. If genetically modified clones are tested, an unmodified control clone or a control clone containing the basic plasmid without any insert should also be tested. The medium is inoculated to an OD υ o of O.5 - 1.5 using cells grown on agar plates, such as CM plates (10 g/1 glucose, 2,5 g/1 NaCl, 2 g/1 urea, 10 g/1 polypeptone, 5 g/1 yeast extract, 5 g/1 meat extract, 22 g/1 NaCl, 2 g/1 urea, 10 g/1 polypeptone, 5 g/1 yeast extract, 5 g/1 meat extract, 22 g/1 agar, pH 6.8 with 2M NaOH) that had been incubated at 30°C. Inoculation of the media is accomplished by either introduction of a saline suspension of C. glutamicum cells from CM plates or addition of a liquid preculture of this bacterium. Example S —In vitro Analysis of the Function of Mutant Proteins The determination of activities and kinetic parameters of enzymes is well established in the art. Experiments to determine the activity of any given altered enzyme must be tailored to the specific activity of the wild-type enzyme, which is well within the ability of one of ordinary skill in the art. Overviews about enzymes in general, as well as specific details concerning structure, kinetics, principles, methods, applications and examples for the determination of many enzyme activities may be found, for example, in the following references: Dixon, M., and Webb, E.C., (1979) Enzymes. Longmans: London; Fersht, (1985) Enzyme Structure and Mechanism. Freeman: New York; Walsh, (1979) Enzymatic Reaction Mechanisms. Freeman: San Francisco; Price, N.C., Stevens, L. (1982) Fundamentals of Enzymology. Oxford Univ. Press: Oxford; Boyer, P.D., ed. (1983) The Enzymes, 3 rd ed. Academic Press: New York; Bisswanger, H., (1994) Enzymkinetik, 2 nd ed. VCH: Weinheim (ISBN 3527300325); Bergmeyer, H.U., Bergmeyer, J., GraBl, M., eds. (1983-1986) Methods of Enzymatic Analysis, 3 rd ed., vol. I-XII, Verlag Chemie: Weinheim; and Ullmann's Encyclopedia of Industrial Chemistry (1987) vol. A9, "Enzymes". VCH: Weinheim, p. 352-363. The activity of proteins which bind to DNA can be measured by several well- established methods, such as DNA band-shift assays (also called gel retardation assays). The effect of such proteins on the expression of other molecules can be measured using reporter gene assays (such as that described in Kolmar, H. et al. (1995) EMBO J. 14: 3895-3904 and references cited therein). Reporter gene test systems are well known and established for applications in both pro- and eukaryotic cells, using enzymes such as beta-galactosidase, green fluorescent protein, and several others. The determination of activity of membrane-transport proteins can be performed according to techniques such as those described in Gennis, R.B. (1989) "Pores, Channels and Transporters", in Biomembranes, Molecular Structure and Function, Springer: Heidelberg, p. 85-137; 199-234; and 270-322. Example 9: Analysis of Impact of Mutant Protein on the Production of the Desired Product The effect of the genetic modification in C glutamicum on production of a desired compound (such as an amino acid) can be assessed by growing the modified microorganism under suitable conditions (such as those described above) and analyzing the medium and/or the cellular component for increased production of the desired product (i.e. , an amino acid). Such analysis techniques are well known to one of ordinary skill in the art, and include spectroscopy, thin layer chromatography, staining methods of various kinds, enzymatic and microbiological methods, and analytical chromatography such as high performance liquid chromatography (see, for example, Ullman, Encyclopedia of Industrial Chemistry, vol. A2, p. 89-90 and p. 443-613, VCH: Weinheim (1985); Fallon, A. et al, (1987) "Applications of HPLC in Biochemistry" in: Laboratory Techniques in Biochemistry and Molecular Biology, vol. 17; Rehm et al. (1993) Biotechnology, vol. 3, Chapter III: "Product recovery and purification", page 469-714, VCH: Weinheim; Belter, P. A. et al. (1988) Bioseparations: downstream processing for biotechnology, John Wiley and Sons; Kennedy, J.F. and Cabral, J.M.S. (1992) Recovery processes for biological materials, John Wiley and Sons; Shaeiwitz, J.A. and Henry, J.D. (1988) Biochemical separations, in: Ulmann's Encyclopedia of Industrial Chemistry, vol. B3, Chapter 11, page 1-27, VCH: Weinheim; and Dechow, F.J. (1989) Separation and purification techniques in biotechnology, Noyes Publications.) In addition to the measurement of the final product of fermentation, it is also possible to analyze other components of the metabolic pathways utilized for the production of the desired compound, such as intermediates and side-products, to determine the overall efficiency of production of the compound. Analysis methods include measurements of nutrient levels in the medium (e.g., sugars, hydrocarbons, nitrogen sources, phosphate, and other ions), measurements of biomass composition and growth, analysis of the production of common metabolites of biosynthetic pathways, and measurement of gasses produced during fermentation. Standard methods for these measurements are outlined in Applied Microbial Physiology, A Practical Approach, P.M. Rhodes and P.F. Stanbury, eds., IRL Press, p. 103-129; 131-163; and 165-192 (ISBN: 0199635773) and references cited therein. Example 10: Purification of the Desired Product from C. glutamicum Culture Recovery of the desired product from the C. glutamicum cells or supernatant of the above-described culture can be performed by various methods well known in the art. If the desired product is not secreted from the cells, the cells can be harvested from the culture by low-speed centrifugation, the cells can be lysed by standard techniques, such as mechanical force or sonication. The cellular debris is removed by centrifugation, and the supernatant fraction containing the soluble proteins is retained for further purification of the desired compound. If the product is secreted from the C. glutamicum cells, then the cells are removed from the culture by low-speed centrifugation, and the supernate fraction is retained for further purification. The supernatant fraction from either purification method is subjected to chromatography with a suitable resin, in which the desired molecule is either retained on a chromatography resin while many of the impurities in the sample are not, or where the impurities are retained by the resin while the sample is not. Such chromatography steps may be repeated as necessary, using the same or different chromatography resins. One of ordinary skill in the art would be well-versed in the selection of appropriate chromatography resins and in their most efficacious application for a particular molecule to be purified. The purified product may be concentrated by filtration or ultrafiltration, and stored at a temperature at which the stability of the product is maximized. There are a wide array of purification methods known to the art and the preceding method of purification is not meant to be limiting. Such purification techniques are described, for example, in Bailey, J.E. & Ollis, D.F. Biochemical Engineering Fundamentals, McGraw-Hill: New York (1986). The identity and purity of the isolated compounds may be assessed by techniques standard in the art. These include high-performance liquid chromatography (HPLC), spectroscopic methods, staining methods, thin layer chromatography, NIRS, enzymatic assay, or microbiologically. Such analysis methods are reviewed in: Patek et al (1994) Appl. Environ. Microbiol. 60: 133-140; Malakhova et al (1996) Biotekhnologiya 11 : 27- 32; and Schmidt et al. (1998) Bioprocess Engineer. 19: 67-70. Ulmann's Encyclopedia of Industrial Chemistry, (1996) vol. A27, VCH: Weinheim, p. 89-90, p. 521-540, p. 540- 547, p. 559-566, 575-581 and p. 581-587; Michal, G. (1999) Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology, John Wiley and Sons; Fallon, A. et al. (1987) Applications of HPLC in Biochemistry in: Laboratory Techniques in Biochemistry and Molecular Biology, vol. 17. Example 11: Analysis of the Gene Sequences of the Invention The comparison of sequences and determination of percent homology between two sequences are art-known techniques, and can be accomplished using a mathematical algorithm, such as the algorithm of Karlin and Altschul (1990) Proc. Natl Acad. Sci. USA 87:2264-68, modified as in Karlin and Altschul (1993) Proc. Natl Acad. Sci. USA 90:5873-77. Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to HA nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to HA protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. , (1997) Nucleic Acids Res. 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, one of ordinary skill in the art will know how to optimize the parameters of the program (e.g., XBLAST and NBLAST) for the specific sequence being analyzed. Another example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Meyers and Miller ((1988) Comput. Appl. Biosci. 4: 11- 17). Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. Additional algorithms for sequence analysis are known in the art, and include ADVANCE and ADAM, described in Torelli and Robotti (1994) Comput. Appl Biosci. 10:3-5; and FASTA, described in Pearson and Lipman (1988) P.N.A.S. 85:2444-8. The percent homology between two amino acid sequences can also be accomplished using the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blosum 62 matrix or a PAM250 matrix, and a gap weight of 12, 10, 8, 6, or 4 and a length weight of 2, 3, or 4. The percent homology between two nucleic acid sequences can be accomplished using the GAP program in the GCG software package, using standard parameters, such as a gap weight of 50 and a length weight of 3. A comparative analysis of the gene sequences of the invention with those present in Genbank has been performed using techniques known in the art (see, e.g. , Bexevanis and Ouellette, eds. (1998) Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins. John Wiley and Sons: New York). The gene sequences of the invention were compared to genes present in Genbank in a three-step process. In a first step, a BLASTN analysis (e.g., a local alignment analysis) was performed for each of the sequences of the invention against the nucleotide sequences present in Genbank, and the top 500 hits were retained for further analysis. A subsequent FASTA search (e.g., a combined local and global alignment analysis, in which limited regions of the sequences are aligned) was performed on these 500 hits. Each gene sequence of the invention was subsequently globally aligned to each of the top three FASTA hits, using the GAP program in the GCG software package (using standard parameters). In order to obtain correct results, the length of the sequences extracted from Genbank were adjusted to the length of the query sequences by methods well-known in the art. The results of this analysis are set forth in Table 4. The resulting data is identical to that which would have been obtained had a GAP (global) analysis alone been performed on each of the genes of the invention in comparison with each of the references in Genbank, but required significantly reduced computational time as compared to such a database-wide GAP (global) analysis. Sequences of the invention for which no alignments above the cutoff values were obtained are indicated on Table 4 by the absence of alignment information. It will further be understood by one of ordinary skill in the art that the GAP alignment homology percentages set forth in Table 4 under the heading "% homology (GAP)" are listed in the European numerical format, wherein a ',' represents a decimal point. For example, a value of "40,345" in this column represents "40.345%". Example 12: Construction and Operation of DNA Microarrays The sequences of the invention may additionally be used in the construction and application of DNA microarrays (the design, methodology, and uses of DNA arrays are well known in the art, and are described, for example, in Schena, M. et αl. (1995) Science 270: 467-470; Wodicka, L. et αl. (1997) Nature Biotechnology 15: 1359-1367; DeSaizieu, A. et al (1998) Nature Biotechnology 16: 45-48; and DeRisi, J.L. et al (1997) Science 278: 680-686). DNA microarrays are solid or flexible supports consisting of nitrocellulose, nylon, glass, silicone, or other materials. Nucleic acid molecules may be attached to the surface in an ordered manner. After appropriate labeling, other nucleic acids or nucleic acid mixtures can be hybridized to the immobilized nucleic acid molecules, and the label may be used to monitor and measure the individual signal intensities of the hybridized molecules at defined regions. This methodology allows the simultaneous quantification of the relative or absolute amount of all or selected nucleic acids in the applied nucleic acid sample or mixture. DNA microarrays, therefore, permit an analysis of the expression of multiple (as many as 6800 or more) nucleic acids in parallel (see, e.g. , Schena, M. (1996) BioEssays 18(5): 427-431). The sequences of the invention may be used to design ohgonucleotide primers which are able to amplify defined regions of one or more C. glutamicum genes by a nucleic acid amplification reaction such as the polymerase chain reaction. The choice and design of the 5' or 3' ohgonucleotide primers or of appropriate linkers allows the covalent attachment of the resulting PCR products to the surface of a support medium described above (and also described, for example, Schena, M. et al. (1995) Science 270: 467-470). Nucleic acid microarrays may also be constructed by in situ ohgonucleotide synthesis as described by Wodicka, L. et al. (1997) Nature Biotechnology 15: 1359- 1367. By photolithographic methods, precisely defined regions of the matrix are exposed to light. Protective groups which are photolabile are thereby activated and undergo nucleotide addition, whereas regions that are masked from light do not undergo any modification. Subsequent cycles of protection and light activation permit the synthesis of different ohgonucleotides at defined positions. Small, defined regions of the genes of the invention may be synthesized on microarrays by solid phase ohgonucleotide synthesis. The nucleic acid molecules of the invention present in a sample or mixture of nucleotides may be hybridized to the microarrays. These nucleic acid molecules can be labeled according to standard methods. In brief, nucleic acid molecules (e.g., mRNA molecules or DNA molecules) are labeled by the incorporation of isotopically or fluorescently labeled nucleotides, e.g., during reverse transcription or DNA synthesis. Hybridization of labeled nucleic acids to microarrays is described (e.g., in Schena, M. et al (1995) supra; Wodicka, L. et al (1997), supra; and DeSaizieu A. et al. (1998), supra). The detection and quantification of the hybridized molecule are tailored to the specific incorporated label. Radioactive labels can be detected, for example, as described in Schena, M. et al. (1995) supra) and fluorescent labels may be detected, for example, by the method of Shalon et al. (1996) Genome Research 6: 639-645). The application of the sequences of the invention to DNA microarray technology, as described above, permits comparative analyses of different strains of C. glutamicum or other Corynebacteria. For example, studies of inter-strain variations based on individual transcript profiles and the identification of genes that are important for specific and/or desired strain properties such as pathogenicity, productivity and stress tolerance are facilitated by nucleic acid array methodologies. Also, comparisons of the profile of expression of genes of the invention during the course of a fermentation reaction are possible using nucleic acid array technology. Example 13: Analysis of the Dynamics of Cellular Protein Populations (Proteomics) The genes, compositions, and methods of the invention may be applied to study the interactions and dynamics of populations of proteins, termed 'proteomics'. Protein populations of interest include, but are not limited to, the total protein population of C. glutamicum (e.g., in comparison with the protein populations of other organisms), those proteins which are active under specific environmental or metabolic conditions (e.g., during fermentation, at high or low temperature, or at high or low pH), or those proteins which are active during specific phases of growth and development. Protein populations can be analyzed by various well-known techniques, such as gel electrophoresis. Cellular proteins may be obtained, for example, by lysis or extraction, and may be separated from one another using a variety of electrophoretic techniques. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) separates proteins largely on the basis of their molecular weight. Isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) separates proteins by their isoelectric point (which reflects not only the amino acid sequence but also posttranslational modifications of the protein). Another, more preferred method of protein analysis is the consecutive combination of both IEF-PAGE and SDS-PAGE, known as 2-D-gel electrophoresis (described, for example, in Hermann et al. (1998) Electrophoresis 19: 3217-3221; Fountoulakis et al. (1998) Electrophoresis 19: 1193-1202; Langen et al (1997) Electrophoresis 18: 1184-1192; Antelmann et al. (1997) Electrophoresis 18: 1451-1463). Other separation techniques may also be utilized for protein separation, such as capillary gel electrophoresis; such techniques are well known in the art. Proteins separated by these methodologies can be visualized by standard techniques, such as by staining or labeling. Suitable stains are known in the art, and include Coomassie Brilliant Blue, silver stain, or fluorescent dyes such as Sypro Ruby (Molecular Probes). The inclusion of radioactively labeled amino acids or other protein precursors (e.g., 35 S-methionine, 35 S-cysteine, l4 C-labelled amino acids, 15 N-amino acids, 15 NO or 15 NH 4 + or 13 C-labelled amino acids) in the medium of C. glutamicum permits the labeling of proteins from these cells prior to their separation. Similarly, fluorescent labels may be employed. These labeled proteins can be extracted, isolated and separated according to the previously described techniques. Proteins visualized by these techniques can be further analyzed by measuring the amount of dye or label used. The amount of a given protein can be determined quantitatively using, for example, optical methods and can be compared to the amount of other proteins in the same gel or in other gels. Comparisons of proteins on gels can be made, for example, by optical comparison, by spectroscopy, by image scanning and analysis of gels, or through the use of photographic films and screens. Such techniques are well-known in the art. To determine the identity of any given protein, direct sequencing or other standard techniques may be employed. For example, N- and/or C-terminal amino acid sequencing (such as Edman degradation) may be used, as may mass spectrometry (in particular MALDI or ESI techniques (see, e.g., Langen et al (1997) Electrophoresis 18: 1184-1192)). The protein sequences provided herein can be used for the identification of C. glutamicum proteins by these techniques. The information obtained by these methods can be used to compare patterns of protein presence, activity, or modification between different samples from various biological conditions (e.g., different organisms, time points of fermentation, media conditions, or different biotopes, among others). Data obtained from such experiments alone, or in combination with other techniques, can be used for various applications, such as to compare the behavior of various organisms in a given (e.g. , metabolic) situation, to increase the productivity of strains which produce fine chemicals or to increase the efficiency of the production of fine chemicals. E uivalents Those of ordinary skill in the art will recognize, or will be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Claims: What is claimed: 1. An isolated nucleic acid molecule from Corynebacterium glutamicum encoding an HA protein, or a portion thereof, provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1. 2. The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule encodes an HA protein involved in the production of a fine chemical. 3. An isolated Corynebacterium glutamicum nucleic acid molecule selected from the group consisting of those sequences set forth as odd-numbered SEQ ID NOs of the Sequence Listing, or a portion thereof, provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1. 4. An isolated nucleic acid molecule which encodes a polypeptide sequence selected from the group consisting of those sequences set forth as even-numbered SEQ ID NOs of the Sequence Listing, provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1. 5. An isolated nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide selected from the group of amino acid sequences consisting of those sequences set forth as even-numbered SEQ ID NOs of the Sequence Listing, provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1. 6. An isolated nucleic acid molecule comprising a nucleotide sequence which is at least 50% homologous to a nucleotide sequence selected from the group consisting of those sequences set forth as odd-numbered SEQ ID NOs of the Sequence Listing, or a portion thereof, provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1. 7. An isolated nucleic acid molecule comprising a fragment of at least 15 nucleotides of a nucleic acid comprising a nucleotide sequence selected from the group consisting of those sequences set forth as odd-numbered SEQ ID NOs of the Sequence Listing, provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1. 8. An isolated nucleic acid molecule which hybridizes to the nucleic acid molecule of any one of claims 1-7 under stringent conditions. 9. An isolated nucleic acid molecule comprising the nucleic acid molecule of any one of claims 1-8 or a portion thereof and a nucleotide sequence encoding a heterologous polypeptide. 10. A vector comprising the nucleic acid molecule of any one of claims 1-9. 11. The vector of claim 10, which is an expression vector. 12. A host cell transfected with the expression vector of claim 11. 13. The host cell of claim 12, wherein said cell is a microorganism. 14. The host cell of claim 13, wherein said cell belongs to the genus Corynebacterium or Brevibacterium. 15. The host cell of claim 12, wherein the expression of said nucleic acid molecule results in the modulation in production of a fine chemical from said cell. 16. The host cell of claim 15, wherein said fine chemical is selected from the group consisting of: organic acids, proteinogenic and nonproteinogenic amino acids, purine and pyrimidine bases, nucleosides, nucleotides, lipids, saturated and unsaturated fatty acids, diols, carbohydrates, aromatic compounds, vitamins, cofactors, polyketides, and enzymes. 17. A method of producing a polypeptide comprising culturing the host cell of claim 12 in an appropriate culture medium to, thereby, produce the polypeptide. 18. An isolated HA polypeptide from Corynebacterium glutamicum, or a portion thereof. 19. The polypeptide of claim 18, wherein said polypeptide is involved in the production of a fine chemical production. 20. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of those sequences set forth as even-numbered SEQ ID NOs of the Sequence Listing, provided that the amino acid sequence is not encoded by any of the F-designated genes set forth in Table 1. 21. An isolated polypeptide comprising a naturally occurring allelic variant of a polypeptide comprising an amino acid sequence selected from the group consisting of those sequences set forth in as even-numbered SEQ ID NOs of the Sequence Listing, or a portion thereof, provided that the amino acid sequence is not encoded by any of the F-designated genes set forth in Table 1. 22. The isolated polypeptide of any of claims 18-21, further comprising heterologous amino acid sequences. 23. An isolated polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 50% homologous to a nucleic acid selected from the group consisting of those sequences set forth as odd-numbered SEQ ID NOs of the Sequence Listing, provided that the nucleic acid molecule does not consist of any of the F-designated nucleic acid molecules set forth in Table 1. 24. An isolated polypeptide comprising an amino acid sequence which is at least 50% homologous to an amino acid sequence selected from the group consisting of those sequences set forth as even-numbered SEQ ID NOs of the Sequence Listing, provided that the amino acid sequence is not encoded by any of the F-designated genes set forth in Table 1. 25. A method for producing a fine chemical, comprising culturing a cell containing a vector of claim 12 such that the fine chemical is produced. 26. The method of claim 25, wherein said method further comprises the step of recovering the fine chemical from said culture. 27. The method of claim 25, wherein said method further comprises the step of transfecting said cell with the vector of claim 11 to result in a cell containing said vector. 28. The method of claim 25, wherein said cell belongs to the genus Corynebacterium or Brevibacterium. 29. The method of claim 25, wherein said cell is selected from the group consisting of: Corynebacterium glutamicum, Corynebacterium herculis, Corynebacterium lilium, Corynebacterium acetoacidophilum, Corynebacterium acetoglutamicum, Corynebacterium acetophilum, Corynebacterium ammoniagenes, Corynebacterium fujiokense, Corynebacterium nitrilophilus, Brevibacterium ammoniagenes, Brevibacterium butanicum, Brevibacterium divaricatum, Brevibacterium flavum, Brevibacterium healii, Brevibacterium ketoglutamicum, Brevibacterium ketosoreductum, Brevibacterium lactofermentum, Brevibacterium linens, Brevibacterium parafβnolyticum, and those strains set forth in Table 3. 30. The method of claim 25, wherein expression of the nucleic acid molecule from said vector results in modulation of production of said fine chemical. 31. The method of claim 25, wherein said fine chemical is selected from the group consisting of: organic acids, proteinogenic and nonproteinogenic amino acids, purine and pyrimidine bases, nucleosides, nucleotides, lipids, saturated and unsaturated fatty acids, diols, carbohydrates, aromatic compounds, vitamins, cofactors, polyketides, and enzymes. 32. The method of claim 25, wherein said fine chemical is an amino acid. 33. The method of claim 32, wherein said amino acid is drawn from the group consisting of: lysine, glutamate, glutamine, alanine, aspartate, glycine, serine, threonine, methionine, cysteine, valine, leucine, isoleucine, arginine, proline, histidine, tyrosine, phenylalanine, and tryptophan. 34. A method for producing a fine chemical, comprising culturing a cell whose genomic DNA has been altered by the inclusion of a nucleic acid molecule of any one of claims 1-9. 35. A method for diagnosing the presence or activity of Corynebacterium diphtheriae in a subject, comprising detecting the presence of one or more of SEQ ID NOs 1 through 440 of the Sequence Listing in the subject, provided that the sequences are not or are not encoded by any of the F-designated sequences set forth in Table 1, thereby diagnosing the presence or activity of Corynebacterium diphtheriae in the subject. 36. A host cell comprising a nucleic acid molecule selected from the group consisting of the nucleic acid molecules set forth as odd-numbered SEQ ID NOs of the Sequence Listing, wherein the nucleic acid molecule is disrupted. 37. A host cell comprising a nucleic acid molecule selected from the group consisting of the nucleic acid molecules set forth as odd-numbered SEQ ID NOs in the Sequence Listing, wherein the nucleic acid molecule comprises one or more nucleic acid modifications from the sequence set forth as odd-numbered SEQ ID NOs of the Sequence Listing s. 38. A host cell comprising a nucleic acid molecule selected from the group consisting of the nucleic acid molecules set forth as odd-numbered SEQ ID NOs of the Sequence Listing, wherein the regulatory region of the nucleic acid molecule is modified relative to the wild-type regulatory region of the molecule.

Inventors: HABERHAUER GREGOR, KROEGER BURKHARD, POMPEJUS MARKUS, SCHROEDER HARTWIG, ZELDER OSKAR, HABERHAUER, GREGOR, KROEGER, BURKHARD, POMPEJUS, MARKUS, SCHROEDER, HARTWIG, ZELDER, OSKAR
Applicants: BASF AG, BASF AKTIENGESELLSCHAFT
Application year: 2000
Main classification: C12N15
IPC codes: C07K14, C12N1, C12N9, C12N15, C12P13, C12P21, C12R1